

Cancer In Louisiana

2015 - 2019

Volume 37

August 2022

LSU Health
NEW ORLEANS
Louisiana Tumor Registry

Editors

Lauren Maniscalco, MPH
Meichin Hsieh, PhD, MSPH, CTR
Christina Lefante, MPH, CTR
Yong Yi, MS, PhD
Lisa Pareti, BS, RHIT, CTR
Brent Mumphrey, BS
Mary Anne Lynch, MPH
Xiao-Cheng Wu, MD, MPH, CTR

The contents of the monograph are the responsibility solely of the editors.

§

Student Researchers

Tingting Li, MPH
Chika Eni-Ikeh, MBBS

The above student researchers contributed to the preparation of this monograph.

§

The work on this monograph was supported in part by:

SEER Contract HHSN261201800007I/HHSN26100002 from the National Cancer Institute,
Cooperative Agreement NU58DP006332
from the Centers for Disease Control and Prevention, and
the State of Louisiana.

§

Cover design by Quintrelé Jones.

This volume will be published solely as an online document.

Previous volumes of *Cancer in Louisiana* are available at
<http://sph.lsuhscl.edu/monographs-publications>

All information in this report is in the public domain and may be reproduced or copied without permission. Citation of source, however, is appreciated.

Suggested Citation:

Maniscalco L, Hsieh M, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2015-2019. New Orleans: Louisiana Tumor Registry, 2022. (Cancer in Louisiana; Vol. 37.)

§

For more information about the Louisiana Tumor Registry, please visit our website:

<http://louisianatumorregistry.lsuhscl.edu>

Or email us:

LTR-info@lsuhsc.edu

Table of Contents

Acknowledgments	7
Introduction	8
Presentation of the Data.....	12
Cautions in Interpretation	17
Summary	19
Incidence, 2015-2019.....	19
Cancer Deaths, 2015-2019.....	21
Figures.....	22
Figure 1. All Cancers Combined	22
Figure 2. Time Trends: All Cancers Combined	24
Figure 3. Lung Cancer.....	25
Figure 4. Colorectal Cancer	27
Figure 5. Female Breast Cancer	29
Figure 6. Prostate Cancer.....	31
Figure 7. Cervical Cancer.....	33
Figure 8. Tobacco-Related Cancers.....	35
Figure 9. Obesity-Related Cancers	36
Figure 10. Human Papillomavirus (HPV)-Related Cancers.....	37
Figure 11. Pediatric Cancer	38
Incidence Tables	40
Table A1. Average Annual Number of Cancer Cases by Site, Race, and Sex, 2015-2019, Louisiana	40
Table A2. Percent Distribution of Cancer Cases by Site, Race, and Sex, 2015-2019, Louisiana	43
Table B. Average Annual Cancer Incidence Rates by Site, Race, and Sex, ¹ 2015-2019, Louisiana	45
Table C1. Average Annual Cancer Incidence Rates by Race and Sex, ¹ 2015-2019: U.S., Louisiana, and 7-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	48
Table C2. Average Annual Cancer Incidence Rates by Race and Sex, ¹ 2015-2019: U.S., Louisiana, and 11-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	49
Table D. Cancer Incidence Rates ¹ among American Indians/Alaska Natives and Asians and Pacific Islanders, 2015-2019: U.S. and Louisiana.....	50

Table E1. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Males.....	51
Table E2. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Females	54
Table E3. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Males	57
Table E4. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Females.....	60
Table F1. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Males.....	63
Table F2. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Females	64
Table F3. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Males	65
Table F4. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Females.....	66
Table G1. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Males.....	67
Table G2. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: White Females	68
Table G3. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Males	69
Table G4. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2015-2019: Black Females.....	70
Table H1. Number of Children and Adolescent Cancer Diagnoses, ¹ 2015-2019 Combined, Louisiana.....	71
Table H2. Percent Distribution of Children and Adolescent Cancers, ¹ 2015-2019, Louisiana.....	72
Table H3. Average Annual Cancer Incidence Rates ¹ of Children and Adolescent Cancers, ² 2015-2019, Louisiana	73
Table I1. Age-specific Number of Cancer Cases ¹ , 2015-2019, Louisiana	74
Table I2. Age-Specific Average Annual Cancer Incidence Rates, ¹ 2015-2019, Louisiana.....	78
Mortality Tables.....	82
Table J1. Average Annual Number of Cancer Deaths by Site, Race, and Sex, 2015-2019, Louisiana	82
Table J2. Percent Distribution of Cancer Deaths by Site, Race, and Sex, 2015-2019, Louisiana	85
Table K. Average Annual Death Rate ¹ by Site, Race, and Sex, 2015-2019, Louisiana.....	87

Table L1. Average Annual Death Rates ¹ for Selected Cancers by Race and Sex, 2015-2019: U.S., Louisiana, and 7-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	89
Table L2. Average Annual Death Rates ¹ for Selected Cancers by Race and Sex, 2015-2019: U.S., Louisiana, and 11-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	90
Table M1. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2015-2019: White Males	91
Table M2. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2015-2019: White Females	94
Table M3. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Males	97
Table M4. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Females	100
Table N1. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2015-2019: White Males	103
Table N2. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2015-2019: White Females	104
Table N3. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Males	105
Table N4. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Females	106
Table O1. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2015-2019: White Males	107
Table O2. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2015-2019: White Females	108
Table O3. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Males	109
Table O4. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2015-2019: Black Females	110
Survival and Prevalence Tables.....	111
Table P. 5-Year Relative Survival, 2008-2018, Louisiana	111
Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2019 ^{1,2}	114
Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers Only, January 1, 2019 ^{1,2}	115
Other Tables.....	116

Table S. Percent of Cases ^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2015-2019, Louisiana	116
References	117
Appendices	118
Appendix A. Abbreviations and Symbols	118
Appendix B. Regions of Louisiana	119
Regions of the Louisiana Tumor Registry.....	120
Regions of the Office of Public Health	121
Appendix C. Host Institutions of the LTR Regional Registries.....	122
Appendix D. Cancer-Related Organizations.....	123
Appendix E. Data Use.....	124

Acknowledgments

As with all reports produced by the Louisiana Tumor Registry, much appreciation goes to those whose dedication and hard work assist in the timely collection of high-quality data for this monograph. The LTR sincerely thanks:

Louisiana Tumor Registry Regional Directors/Managers

Angela Crossgrow, CTR, Manager, Regions 1 & 3
Danielle Ritchie, CTR, Director, Regions 2 & 5
Lea G. Guidry, RHIA, CTR, Director, Region 4
Candace B. Crowe, CTR, Director: Regions 6–8, Coordinator: Region 7
Ramona Rachal, CTR, Coordinator, Region 6
Paula Franklin, RHIA, CTR, Coordinator, Region 8

Host Institutions

Regions 1 & 3: LSU Board of Supervisors and LSU Health Sciences Center-New Orleans (since 1995)
Region 2: Mary Bird Perkins Cancer Center (since 1983)
Region 4: Acadiana Medical Research Foundation (since 1983)
Region 5: Mary Bird Perkins Cancer Center (since 2013)
Regions 6, 7, & 8: University of Louisiana at Monroe (since 1988)

Regional registrars and staff members of the Louisiana Tumor Registry

Central office staff members

Lili Bao, MD, MS, CTR	Lisa Moses, MS, MPH, LCSW
Anna Brewer, BS, RHIA, CTR	Reem Muhsen, BA
Mary Davidson, MN, RN, CTR	Nektarios Pappas, MD, CTR
Natalie Gomez, BSN, RN	Lisa Peterson, BA, RHIT, CTR
Betty Gonzales, MBA	

Hospital cancer registries in Louisiana

Louisiana Cancer Registrars' Association

Physicians and staff members in:

Medical records offices, Pathology laboratories, Physician offices and clinics,
Free-standing treatment facilities, Hospice programs

School of Public Health, LSU Health Sciences Center–New Orleans

Louisiana Cancer and Lung Trust Fund Board

Louisiana Health Care Services Division

Coroners' offices

Louisiana Department of Health: Office of Public Health (STD/HIV Program, Immunization Program), Office of the State Registrar and Vital Records, Bureau of Health Informatics (Louisiana Hospital Inpatient Discharge Database)

Introduction

The Louisiana Tumor Registry (LTR) is pleased to present Volume 37 of its annual ***Cancer in Louisiana*** monograph series, documenting cancer incidence and mortality from 2015 to 2019 in Louisiana as well as incidence and mortality trends from 1988 to 2019. Survival statistics are for cases diagnosed from 2008 to 2018 and followed into 2019. Prevalence is also presented for cancer cases diagnosed from January 1, 2000 to January 1, 2018.

Purpose of the Registry

The state legislature authorized the establishment of the LTR in 1978. In the early 1980s, the state began providing funding support to the LTR for the collection, analysis, and dissemination of information on cancer in Louisiana.

Cancer is a reportable disease in all states of the United States (U.S.). Using the data collected by statewide population-based registries, cancer incidence counts and rates by age, race, sex, and geographic region, as well as trends over time, are calculated. With these statistics, data-driven cancer prevention and control programs can be implemented to reduce cancer morbidity and mortality. Registry data provide the foundation not only for cancer surveillance but also for studies evaluating screening and early detection programs, health care planning, clinical therapies, cancer research (including etiology and disparity studies), and other cancer prevention and control initiatives. Registry information directs efforts to lessen the burden of cancer in our state.

Historical Background of the LTR

Achieving Statewide Cancer Surveillance Coverage

Cancer registration in Louisiana began in 1947 in the Charity Hospital Tumor Registry in New Orleans and was limited to patients in that facility. In 1974, as part of its Surveillance, Epidemiology and End Results (SEER) Program, the National Cancer Institute (NCI) provided funds for a population-based cancer incidence and survival registry, which then encompassed only Jefferson, Orleans, and St. Bernard parishes; the data were included in the 1974–1977 SEER national incidence rates.

In 1979, the LTR was transferred to Louisiana’s Office of Public Health (OPH). The catchment area for the LTR was expanded in 1983 to include 35 parishes of South Louisiana (LTR Regions 1–5). In 1988, when the 29 parishes of North Louisiana (LTR Regions 6–8) were added, statewide coverage was achieved. In 1995, the LTR was transferred from the OPH to the LSU Board of Supervisors. Since then, the LSU Health Sciences Center in New Orleans has been responsible for the cancer registry program and has provided state funds for its work. State funding provided to the LTR supports the collection of cancer data for the in-house regions (Regions 1 and 3), as well as the LTR’s subcontractors located at non-profit organizations around the state (Mary Bird Perkins Cancer Center, Acadiana Medical Research Foundation, Christus St. Patrick Hospital (contract ended 06/30/3014), and the University of Louisiana at Monroe). Oversight of the

registry has been exercised by the Louisiana Cancer and Lung Trust Fund Board, whose members represent various health institutions throughout the state and are appointed by the governor (see [Acknowledgements](#), above). Vivien W. Chen, Ph.D., served as the director of the registry from 1991 until 2012. On July 1, 2012, Xiao-Cheng Wu, MD, MPH, CTR, assumed the directorship.

Joining the CDC's National Program of Cancer Registries (NPCR)

Since 1994, the Centers for Disease Control and Prevention (CDC) has provided funds for most states, including Louisiana, to participate in the National Program of Cancer Registries (NPCR).

Joining the NCI's Surveillance, Epidemiology, and End Results (SEER) Program

In 2001, after a competitive application process, the LTR was selected to join the NCI's SEER Program as an expansion registry on a provisional basis. Four years later, it became a full member of SEER. In 2017, the LTR again participated in a competitive application process and was awarded funding for 10 years (2018-2028).

Operations of the Registry

The operations of the registry are mandated by public law, R.S. 40:1105.1 et seq., which requires all medical facilities and health care providers to provide information on all reportable cancer cases defined by national standards to the registry or provide access to medical records so that LTR staff members can collect the required information. The legislative rules require strict confidentiality of all data.

Central Office and Regional Registries

The LTR comprises a central office and eight regional registries, based on Louisiana's historic Office of Public Health districts ([Appendix B](#)), at four locations (New Orleans, Baton Rouge, Lafayette, and Monroe) that collect and process cancer incidence data from corresponding catchment areas.

Collection of Cancer Incidence Data

Each regional registry is responsible for the complete ascertainment of cancer cases diagnosed and treated in its region. About one-fourth of all hospitals in Louisiana maintain their own cancer registries which covers about two-thirds of incident cases, and the regional registries are responsible for abstracting cases from the remaining hospitals and other facilities such as treatment centers, outpatient surgical facilities, physician offices, and freestanding pathology laboratories.

Regional registries monitor the facilities in their area for completeness of case ascertainment, as well as consolidate multiple reports from multiple sources to obtain accurate cancer information on the same case. The central office oversees and monitors operations of regional registries, conducts quality assurance and case completeness audits, and coordinates regional offices to ensure the quality, completeness, and timeliness of reporting. The central office leads the direction of the Louisiana cancer surveillance system by promulgating new legislative rules to meet the needs of cancer registry operations, building infrastructure to electronically capture

and report cancer cases, establishing new procedures to improving the efficiency of data processing, and training new hospital registry employees on state requirements. The central office also assists the regional offices by resolving issues with non-compliant reporting facilities. Additionally, the central office plays an essential role in enhancing the use of cancer registry data by conducting research and participating in or supporting cancer research with partners and stakeholders. Furthermore, its research staff respond to data requests, prepare publications, and participate in research activities.

Unrecorded cancer diagnoses identified among Louisiana residents through an annual linkage with death certificates are traced back to hospitals, other facilities, or physician offices to be abstracted. If the original diagnostic information cannot be located, the case is considered a “death-certificate-only” case, and the date of death is recorded as the diagnosis date in compliance with standard practices of cancer surveillance. The LTR also conducts annual casefinding audits using disease indices, as well as the Louisiana Hospital Inpatient Discharge Database (HIDD) file, to capture missed cases of the brain, kidney and pancreas, which are more likely to be clinically diagnosed, to ensure complete case ascertainment.

Exchange of data with other state cancer registries began in 1997 in order to ensure a higher level of case ascertainment and data completeness. This permits the LTR to obtain cancer data on residents of Louisiana who have traveled out of state for cancer diagnosis and/or treatment. In October of 2014, Louisiana signed the National Interstate Data Exchange Agreement. Louisiana now has established agreements with 48 population-based cancer registries, including 43 states (all neighboring states), Washington D.C., three United States territories (Guam, Puerto Rico, and the Virgin Islands), and Bermuda. Strict protocols on patient confidentiality are followed.

Reportable Diagnoses

The LTR complies with national standards in requiring that all in situ and invasive neoplasms (cancers with behavior codes 2 or 3 in the *ICD-O-3* [1]) are reported. Carcinoma in situ of the cervix and cervical intraepithelial neoplasia III (CIN III) were reportable for cases diagnosed before 1996. CIN III was again deemed reportable for cases diagnosed after 2008 in Louisiana and 3 other state cancer registries with funding support from the CDC-NPCR. Non-reportable cancers include intraepithelial carcinoma of the prostate diagnosed in 2011 and after and basal cell as well as squamous cell carcinomas of the skin regardless of diagnosis year.

Benign and borderline tumors of the brain and central nervous system are also reportable in accordance with national standards if diagnosed in 2004 and after, but rates and counts are only presented for children and adolescents (ages 0-19) in this monograph in compliance with nationwide cancer surveillance monographs. Rates and counts for these tumors are not reported for adults, because the completeness of these benign tumors is uncertain. In addition, pilocytic astrocytomas are classified as benign by the World Health Organization but as malignant in North America.

Data Quality

Quality assurance procedures in the LTR regional registries and central office minimize abstracting and coding errors and ensure and evaluate the completeness of case ascertainment.

To enhance the quality of incidence data across the U.S., the North American Association of Central Cancer Registries (NAACCR) sets standards for quality, timeliness, and completeness. Data from U.S. central cancer registries that meet those standards are used in calculating the “U.S. Combined Cancer Incidence Rates,” which are reported in NAACCR’s annual publication, *Cancer in North America*. LTR data have qualified for inclusion every year since the inception of the certification process in 1997 and have been certified at the gold level for high quality and timely data every year since 1997. The LTR has also received the first place award every year since 2009 from the SEER program for meeting all data quality benchmarks on completeness, timeliness, and follow-up rates. In addition, the LTR has achieved the NPCR Standards for Data completeness, Timeliness, and Quality since 2002 and received a Registry of Excellence or Distinction award from the CDC’s NPCR since 2015.

Data Use

LTR data are included in many cancer surveillance publications that accept only high-quality data: *Cancer Incidence in Five Continents*, published by the World Health Organization’s International Association for Research on Cancer; *United States Cancer Statistics*, published by the CDC and the NCI; *SEER Cancer Statistics Review*, published by the SEER Program; CINA Deluxe, published by NAACCR; State Cancer Profiles, published by the CDC; and the SEER Public Use data file. Links to several of these publications can be found in [Appendix E](#).

To enhance cancer registry data dissemination and access to LTR data, in 2019, the LTR launched an interactive, user-friendly [data visualization tool](#) on its website presenting cancer incidence, mortality, and survival rates, as well as region and parish-specific statistics and prevalence counts. In 2021, LTR released a dashboard presenting cancers associated with tobacco, obesity, alcohol, and HPV. Additionally, LTR data are presented in several external data visualization websites: State Cancer Profiles, United States Cancer Statistics: Data Visualizations, American Cancer Society: Cancer Statistics Center, NAACCR: CiNA Explorer, and SEER*Explorer.

Confidentiality of Data

Confidentiality is of the highest priority in LTR operations. Louisiana law mandates strict confidentiality of data about cancers and health care providers and protects participating facilities and physicians from any liability that may arise from reporting to the cancer registry program. LTR Data Release Policies are in accordance with HIPAA rules and state law. Any request for case-level cancer data will be reviewed and approved by the LTR Research Committee as required by law.

LTR personnel sign an “Agreement to Maintain Confidentiality of Data” and are subject to penalty if they disclose confidential information. LTR data are published in aggregate form only. Data released in public presentations or publications are not intended to correspond to individual cases.

Presentation of the Data

Volume 37 of *Cancer in Louisiana* presents cancer incidence and mortality information about residents of Louisiana diagnosed with cancer between January 1, 2015 and December 31, 2019. Statistics on incidence are found in Tables A–I, and Tables J–O contain data on mortality. Survival statistics can be found in Figure 1, Figures 3–7, Figure 11, and Table P. Statistics on prevalence in Louisiana are included in this volume in Tables Q and R.

Incidence and mortality rates are provided for the state, the regions of the LTR, the regions of the OPH and the Louisiana Cancer Prevention and Control Programs, the Industrial Corridor (7-Parish and 11-Parish), and individual parishes. While parish is the smallest geographic region presented in this monograph, cancer data at the census tract level can be found in our annual report [Cancer Incidence in Louisiana by Census Tract, 2009–2018](#). Visit <http://new.dhh.louisiana.gov/index.cfm/page/394> for descriptions of the OPH and Cancer Control Program regions.

To ensure statistical stability, rates are not presented when based on fewer than 16 cases or deaths, which is in compliance with the rule used by the United States Cancer Statistics (https://www.cdc.gov/cancer/uscs/technical_notes/stat_methods/suppression.htm). Incidence counts are not presented when there are fewer than 6 cases to preserve confidentiality of the data; mortality counts are not presented by the NCI when there are fewer than 10 cases.

Data Use Standards

Incidence

Cancer incidence, the best indicator of cancer risk in a population, is the number of new cancers of a specific site/type diagnosed by medical professionals in a specified population during a year. The LTR follows standard protocols in computing and publishing cancer incidence data so that Louisiana data can be compared with those from other cancer surveillance publications. These conventions include:

- Only primary cancers are included in the LTR database used for calculating incidence counts or rates.
- SEER Multiple Primary and Histology Coding Rules are used to determine whether multiple primary cancers for a given patient are considered one case or more than one.
- For preparing statistics, anatomic subsites are combined according to code groupings compiled by the SEER Program of the NCI (http://seer.cancer.gov/siterecode/icdo3_d01272003/).
- With the exception of bladder cancer, only invasive neoplasms are included in the tables for incidence rates (ICD-0-3=Malignant) to be consistent with other cancer surveillance monographs published by NCI, CDC, NAACCR, and the American Cancer Society (ACS). For cancers of the bladder, both in situ and invasive cases are included. In situ carcinomas of the breast are listed separately from the invasive cancers and are excluded from the “all sites” totals.
- Neoplasms of the lymphatic, hematopoietic, and reticuloendothelial systems (e.g.,

lymphomas and leukemias), as well as mesothelioma and Kaposi sarcoma, are grouped by their histologies and not by the anatomical sites where they occur.

Cancer Deaths (Mortality)

Information on residents of Louisiana who died with cancer as the underlying cause of death was compiled by the National Center for Health Statistics, using mortality data from the Louisiana OPH and its counterparts in other states. Louisiana residents who died out of state are included in Louisiana statistics.

The SEER Program's detailed anatomical site codes from the *International Classification of Diseases, 10th Revision* for calculating mortality statistics can be found at its website: <http://seer.cancer.gov/codrecode/1969+ d09172004/index.html>.

Survival

The SEER program requires follow-up data collection for all cancer patients from the time of diagnosis to death. Survival statistics in this volume were based on cases diagnosed from 2008 through 2018 followed into 2019. The cases diagnosed in 2019 are excluded from the survival analyses since these patients may have less than 1 year of follow-up. For patients with more than one cancer, only the first cancer was included in the analysis. Also excluded are those with unknown age, who are lost to follow-up, and cases diagnosed at death and/or autopsy.

To conduct the survival analysis, cancer stage was coded using Combined Summary Stage, a staging method established by the NCI's SEER program, at diagnosis, and survival rates were grouped by cancer stage at the time of diagnosis. Combined Summary Stage is created from SEER Combined Summary Stage 2000 (2004-2017) and Derived Summary Stage 2018 (2018+). It consists of five categories, which combine the clinical and pathological documentation of disease, although our analysis focuses on Local, Regional, and Distant Stage. The five main categories and a brief description of each are below.

1. In Situ – The presence of malignant cells within the cell group from which they arose, and the abnormal cells have not penetrated the protective basement membrane of the tissue. This diagnosis can only be made microscopically and excludes organs and tissues without an epithelial layer.
2. Localized – A malignancy limited to the organ of origin, but the cancer has invaded the protective epithelial (basement) membrane.
3. Regional – The broadest category, can include malignant cancer that 1) has extended beyond the organ of origin directly into surrounding organs or tissue; 2) involves the regional lymph nodes; or 3) has both regional extension and involvement of regional lymph nodes.
4. Distant – A malignancy that has broken away from the primary tumor and has travelled to other parts of the body and begun growth. This stage is often referred to as metastasis.
5. Unknown – A malignancy with an unknown primary site or for which crucial staging data were not recorded will be assigned an unknown summary stage.

Prevalence

Cancer prevalence is defined as the number or percent of people alive on a certain date in a population who previously had a diagnosis of cancer, which includes new (incidence) and pre-existing cases. Prevalence provides little information on the risk of cancer in a population. [See Overview of Prevalence at <https://surveillance.cancer.gov/prevalence/>]

For prevalence statistics, 19-Year limited duration prevalence is presented. For all sites, the first invasive tumor for each person diagnosed during the previous 19 years (2000-2018) is counted. For each specific cancer site, the first invasive tumor for each site diagnosed during the previous 19 years (2000-2018) is included. Breast tumors include both sexes, and the urinary bladder category includes in situ cases.

Race

Race for cancer cases is based primarily on information contained in a patient's medical record, supplemented by information on death certificates, the HIDD file, and voter registration files.

Louisiana cancer incidence and mortality data in this volume include the racial categories of all races combined, White, Black, American Indian/Alaska Native, and Asian Pacific Islander. Counts and rates for American Indians/Alaska Natives and Asian Pacific Islanders are included in Tables A1, A2, and D. Other groups were not analyzed separately because of small case numbers. Less than one percent of 2015-2019 cases were of unknown race. Cases with unknown race were included in the calculations of rates for "all races" but not in the race-specific computations.

Population Estimates

Five-year population estimates by race, sex and age for Louisiana and the U.S. were obtained from the NCI and are based on the U.S. Census Bureau's estimates of the populations for 2015-2019 or specified years. More details regarding the population estimates utilized can be found here: <https://seer.cancer.gov/popdata/methods.html>.

Age Adjustment

Age adjustment allows meaningful comparisons of cancer risk across different populations by controlling for differences in the age distributions of those populations. This is important because cancer is diagnosed more frequently among the elderly. Age-adjusted rates are the weighted average of the age-specific rates, where the weights represent the age distribution of a standard population.

Rates in this monograph are age adjusted to the 2000 U.S. standard population. Rates in earlier publications (with data predating 1999), however, were age adjusted to the 1970 U.S. standard population. Because the U.S. populace was older in 2000 than in 1970, the new standard will cause most rates to appear to rise markedly. Thus, incidence and mortality rates in Volumes 1-16 of this series should not be compared with those in subsequent volumes.

Comparison Groups

Incidence

Estimates of the average annual age-adjusted incidence rates for the U.S. were calculated using data from the SEER Program of the NCI. Data from the SEER Program are recognized for their high quality, and SEER estimates have been traditionally cited as national rates.

The SEER Program estimates in this volume are based on data representing up to 28% of the U.S. population. The SEER 8 (previously 9) includes five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and three metropolitan areas (Atlanta, San Francisco – Oakland, and Seattle/Puget Sound). The SEER 17 (previously 18) includes nine states (California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico and Utah), one metropolitan areas (Seattle/Puget Sound), and the American Indian/Alaska Natives of Arizona and Alaska. For more information on registry groupings in SEER data and statistics, please visit: <https://seer.cancer.gov/registries/terms.html>.

Mortality

Mortality statistics for the U.S. are based on data from the National Center for Health Statistics, to which all states submit death certificate information.

Calculations

The following databases in SEER*Stat, developed by the NCI, were used for all calculations:

Incidence

Frequency Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Rate Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Rate Session, Time Trends:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 8 Registries, Nov 2021 Sub (1975-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Mortality

Frequency Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1969-2019) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Rate Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1969-2019) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Rate Session, Time Trends:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2019) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Survival

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Prevalence

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Cautions in Interpretation

Misperceptions, Misinterpretation and Misapplication of Cancer Registry Data

Population-based cancer registry data is intended to support cancer prevention, control and research. Cancer registry data allows us to monitor cancer incidence over time, guide cancer control programs, identify priorities for allocation of healthcare resources, and advance clinical, epidemiologic, and health services research. In comparing rates among geographic areas, it is important to keep in mind that various factors, in addition to true differences in the risk of developing or dying from cancer, can contribute to variations in cancer rates. Therefore, geographic differences should be interpreted with caution and used to generate, not test, hypotheses.

Summary cancer incidence rates for geographies within the state (i.e., Regions, Industrial Corridor, Parishes, etc.) do not represent cancer incidence in subset populations within that geography, such as fenceline communities. Fenceline communities (those communities bordering or near industrial facilities) are a much smaller geographic area. To study the impact of industrial facilities on the risk of cancer, in-depth research that considers facility-specific exposures, confounding variables, disease latency, sampling error, and systematic and random error would need to be conducted. Such research is beyond the scope of population-based cancer registry data and LTR's essential responsibilities.

The lack of significantly higher cancer rates in census tracts, parishes, regions, etc., does not indicate no problem associated with environmental exposures in smaller geographic areas, like fenceline communities. This is a common misperception that we feel very strongly is important to correct.

The following facts explain why such assertions are fundamentally scientifically unsound:

- **Ecological Fallacy:** One cannot conclude that data for a wider geographic area apply to a smaller population within that area that is differentially exposed to other sources. Not everyone in a parish or even a census tract will be exposed to the same pollution levels emitted from a specific facility. Therefore, measures of diseases among an exposed community could be diluted when using a summary statistic from a larger unexposed population.
- **Causal Associations:** The various chemical emissions and releases and the variety of industry sources in some areas make it extremely difficult, if not impossible, to establish a specific link between one disease and particular chemical emission or release when using population-based data. For example, gaps in our understanding of long-term health impacts of early-life low-dose chronic exposures to one chemical and chemical mixtures present a problem for establishing links, as frequently we do not know which diseases to look for in relation to those compounds and mixtures. Another complicating

factor is when there are multiple possible health outcomes from the same exposures or a mix of exposures.

- **Non-Cancer Health Effects:** There are many chemical compounds to which exposures can manifest as different diseases - besides cancer. For example, particulate matter can produce respiratory or cardiovascular disease. Other disease outcomes include asthma, chronic obstructive pulmonary disease, adverse reproductive and developmental outcomes, irritation of the nose, eyes, throat, and lungs, and immune system diseases.
- **Cancer Risk Factors:** Health statistics are impacted not just by the outside environment but also by other risk factors, including confounders. For example, the age of the population, their diet, their smoking status, their access to and use of health care services, differences in genetic predispositions, different behaviors like outdoor activities, and a variety of other factors can influence the exposures or health outcomes of interest that one would expect in a population, as these factors will be unevenly distributed within a population. Moreover, it is always possible that the majority of a fenceline community can consist of workers in those nearby factories. Workers are usually subject to what is called the “healthy worker effect,” in that they are often healthier than the general population, which also consists of children, the elderly, the sick, pregnant women, etc.
- **Cancer Latency:** The long latency of some cancers, that is, the years to decades it takes to manifest between the time it is triggered and the time a diagnosis is made, makes it impossible to assert that a lack of significantly higher cancer rates in one area suggests there is no problem with the current environmental conditions. This factor is further complicated when the population is susceptible to mobility due to either natural disasters, the search for job opportunities, or the need for specialized health care not available in their area. Latent periods for some cancers can be as long as 40 years.
- **Sample Size:** Small population sizes often lack statistical power. Any summary statistic for a small population can be an artifact of the small number of people in the area. It is less likely that an effect will be detected in a smaller (vs. larger) population because smaller datasets yield less precise estimates due to more significant impacts from sampling error and random error.

Summary

Incidence, 2015-2019

1. Number of new cancer cases: New diagnoses of invasive cancer averaged 26,426 cases per year among Louisiana residents ([Table A1](#)).
2. Most frequently diagnosed cancers: For all Louisianans combined, the most frequently diagnosed cancers were prostate (14.2% of all new cases), breast (13.9%), lung (13.5%), colorectal (9.2%), and kidney (4.6%) ([Table A2](#)).
3. Highest annual incidence rates per 100,000 person-years: The 5 most frequently diagnosed cancers in Louisiana are: (1) breast (69.4), (2) lung (63.4), (3) prostate (63.3), (4) colorectal (45.1), and (5) kidney/renal pelvis (22.5). In the U.S., however, the following is the order of highest rates: breast, prostate, lung, colorectal, and melanoma of the skin [2]. The five most common invasive cancers by race/sex group in Louisiana were ([Table B](#)):
 - a. White men: prostate (120.8 cases per 100,000 person-years), lung (73.9), colorectal (49.2), bladder (36.3), and melanoma of the skin (33.3).
 - b. Black men: prostate (189.8), lung (92.1), colorectal (63.8), kidney (28.7), and liver/bile duct (23.4).
 - c. White women: breast (126.5), lung (55.3), colorectal (36.6), thyroid (25.2), and uterus (19.7).
 - d. Black women: breast (134.9), lung (44.6), colorectal (45.0), uterus (22.6), and kidney (15.2).
4. Louisiana vs. nationwide rates: The incidence rates for cancers of all sites combined among all race/sex groups in Louisiana were significantly higher than those for their national counterparts ($p < 0.05$) ([Table C1](#)).
5. 7-Parish Industrial Corridor: The 7-Parish Industrial Corridor includes Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes. The incidence rates for all cancers combined in white men were significantly higher than the statewide rate. Rates for all cancers combined for black men, white women, and black women did not differ significantly from the Louisiana rates ([Table C1](#)).
6. 11-Parish Industrial Corridor: The 11-Parish Industrial Corridor includes Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes. The incidence rates for all cancers combined in all race/sex groups were significantly lower than the statewide rate. ([Table C2](#)).
7. American Indians/Alaska Natives, Asians and Pacific Islanders (AI/AN and APIs): The incidence rates for cancers of all sites combined among AI/AN and APIs in Louisiana are significantly lower than those of their national counterparts for women and did not differ significantly for men. Louisiana AI/AN and APIs also have significantly lower incidence rates of breast, uterus, and pancreatic cancer among women, significantly lower incidence rates of stomach and pancreatic cancer among men, and significantly higher incidence rate of liver/bile duct cancer among men ([Table D](#)).

8. Cancer among children and adolescents: Louisiana's incidence rates for all sites combined among children and adolescents (aged 0–19) were lower than U.S. rates for both boys and girls, but only the rate for girls was significantly lower ([Figure 11](#)). The most common cancers among children and adolescents in Louisiana are central nervous system tumors ([Tables H1-H3](#)).
9. Tobacco-Related Cancers: The incidence rates of tobacco-related cancers are significantly higher in Louisiana than in the U.S. for all race and sex groups ([Figure 8](#)).
10. Obesity-Related Cancers: Incidence rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups, with the exception of incidence for white women, which is not significantly different from the national rate ([Figure 9](#)).
11. HPV-Related Cancers: Incidence rates for HPV-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups ([Figure 10](#)).


Cancer Deaths, 2015-2019

1. Total cancer deaths: An average of 9,385 deaths were attributed to cancer each year, 2015-2019 ([Table J1](#)). Only heart disease caused more deaths (an average of 11,102 per year in Louisiana) than cancer.
2. Leading causes of cancer death: For all Louisiana residents combined, cancer mortality was highest for cancer of the lung (26.9% of all cancer deaths), colorectum (9.2%), pancreas (7.3%), breast (7.1%), and liver/bile duct (5.5%) ([Table J2](#)).
3. Highest annual mortality rates: The highest rates for cancer death in Louisiana were ([Table K](#)):
 - a. White men: lung (57.8 per 100,000 person-years), colorectum (17.3), prostate (16.1), pancreas (13.8), and liver/bile duct (11.6).
 - b. Black men: lung (71.9), prostate (34.5), colorectal (26.5), liver/bile duct (18.8), and pancreas (16.5).
 - c. White women: lung (37.2), breast (19.7), colorectal (11.7), pancreas (10.5), and ovary (6.0).
 - d. Black women: lung (31.6), breast (29.6), colorectal (16.8), pancreas (13.2), and uterus (7.7).
4. Louisiana vs. nationwide rates: Statewide, each of the four major race/sex groups had a significantly higher death rate for all sites combined than its national counterpart. Lung, liver, pancreas, and kidney mortality rates were significantly higher in Louisiana than in the U.S. for all four race-sex groups ([Table L1](#)).
5. 7-Parish Industrial Corridor: Death rates for all cancers combined in the Industrial Corridor were significantly lower than those for Louisiana among whites; blacks in the Industrial Corridor experienced the same mortality rates as their counterparts statewide ([Table L1](#)).
6. 11-Parish Industrial Corridor: Death rates for all cancers combined in the Industrial Corridor were significantly lower than those for Louisiana among all race/sex groups ([Table L2](#)).
7. Cancer death among those aged 0-19: In Louisiana's 0–19 age-group, the mortality rates were about the same in Louisiana and the U.S. for girls, but the rate for boys in Louisiana was significantly lower than their national counterparts ([Figure 11](#)).
8. Tobacco-Related Cancers: The mortality rates of tobacco-related cancers are significantly higher in Louisiana than in the U.S. for all race and sex groups ([Figure 8](#)).
9. Obesity-Related Cancers: The mortality rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups ([Figure 9](#)).
10. HPV-Related Cancers: The mortality rate for HPV-related cancers is significantly higher for black men, black women and white women in Louisiana when compared to their national counterparts ([Figure 10](#)).

Note: All incidence and death rates in this volume are average annual rates per 100,000 person-years for the five-year period, with the exception of incidence rates for those 0-19 years of age, which are presented as average annual rates per 1,000,000 person-years for the five-year period. They are age adjusted to the U.S. 2000 standard and should **not** be compared with rates that are adjusted to the 1970 population.

Figures

Figure 1. All Cancers Combined



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).



U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence

- An average of **26,426 new cases of invasive cancer** were diagnosed each year, 2015-2019, in Louisiana ([Table A1](#)).
- Invasive cancer incidence rates are significantly higher in Louisiana for all race-sex groups when compared to their national counterparts (Figure 1a, above).

Mortality

- An average of 9,385 deaths had an underlying cause of death of cancer in Louisiana each year, 2015-2019 ([Table J1](#)).
- Cancer mortality rates in Louisiana are significantly higher for all four race-sex groups when compared to their national counterparts (Figure 1b, above).
- Over half (50.5%) of the cancer deaths in Louisiana from 2015-2019 were attributed to lung, colorectal, breast, and pancreatic cancers ([Table J2](#)).




*Cases diagnosed from 2008 through 2018 and followed into 2019

Survival rates calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- Five-year relative survival for all cancers combined diagnosed in Louisiana between 2008 and 2018 showed a steady decline by summary stage at diagnosis for males (87.1%, 57.5%, and 24.8% for localized, regional, and distant stage, respectively) and females (87.1%, 64.4%, and 27.3%, respectively) of both races.
- White males diagnosed at regional and distant stages had a significantly higher survival rate compared to black males in the same category; no significant difference was identified at the localized stage.
- White females had significantly higher 5-year relative survival rates than black females at all stages of diagnosis.

Figure 2. Time Trends: All Cancers Combined



¹U.S. incidence rates are based on 8 regions from the SEER Program of the National Cancer Institute.


²Underlying mortality data provided by NCHS (National Center for Health Statistics).

*Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

Incidence & Mortality

- Cancer incidence and mortality are higher for men in Louisiana than in the U.S.
- Over time, however, both trends have been declining for men in Louisiana and in the U.S.
- For women, mortality is declining in Louisiana and the U.S., but this trend is not seen in the overall cancer incidence rates.

Figure 3. Lung Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).



Risk factors for lung cancer include [3]:		
Cigarette use	Certain metals (chromium, cadmium, arsenic)	<u>Other occupational risks:</u> Rubber manufacturing, paving, roofing, painting, and chimney sweeping
Cigar and pipe smoking	Some organic chemicals	
Secondhand smoke	Radiation	
Radon gas	Air pollution	
Asbestos	Diesel exhaust	

Incidence

- Lung cancer incidence rates are significantly higher in Louisiana than in the U.S. for white and black men and white women (Figure 3a, above).
- Lung cancer accounted for 13.5% of all new cancer diagnoses from 2015 to 2019 in Louisiana ([Table A2](#)).
- For all four race-sex groups, lung cancer incidence rates in the 7-Parish Industrial Corridor are significantly lower than the statewide rates ([Table C1](#)). For the 11-Parish Industrial Corridor, lung cancer incidence rates are significantly lower than the statewide rates for all race-sex groups except black women ([Table C2](#)).

Mortality

- Louisiana mortality is significantly higher than the national levels for all four race-sex groups (Figure 3b, above).
- Lung cancer accounted for 26.9% of all cancer deaths from 2015-2019 in Louisiana ([Table J2](#)).




*Cases diagnosed from 2008 through 2018 and followed into 2019

Survival rates calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- For lung cancer diagnosed in Louisiana (2008-2018), the 5-year relative survival consistently dropped based on the summary stage at diagnosis for both males (43.2%, 23.1%, and 4.4% for localized, regional, and distant stage respectively) and females (53.0%, 28.7%, and 6.0%, respectively).
- Females had a 5-year relative survival significantly higher than males at all stages of diagnosis. There was no statistically significant difference among black and white sex-specific survival at the localized and regional stage at diagnosis; however, 5-year survival at a distant stage at diagnosis was significantly higher for black males and females.

Figure 4. Colorectal Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Risk factors for colorectal cancer include [3]:



Excess body weight	Heavy alcohol consumption	Type 2 Diabetes
Physical inactivity	Very low intake of fruits, veggies, and whole-grain fiber	Low calcium intake
Long-term smoking	Personal or family history of colorectal cancer and/or polyps	Certain inherited genetic conditions
Diet high in red or processed meat		Personal history of chronic inflammatory bowel disease

Incidence & Mortality

- Colorectal cancer incidence and mortality rates are significantly higher in Louisiana than in the U.S. for all race-sex groups (Figure 4a-4b, above).
- Colorectal cancer accounted for 9.2% of all new cancer diagnoses and 9.2% of all cancer deaths from 2015 through 2019 in Louisiana ([Table A2](#), [Table J2](#)).
- Incidence and mortality rates of colorectal cancer have decreased in the U.S. and in Louisiana for several decades, which has been attributed to colorectal cancer screening tests, changes in risk factors, and improvements in treatment [3].

Screening

- Men and women at average risk for colorectal cancer should begin screening by the age of 45 and continue up to age 75 depending on health status and prior screening history. Screening provides an opportunity to detect and remove precancerous and cancerous growths; it can identify cancer at an early stage when it is easier to treat. Following screening guidelines can reduce the number of premature deaths related to colorectal cancer [3]. Everyone should discuss the timing and type of screening procedure with his or her physician.




* Cases diagnosed from 2008 through 2018 and followed into 2019

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- For cancers of the colon and rectum diagnosed in Louisiana between 2008 and 2018, the 5-year relative survival fell dramatically between regional and distant stage at diagnosis for both males (85.0%, 69.3%, and 12.3% for localized, regional, and distant stage, respectively) and females (87.4%, 71.5%, 12.6%, respectively).
- Females diagnosed at a localized stage had a significantly higher 5-year relative survival than their male counterparts; however, there was no statistically significant difference between sexes at the regional and distant stages.
- White males diagnosed at regional or distant stages had significantly higher ($p < 0.05$) 5-year relative survival than black males in the same categories (Fig. 4c). There was no statistically significant difference among black and white sex-specific survival for males with localized stage at diagnosis or among females at all stages of diagnosis.

Figure 5. Female Breast Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.


Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence & Mortality

- Breast cancer is the most frequently diagnosed cancer among women, both in Louisiana and the U.S. ([Table C](#)).
- Black women in Louisiana have significantly higher incidence and mortality rates than their national counterparts (Figures 5a-5b, [Table C](#), and [Table L](#)).
 - Continued efforts to expand early detection programs can narrow these gaps. Information about no-cost or reduced-cost mammograms is available through the Louisiana Breast and Cervical Health Program at www.lbchp.org or by calling (888) 599-1073.
- In recent years, breast cancer incidence rates have increased slightly over time. However, since 1989, declines in breast cancer mortality in the U.S. among women have been observed and attributed to both early detection and advances in treatment. Between 1989 and 2019, the mortality rate decreased by 42% in the U.S. [3].

Risk Factors

- Increasing age, family history of breast or ovarian cancer, a long menstrual history, never having had children, having a first child after age 30, recent use of hormonal contraceptives, certain inherited mutations in BRCA1 or BRCA2, certain benign breast conditions, and high breast tissue density are risk factors associated with breast cancer [3].
- Weight gain after the age of 18, being overweight or obese, use of menopausal hormone therapy (combined estrogen and progestin), physical inactivity, and alcohol consumption are potentially modifiable risk factors associated with increased risk of breast cancer [3].




* Cases diagnosed from 2008 through 2018 and followed into 2019

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- For Louisiana women, breast cancer 5-year relative survival rates for those diagnosed between 2008 and 2018 differed significantly by race for each stage at diagnosis.
- The 5-year relative survival for white females (97.0%, 85.6%, and 28.7% for localized, regional, and distant stage, respectively) was significantly higher than that for black females (93.9%, 76.2%, and 21.0% for localized, regional, and distant stage, respectively) diagnosed at the same stage.

Figure 6. Prostate Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence & Mortality


- Prostate cancer incidence rates are significantly higher in Louisiana than in the U.S. for both white and black men (Figure 6a, above).
- Prostate cancer incidence and mortality are notably higher among black men than white men (Figure 6a and 6b, above). This discrepancy is not fully understood.
- Prostate cancer accounted for 26.7 of all new cancer diagnoses and 8.5 of all cancer deaths from 2015-2019 for Louisiana men ([Table A2](#), [Table J2](#)).

Risk Factors

- Well-established risk factors include increasing age, African ancestry, family history of the disease, and certain inherited genetic conditions [3].
- Inherited conditions associated with increased risk include Lynch syndrome and BRCA1 and BRCA2 mutations. Smoking and excess body weight may increase the risk of fatal prostate cancer [3].

Screening

- The prostate-specific antigen (PSA) test permits the early detection of prostate cancer. The American Cancer Society recommends that men 50 or older discuss the benefits and limitations of a PSA test with their physicians. Those men at higher risk (i.e. family history of prostate cancer) are encouraged to speak with their care providers at an earlier age of 45 [3].




*Cases diagnosed from 2008 through 2018 and followed into 2019

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- The 5-year relative survivals for prostate cancer diagnosed at localized and regional stages are nearly 100% for both white and black males in Louisiana.
- However, white males had a statistically significantly higher 5-year relative survival than black males (100.0% vs. 99.1%) when diagnosed at the localized stage in Louisiana between 2008 and 2018.
- Although 5-year relative survival for white men with distant disease (33.3% for White; 30.0% for Black) appears to be better than blacks diagnosed at the same stage, the observed difference was not statistically significant ($p = 0.28$).

Figure 7. Cervical Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence & Mortality


- Cervical cancer incidence and mortality rates are significantly higher in Louisiana than in the U.S. for black and white women (Figure 7a-7b, above).
- Among women, cervical cancer accounted for 1.8% of all new cancer diagnoses and 1.9% of all cancer deaths from 2015 through 2019 in Louisiana ([Table A2](#), [Table J2](#)).
- Both incidence and mortality have declined over the past several decades, but these declines have begun to taper off in recent years [3].

Risk Factors

- Risk factors for cervical cancer include persistent infection with certain types of human papillomavirus (HPV), having sex at an early age or with multiple partners, immunosuppression, a high number of childbirths, cigarette smoking, and long-term use of oral contraceptives [3].

Prevention & Screening

- Cervical cancer attributed to the most common types of HPV can be prevented through vaccination. These vaccines are available for use in those that are 9 to 12 years of age, with catch-up vaccination through age 26 [3].
- Screening with the Pap test is still recommended and allows for early detection and removal of precancerous lesions [3].



* Cases diagnosed from 2008 through 2018 and followed into 2019

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected

5-Year Relative Survival

- For Louisiana women, 5-year relative survival for cervical cancer for those diagnosed between 2008 and 2018 did not differ significantly by race for localized and regional stages at diagnosis.
- White females diagnosed at a distant stage had significantly higher ($P < 0.05$) 5-year relative survival (18.4%) than black females in the same category (12.0%) (Fig. 7c).

Pre-Invasive Cervical Lesions by Age and Race


To assess the impact of the HPV vaccine, the LTR collects data on pre-invasive cervical lesions (CIN3). The frequency of these lesions by diagnosis year and age and race can be found in the tables below:

Diagnosis Year	Count	%
2015	1,118	16.0
2016	1,306	18.6
2017	1,208	17.2
2018	1,240	17.7
2019	2,136	30.5
Total	7,008	100.0

Age Group	White	Black	Other	Total
20-29	1,467 (33.7)	842 (37.3)	68 (28.8)	2,377 (34.8)
30-39	1,814 (41.7)	883 (39.2)	97 (41.1)	2,794 (40.8)
40-49	647 (14.9)	276 (12.2)	52 (22.0)	975 (14.3)
50-59	255 (5.9)	151 (6.7)	12 (5.1)	418 (6.1)
60+	166 (3.8)	103 (4.6)	7 (3.0)	276 (4.0)
Total	4,349 (63.6)	2,255 (33.0)	236 (3.5)	6,840 (100.0)

Exclusion Criteria: Cases aged <20 and unknown race.

Figure 8. Tobacco-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality rates include all cancers listed in the table below. Underlying mortality data provided by NCHS (National Center for Health Statistics).


Tobacco Use (cigarettes, smokeless tobacco products, and cigars) increases your risk for cancers listed below [3]:

oral cavity	esophagus	bladder	acute myeloid leukemia
pharynx	pancreas	stomach	trachea
larynx	uterine cervix	colorectum	
lung and bronchus	kidney	liver	

Incidence & Mortality

- Incidence and mortality rates for tobacco-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups (Figures 8a-8b).
 - Despite this, Louisiana is ranked 38th in the nation for its cigarette tax of \$1.08 [4].
- While the risk of these cancers increases with tobacco use, not all of the cases utilized to calculate these rates are tobacco related. In other words, it is not known how many of these cases can actually be attributed to tobacco use.

Figure 9. Obesity-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate (p < 0.05).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality rates include the following sites due to limitations of the cause of death recode: postmenopausal female breast, colorectum, liver, gallbladder, pancreas, corpus uterus, ovary, kidney, thyroid, myeloma, stomach, and esophagus. Underlying mortality data provided by NCHS (National Center for Health Statistics).


Obesity increases your risk for the cancers listed below [5]:

Colorectum	Liver	Gallbladder	Pancreas
Corpus Uterus	Ovary	Kidney	Thyroid
Multiple Myeloma	Postmenopausal Female Breast	Gastric Cardia	Meningioma
Esophageal adenocarcinoma			

Incidence & Mortality

- Incidence and mortality rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups, with the exception of incidence for white women, which is lower than the national rate (Figures 9a-9b).
 - Rates of cancers associated with overweight and obesity, with the exception of colorectal cancer, increased by 7% from 2005 to 2014 [5].
 - While all states had more than 20% of adults with obesity, Louisiana ranks 4th highest for self-reported obesity at 38.1% [6].
- While the risk of these cancers increases with adult obesity, not all of the cases utilized to calculate these rates are obesity related. In other words, it is not known how many of these cases can actually be attributed to adult obesity.

Figure 10. Human Papillomavirus (HPV)-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality data includes all cervical, anal, vulvar, vaginal, penile, rectal, and oropharyngeal cancers. Underlying mortality data provided by NCHS (National Center for Health Statistics).

HPV increases your risk for cancers listed below as defined by the CDC [7]:

Cervical

Squamous cell carcinomas of:

Oropharynx

Penis

Anus

Vulva

Vagina

Rectum


Incidence & Mortality

- Incidence rates for HPV-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups (Figure 9a).
- The mortality rate for HPV-related cancers is significantly higher for black men, black women and white women in Louisiana when compared to their national counterparts (Figure 9b).
- While the risk of these cancers increases with HPV, not all of the cases utilized to calculate these rates are HPV related. In other words, it is not known how many of these cases can actually be attributed to HPV.

Prevention

- CDC recommends that all children who are 11 or 12 years of age should receive the HPV vaccine.
- If not vaccinated previously, HPV vaccination is also recommended for everyone through age 26 [8].

Figure 11. Pediatric Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 1,000,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).


U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence rates include myelodysplastic syndromes, benign/borderline brain/CNS tumors, and in situ bladder tumors.

Incidence & Mortality

- Pediatric cancer incidence rates for boys and girls are lower in Louisiana when compared to their national counterparts; however, only the incidence rate for girls in Louisiana and the U.S. are significantly different (Figure 11a, above).
- The cancers most commonly diagnosed in Louisiana among the 0-19 age group continue to be brain and central nervous system tumors, leukemia, and lymphoma ([Table H3](#)).
- The mortality rate for boys and girls aged 0-19 was significantly lower for Louisiana than the U.S. (18.0 vs. 22.2 per 1,000,000, respectively).
- Advances in treatment have led to a steady decline in cancer deaths for children and adolescents. In 1975, the mortality rate was 50.7 per 1,000,000 youth, age 0-19, in the U.S., but this has dropped to 22.2 per 1,000,000 youth (2015-2019).



*Cases diagnosed from 2008 through 2018 and followed into 2019

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected
Survival rates exclude benign/borderline brain/CNS tumors.

5-Year Relative Survival

- The 5-year relative survival for all pediatric cancers combined diagnosed in Louisiana between 2008 and 2018 falls between 87.6%, for white females, and 78.7%, for black males.
- White female 5-year relative survival was statistically higher than black female survival (White: 87.6%, Black: 79.8%). Although white male survival is higher than black male survival (White: 83.7%, Black: 78.7%), the difference was not statistically significant.
- No statistically significant difference was found by gender when all races were combined (Male: 82.7% and Female: 86.5%).

Incidence Tables

Table A1. Average Annual Number of Cancer Cases by Site, Race, and Sex, 2015-2019, Louisiana

Primary Site	All races			White			Black			AI/AN ¹ & APIs ²		
<i>Invasive Cancers³</i>	Total ⁴	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	26,426	14,106	12,320	18,506	9,901	8,604	7,460	3,955	3,506	317	160	157
Oral Cavity and Pharynx	722	528	194	557	409	149	152	111	41	10	6	3
Lip	33	25	8	32	24	8	^	^	^	^	^	^
Tongue	224	162	62	187	135	52	35	26	9	3	^	1
Salivary Gland	60	37	24	45	29	16	15	7	8	^	^	^
Floor of Mouth	39	28	10	25	18	7	13	10	3	^	^	^
Gum and Other Mouth	99	62	37	72	44	28	24	15	9	2	^	^
Nasopharynx	32	24	8	19	15	5	10	8	3	2	2	^
Tonsil	133	112	21	107	89	18	24	21	3	^	^	^
Oropharynx	45	34	11	34	26	8	11	8	3	^	^	^
Hypopharynx	38	30	8	24	18	5	14	11	2	^	^	^
Other Oral Cavity and Pharynx	19	15	4	14	11	3	6	4	2	^	^	^
Digestive System	4,978	2,849	2,129	3,240	1,865	1,375	1,644	924	720	77	49	27
Esophagus	250	198	52	182	149	33	67	47	19	2	2	^
Stomach	370	231	139	206	134	72	155	91	63	7	5	2
Small Intestine	174	90	84	102	57	45	70	32	38	2	^	^
Colon and Rectum	2,429	1,306	1,123	1,597	866	731	789	414	375	35	21	14
Colon excluding Rectum	1,697	875	823	1,112	578	533	561	282	279	21	12	9
Cecum	331	152	179	219	102	117	108	48	60	4	2	2
Appendix	93	40	53	69	29	40	22	10	12	^	^	^
Ascending Colon	327	154	173	213	100	112	112	52	60	1	^	^
Hepatic Flexure	80	44	36	53	29	24	26	14	12	^	^	^
Transverse Colon	161	86	75	106	57	49	54	29	26	1	^	^
Splenic Flexure	49	27	22	28	17	11	21	9	11	^	^	^
Descending Colon	113	64	49	69	41	28	42	22	20	2	^	^
Sigmoid Colon	444	258	185	292	171	122	140	81	60	9	6	3
Large Intestine, NOS	100	50	50	63	32	31	36	17	18	^	^	^
Rectum and Rectosigmoid Junction	731	431	300	486	288	198	228	132	96	14	9	5
Rectosigmoid Junction	139	78	60	95	54	41	40	22	18	3	2	^
Rectum	593	353	240	391	234	157	188	110	78	11	7	4
Anus, Anal Canal and Anorectum	112	46	66	84	33	51	27	13	14	^	^	^
Liver and Intrahepatic Bile Duct	625	474	151	377	278	99	225	178	47	20	16	4
Liver	555	436	119	328	252	75	205	166	39	18	15	3
Intrahepatic Bile Duct	70	38	32	49	25	24	20	12	8	^	^	^
Gallbladder	71	23	48	42	13	29	26	9	17	2	^	^
Other Biliary	85	49	37	59	34	25	24	13	10	2	^	1
Pancreas	788	404	384	540	283	257	238	116	122	7	4	3
Retroperitoneum	15	7	9	9	5	5	6	2	4	^	^	^
Peritoneum, Omentum and Mesentery	20	3	18	15	1	13	6	^	4	^	^	^
Other Digestive Organs	39	19	20	26	12	14	12	6	6	^	^	^
Respiratory System	3,890	2,219	1,671	2,760	1,518	1,243	1,075	670	406	45	26	19
Nose, Nasal Cavity and Middle Ear	39	23	17	31	19	13	7	4	3	^	^	^
Larynx	285	221	65	190	145	45	93	74	19	2	1	^
Lung and Bronchus	3,557	1,971	1,586	2,533	1,350	1,183	973	591	382	43	24	19
Pleura	2	2	^	2	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other Respiratory	6	3	3	4	2	2	2	^	^	^	^	^
Organs	6	3	3	4	2	2	2	^	^	^	^	^
Bones and Joints	39	20	20	28	13	15	11	6	5	^	^	^

Soft Tissue including Heart	198	117	81	143	89	54	51	25	26	2	1	^
Skin excluding Basal and Squamous	1,056	652	404	1,009	629	381	28	12	15	3	2	^
Melanoma of the Skin	950	587	363	922	573	349	13	5	7	2	2	^
Other Non-Epithelial Skin	106	65	41	87	55	32	15	7	8	1	^	^
Breast	3,670	33	3,637	2,485	22	2,463	1,126	10	1,117	47	^	46
Female Genital System	1,256	^	1,256	822	^	822	409	^	409	18	^	18
Cervix Uteri	223	^	223	132	^	132	84	^	84	3	^	3
Corpus and Uterus, NOS	628	^	628	403	^	403	213	^	213	9	^	9
Corpus Uteri	606	^	606	393	^	393	201	^	201	9	^	9
Uterus, NOS	22	^	22	10	^	10	12	^	12	^	^	^
Ovary	256	^	256	180	^	180	71	^	71	4	^	4
Vagina	26	^	26	17	^	17	9	^	9	^	^	^
Vulva	88	^	88	63	^	63	23	^	23	^	^	^
Other Female Genital Organs	37	^	37	27	^	27	10	^	10	^	^	^
Male Genital System	3,901	3,901	^	2,469	2,469	^	1,363	1,363	^	32	32	^
Prostate	3,760	3,760	^	2,357	2,357	^	1,339	1,339	^	30	30	^
Testis	107	107	^	91	91	^	12	12	^	2	2	^
Penis	28	28	^	17	17	^	10	10	^	^	^	^
Other Male Genital Organs	6	6	^	4	4	^	2	2	^	^	^	^
Urinary System	2,258	1,548	710	1,739	1,224	515	486	303	184	20	13	7
Urinary Bladder	981	756	225	813	639	174	155	107	47	8	6	2
Kidney and Renal Pelvis	1,217	756	462	879	554	325	320	190	130	11	6	5
Ureter	30	18	12	27	17	10	2	^	^	^	^	^
Other Urinary Organs	29	17	12	20	14	7	9	4	5	^	^	^
Eye and Orbit	40	23	16	34	21	14	4	2	2	^	^	^
Brain and Other Nervous System	298	169	129	239	134	104	54	32	22	3	2	2
Brain	280	158	122	226	126	100	50	30	20	3	1	1
Cranial Nerves Other Nervous System	18	11	7	13	8	5	5	2	2	^	^	^
Endocrine System	756	203	553	574	162	413	158	35	122	17	4	14
Thyroid	720	182	538	555	150	404	143	27	116	16	3	13
Other Endocrine including Thymus	36	21	15	19	11	8	15	9	7	^	^	^
Lymphoma	1,131	617	514	862	479	383	246	125	121	17	10	7
Hodgkin Lymphoma	133	73	59	93	51	42	36	20	16	2	1	1
Hodgkin - Nodal	131	72	59	92	50	42	36	20	16	2	^	1
Hodgkin - Extranodal	2	2	^	1	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	998	544	455	769	428	342	209	105	105	15	9	6
NHL - Nodal	669	367	302	527	292	234	132	68	63	9	6	3
NHL - Extranodal	329	176	153	243	135	107	77	36	41	6	3	3
Myeloma	451	243	208	242	141	101	202	98	104	5	3	2
Leukemia	736	423	314	561	322	238	163	93	71	8	5	4
Lymphocytic Leukemia	365	221	144	292	176	116	67	41	26	3	1	1
Acute Lymphocytic Leukemia	63	34	28	46	24	22	15	10	6	1	^	^
Chronic Lymphocytic Leukemia	278	170	108	226	138	88	49	30	19	1	^	^
Other Lymphocytic Leukemia	24	16	7	20	14	6	3	2	1	^	^	^
Myeloid and Monocytic Leukemia	343	188	155	249	137	112	88	47	40	5	3	2
Acute Myeloid Leukemia	218	118	100	158	86	72	56	30	26	4	^	^
Acute Monocytic Leukemia	6	4	2	5	3	2	^	^	^	^	^	^
Chronic Myeloid Leukemia	112	63	49	82	46	36	29	16	13	1	^	^
Other Myeloid/Monocytic Leukemia	6	4	3	5	3	2	1	^	^	^	^	^
Other Leukemia	29	14	15	20	9	11	8	4	4	^	^	^
Other Acute Leukemia	9	4	5	5	3	3	3	1	2	^	^	^
Aleukemic, Subleukemic and NOS	20	9	11	14	6	8	5	3	2	^	^	^
Mesothelioma	66	46	20	51	35	16	14	10	4	^	^	^
Kaposi Sarcoma	21	19	2	9	8	1	11	11	^	^	^	^
Miscellaneous	959	498	461	680	363	317	262	125	136	11	5	6
<i>In Situ Cancers (not included above)</i>												
Breast In Situ	727	3	724	469	2	467	247	^	246	9	^	9

¹American Indians/Alaska Natives

²Asians and Pacific Islanders

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴The total case count for each cancer site may not have the same number as the sum of male and female due to rounding.

[^]Count is not displayed due to fewer than 6 cases during the five-year period.

--Not applicable

Table A2. Percent Distribution of Cancer Cases by Site, Race, and Sex, 2015-2019, Louisiana

Primary Site <i>Invasive Cancers</i> ³	All races			White			Black			AI/AN ¹ & APIS ²		
	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Oral Cavity and Pharynx	2.7	3.7	1.6	3.0	4.1	1.7	2.0	2.8	1.2	3.0	3.9	2.2
Lip	0.1	0.2	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0
Tongue	0.8	1.1	0.5	1.0	1.4	0.6	0.5	0.6	0.3	0.8	0.8	0.9
Salivary Gland	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.3	0.1
Floor of Mouth	0.1	0.2	0.1	0.1	0.2	0.1	0.2	0.2	0.1	0.3	0.3	0.3
Gum and Other Mouth	0.4	0.4	0.3	0.4	0.4	0.3	0.3	0.4	0.3	0.7	1.0	0.4
Nasopharynx	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.7	1.1	0.3
Tonsil	0.5	0.8	0.2	0.6	0.9	0.2	0.3	0.5	0.1	0.3	0.3	0.3
Oropharynx	0.2	0.2	0.1	0.2	0.3	0.1	0.1	0.2	0.1	0.0	0.0	0.0
Hypopharynx	0.1	0.2	0.1	0.1	0.2	0.1	0.2	0.3	0.1	0.1	0.1	0.0
Other Oral Cavity and Pharynx	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0
Digestive System	18.8	20.2	17.3	17.5	18.8	16.0	22.0	23.4	20.5	24.1	30.8	17.4
Esophagus	0.9	1.4	0.4	1.0	1.5	0.4	0.9	1.2	0.5	0.5	1.0	0.0
Stomach	1.4	1.6	1.1	1.1	1.4	0.8	2.1	2.3	1.8	2.1	3.0	1.3
Small Intestine	0.7	0.6	0.7	0.6	0.6	0.5	0.9	0.8	1.1	0.5	0.5	0.5
Colon and Rectum	9.2	9.3	9.1	8.6	8.7	8.5	10.6	10.5	10.7	11.0	12.9	9.0
Colon excluding Rectum	6.4	6.2	6.7	6.0	5.8	6.2	7.5	7.1	8.0	6.6	7.4	5.7
Cecum	1.3	1.1	1.5	1.2	1.0	1.4	1.4	1.2	1.7	1.3	1.1	1.4
Appendix	0.4	0.3	0.4	0.4	0.3	0.5	0.3	0.3	0.4	0.4	0.3	0.6
Ascending Colon	1.2	1.1	1.4	1.1	1.0	1.3	1.5	1.3	1.7	0.4	0.3	0.6
Hepatic Flexure	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.4	0.1
Transverse Colon	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.4	0.4	0.5
Splenic Flexure	0.2	0.2	0.2	0.2	0.2	0.1	0.3	0.2	0.3	0.1	0.1	0.1
Descending Colon	0.4	0.5	0.4	0.4	0.4	0.3	0.6	0.5	0.6	0.6	0.6	0.5
Sigmoid Colon	1.7	1.8	1.5	1.6	1.7	1.4	1.9	2.0	1.7	2.7	3.6	1.8
Large Intestine, NOS	0.4	0.4	0.4	0.3	0.3	0.4	0.5	0.4	0.5	0.3	0.6	0.0
Rectum and Rectosigmoid Junction	2.8	3.1	2.4	2.6	2.9	2.3	3.1	3.3	2.7	4.4	5.5	3.3
Rectosigmoid Junction	0.5	0.6	0.5	0.5	0.5	0.5	0.5	0.6	0.5	0.9	1.3	0.6
Rectum	2.2	2.5	1.9	2.1	2.4	1.8	2.5	2.8	2.2	3.5	4.3	2.7
Anus, Anal Canal and Anorectum	0.4	0.3	0.5	0.5	0.3	0.6	0.4	0.3	0.4	0.1	0.0	0.3
Liver and Intrahepatic Bile Duct	2.4	3.4	1.2	2.0	2.8	1.2	3.0	4.5	1.3	6.2	9.9	2.4
Liver	2.1	3.1	1.0	1.8	2.5	0.9	2.8	4.2	1.1	5.8	9.4	2.2
Intrahepatic Bile Duct	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.3
Gallbladder	0.3	0.2	0.4	0.2	0.1	0.3	0.4	0.2	0.5	0.6	0.4	0.9
Other Biliary	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.6	0.5	0.8
Pancreas	3.0	2.9	3.1	2.9	2.9	3.0	3.2	2.9	3.5	2.2	2.4	2.0
Retroperitoneum	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1
Peritoneum, Omentum and												
Mesentery	0.1	0.0	0.1	0.1	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.0
Other Digestive Organs	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.1
Respiratory System	14.7	15.7	13.6	14.9	15.3	14.4	14.4	16.9	11.6	14.3	16.3	12.3
Nose, Nasal Cavity and Middle Ear	0.1	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.3	0.3	0.3
Larynx	1.1	1.6	0.5	1.0	1.5	0.5	1.2	1.9	0.6	0.6	0.9	0.3
Lung and Bronchus	13.5	14.0	12.9	13.7	13.6	13.7	13.0	14.9	10.9	13.5	15.1	11.8
Pleura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Trachea, Mediastinum and Other												
Respiratory Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Bones and Joints	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.3	0.0
Soft Tissue including Heart	0.7	0.8	0.7	0.8	0.9	0.6	0.7	0.6	0.7	0.8	0.9	0.6
Skin excluding Basal and Squamous	4.0	4.6	3.3	5.5	6.3	4.4	0.4	0.3	0.4	1.1	1.5	0.6

Melanoma of the Skin	3.6	4.2	2.9	5.0	5.8	4.1	0.2	0.1	0.2	0.6	1.0	0.3
Other Non-Epithelial Skin	0.4	0.5	0.3	0.5	0.6	0.4	0.2	0.2	0.2	0.4	0.5	0.4
Breast	13.9	0.2	29.5	13.4	0.2	28.6	15.1	0.2	31.9	14.7	0.3	29.4
Female Genital System	4.8	--	10.2	4.4	--	9.6	5.5	--	11.7	5.6	--	11.3
Cervix Uteri	0.8	--	1.8	0.7	--	1.5	1.1	--	2.4	1.0	--	2.0
Corpus and Uterus, NOS	2.4	--	5.1	2.2	--	4.7	2.9	--	6.1	2.8	--	5.7
Corpus Uteri	2.3	--	4.9	2.1	--	4.6	2.7	--	5.7	2.8	--	5.7
Uterus, NOS	0.1	--	0.2	0.1	--	0.1	0.2	--	0.3	0.0	--	0.0
Ovary	1.0	--	2.1	1.0	--	2.1	0.9	--	2.0	1.3	--	2.5
Vagina	0.1	--	0.2	0.1	--	0.2	0.1	--	0.2	0.2	--	0.4
Vulva	0.3	--	0.7	0.3	--	0.7	0.3	--	0.7	0.3	--	0.6
Other Female Genital Organs	0.1	--	0.3	0.1	--	0.3	0.1	--	0.3	0.0	--	0.0
Male Genital System	14.8	27.7	--	13.3	24.9	--	18.3	34.5	--	10.2	20.3	--
Prostate	14.2	26.7	--	12.7	23.8	--	17.9	33.8	--	9.5	18.8	--
Testis	0.4	0.8	--	0.5	0.9	--	0.2	0.3	--	0.6	1.3	--
Penis	0.1	0.2	--	0.1	0.2	--	0.1	0.3	--	0.1	0.3	--
Other Male Genital Organs	0.0	0.0	--	0.0	0.0	--	0.0	0.1	--	0.0	0.0	--
Urinary System	8.5	11.0	5.8	9.4	12.4	6.0	6.5	7.7	5.2	6.2	8.0	4.3
Urinary Bladder	3.7	5.4	1.8	4.4	6.5	2.0	2.1	2.7	1.3	2.6	3.9	1.4
Kidney and Renal Pelvis	4.6	5.4	3.7	4.7	5.6	3.8	4.3	4.8	3.7	3.5	4.0	2.9
Ureter	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0
Other Urinary Organs	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0
Eye and Orbit	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.3
Brain and Other Nervous System	1.1	1.2	1.0	1.3	1.4	1.2	0.7	0.8	0.6	1.1	1.1	1.0
Brain	1.1	1.1	1.0	1.2	1.3	1.2	0.7	0.8	0.6	0.8	0.8	0.9
Cranial Nerves Other Nervous System	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1
Endocrine System	2.9	1.4	4.5	3.1	1.6	4.8	2.1	0.9	3.5	5.4	2.3	8.6
Thyroid	2.7	1.3	4.4	3.0	1.5	4.7	1.9	0.7	3.3	5.0	1.8	8.3
Other Endocrine including Thymus	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.4	0.5	0.4
Lymphoma	4.3	4.4	4.2	4.7	4.8	4.5	3.3	3.2	3.4	5.4	6.1	4.6
Hodgkin Lymphoma	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.8	0.8	0.8
Hodgkin - Nodal	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.8	0.8	0.8
Hodgkin - Extranodal	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-Hodgkin Lymphoma	3.8	3.9	3.7	4.2	4.3	4.0	2.8	2.6	3.0	4.6	5.4	3.8
NHL - Nodal	2.5	2.6	2.5	2.8	3.0	2.7	1.8	1.7	1.8	2.8	3.5	2.0
NHL - Extranodal	1.2	1.3	1.2	1.3	1.4	1.2	1.0	0.9	1.2	1.8	1.9	1.8
Myeloma	1.7	1.7	1.7	1.3	1.4	1.2	2.7	2.5	3.0	1.5	1.8	1.3
Leukemia	2.8	3.0	2.5	3.0	3.3	2.8	2.2	2.3	2.0	2.6	2.9	2.4
Lymphocytic Leukemia	1.4	1.6	1.2	1.6	1.8	1.3	0.9	1.0	0.7	0.8	0.8	0.9
Acute Lymphocytic Leukemia	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.4	0.4	0.4
Chronic Lymphocytic Leukemia	1.1	1.2	0.9	1.2	1.4	1.0	0.7	0.8	0.5	0.4	0.4	0.5
Other Lymphocytic Leukemia	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Myeloid and Monocytic Leukemia	1.3	1.3	1.3	1.3	1.4	1.3	1.2	1.2	1.2	1.6	1.6	1.5
Acute Myeloid Leukemia	0.8	0.8	0.8	0.9	0.9	0.8	0.8	0.8	0.8	1.1	1.3	1.0
Acute Monocytic Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Chronic Myeloid Leukemia	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.5
Other Myeloid/Monocytic Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Leukemia	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.5	0.0
Other Acute Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0
Aleukemic, Subleukemic and NOS	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.0
Mesothelioma	0.2	0.3	0.2	0.3	0.4	0.2	0.2	0.3	0.1	0.2	0.4	0.0
Kaposi Sarcoma	0.1	0.1	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0
Miscellaneous	3.6	3.5	3.7	3.7	3.7	3.7	3.5	3.2	3.9	3.5	3.3	3.7

¹American Indians/Alaska Natives

²Asians and Pacific Islanders

³Except for urinary bladder (in situ and invasive), only invasive cases are included. --Not applicable

Table B. Average Annual Cancer Incidence Rates by Site, Race, and Sex,¹ 2015-2019, Louisiana

Primary Site <i>Invasive Cancers</i> ²	All races			White			Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	484.3	557.3	429.7	484.6	547.1	437.9	492.1	593.0	420.5
Oral Cavity and Pharynx	13.0	20.3	6.7	14.3	22.0	7.4	9.7	15.9	4.9
Lip	0.6	1.0	0.3	0.8	1.3	0.4	^	^	^
Tongue	4.0	6.1	2.2	4.8	7.1	2.7	2.2	3.7	1.1
Salivary Gland	1.1	1.6	0.9	1.2	1.7	0.8	1.0	1.1	0.9
Floor of Mouth	0.7	1.1	0.4	0.7	1.0	0.4	0.8	1.4	^
Gum and Other Mouth	1.8	2.4	1.3	1.8	2.4	1.3	1.6	2.0	1.1
Nasopharynx	0.6	1.0	0.3	0.5	0.8	0.2	0.7	1.2	^
Tonsil	2.4	4.2	0.7	2.7	4.7	0.9	1.6	3.1	^
Oropharynx	0.8	1.3	0.4	0.9	1.4	0.4	0.7	1.1	^
Hypopharynx	0.7	1.1	0.3	0.6	0.9	0.3	0.9	1.6	^
Other Oral Cavity and Pharynx	0.3	0.5	0.1	0.3	0.6	^	0.3	0.6	^
Digestive System	90.6	112.6	72.3	84.0	103.4	67.2	108.8	139.4	86.2
Esophagus	4.4	7.6	1.7	4.5	8.0	1.5	4.2	6.9	2.2
Stomach	6.8	9.3	4.7	5.4	7.6	3.5	10.6	14.6	7.7
Small Intestine	3.2	3.6	3.0	2.7	3.2	2.3	4.8	5.1	4.7
Colon and Rectum	45.1	52.7	38.8	42.4	49.2	36.6	52.9	63.8	45.0
Colon excluding Rectum	31.5	35.5	28.2	29.3	32.8	26.3	37.9	43.9	33.6
Cecum	6.1	6.3	6.0	5.7	5.9	5.5	7.4	7.6	7.3
Appendix	1.9	1.7	2.1	2.1	1.8	2.5	1.5	1.5	1.6
Ascending Colon	6.0	6.4	5.8	5.5	5.8	5.2	7.6	8.3	7.1
Hepatic Flexure	1.5	1.8	1.2	1.4	1.6	1.2	1.8	2.3	1.4
Transverse Colon	3.0	3.5	2.6	2.7	3.2	2.3	3.8	4.7	3.2
Splenic Flexure	0.9	1.1	0.7	0.7	1.0	0.5	1.4	1.5	1.3
Descending Colon	2.1	2.6	1.7	1.8	2.4	1.4	2.7	3.2	2.4
Sigmoid Colon	8.1	10.1	6.5	7.7	9.4	6.3	9.2	12.0	7.1
Large Intestine, NOS	1.8	2.1	1.7	1.6	1.8	1.5	2.5	2.8	2.3
Rectum and Rectosigmoid Junction	13.7	17.3	10.6	13.1	16.3	10.3	14.9	19.9	11.3
Rectosigmoid Junction	2.6	3.1	2.1	2.5	3.0	2.1	2.7	3.5	2.2
Rectum	11.1	14.1	8.5	10.6	13.3	8.3	12.2	16.4	9.1
Anus, Anal Canal and Anorectum	2.1	1.8	2.3	2.2	1.8	2.6	1.8	2.0	1.7
Liver and Intrahepatic Bile Duct	10.5	17.1	4.8	9.2	14.4	4.6	13.2	23.4	5.2
Liver	9.2	15.6	3.8	8.0	13.0	3.5	11.8	21.4	4.3
Intrahepatic Bile Duct	1.2	1.5	1.0	1.2	1.4	1.1	1.3	2.0	0.9
Gallbladder	1.3	0.9	1.5	1.0	0.7	1.3	1.8	1.5	2.0
Other Biliary	1.5	2.0	1.2	1.5	1.9	1.1	1.6	2.2	1.3
Pancreas	14.4	16.3	12.8	13.8	15.7	12.1	16.4	18.5	14.9
Retroperitoneum	0.3	0.3	0.3	0.3	0.3	0.3	0.3	^	0.4
Peritoneum, Omentum and Mesentery	0.4	^	0.6	0.4	^	0.6	0.4	^	0.5
Other Digestive Organs	0.7	0.7	0.7	0.7	0.6	0.7	0.8	1.1	0.6
Respiratory System	69.3	87.7	54.7	69.1	82.9	58.2	70.9	103.7	47.3

Nose, Nasal Cavity and Middle Ear	0.7	0.9	0.6	0.8	1.1	0.6	0.5	0.6	0.4
Larynx	5.0	8.4	2.1	4.7	7.7	2.2	5.9	10.7	2.2
Lung and Bronchus	63.4	78.2	51.9	63.4	73.9	55.3	64.4	92.1	44.6
Pleura	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	0.1	0.2	^	0.1	^	^	^	^	^
Bones and Joints	0.8	0.9	0.8	0.9	0.9	0.9	0.8	1.0	0.6
Soft Tissue including Heart	3.9	5.0	3.0	4.0	5.3	3.0	3.4	3.8	3.1
Skin excluding Basal and Squamous Melanoma of the Skin	20.4	27.6	15.1	27.9	36.6	21.3	2.0	2.1	2.0
	18.3	24.7	13.6	25.6	33.3	19.8	0.9	0.9	0.9
Other Non-Epithelial Skin	2.1	2.9	1.5	2.3	3.3	1.6	1.1	1.2	1.0
Breast	69.4	1.4	128.4	66.9	1.3	126.5	76.8	1.6	134.9
Female Genital System	23.6	--	44.4	22.5	--	43.4	27.1	--	48.3
Cervix Uteri	4.8	--	9.2	4.3	--	8.6	5.9	--	10.8
Corpus and Uterus, NOS	11.2	--	21.0	10.4	--	20.1	13.6	--	24.0
Corpus Uteri	10.8	--	20.2	10.2	--	19.7	12.8	--	22.6
Uterus, NOS	0.4	--	0.7	0.2	--	0.5	0.8	--	1.4
Ovary	4.8	--	8.9	4.8	--	9.2	4.7	--	8.4
Vagina	0.5	--	0.9	0.4	--	0.8	0.6	--	1.1
Vulva	1.7	--	3.2	1.8	--	3.3	1.6	--	2.9
Other Female Genital Organs	0.7	--	1.2	0.7	--	1.3	0.6	--	1.1
Male Genital System	66.3	144.8	--	60.1	128.4	--	83.2	193.6	--
Prostate	63.3	138.5	--	56.3	120.8	--	81.5	189.8	--
Testis	2.4	4.8	--	3.2	6.3	--	0.9	1.8	--
Penis	0.5	1.2	--	0.4	1.0	--	0.7	1.7	--
Other Male Genital Organs	0.1	0.3	--	0.1	0.3	--	^	^	--
Urinary System	41.6	63.3	24.2	45.1	69.0	25.4	32.7	47.3	21.9
Urinary Bladder	18.0	31.7	7.5	20.7	36.3	8.2	10.8	17.7	5.9
Kidney and Renal Pelvis	22.5	30.2	16.0	23.3	31.0	16.5	21.1	28.7	15.2
Ureter	0.6	0.8	0.4	0.7	1.0	0.4	^	^	^
Other Urinary Organs	0.5	0.7	0.4	0.5	0.8	0.3	0.6	0.7	0.6
Eye and Orbit	0.8	1.0	0.6	1.0	1.2	0.7	0.2	^	^
Brain and Other Nervous System	5.9	7.1	4.8	6.9	8.1	5.8	3.6	4.8	2.7
Brain	5.5	6.6	4.5	6.5	7.6	5.5	3.3	4.4	2.4
Cranial Nerves Other Nervous System	0.4	0.5	0.3	0.4	0.5	0.3	0.3	^	^
Endocrine System	15.4	8.3	22.2	17.6	9.6	25.7	10.6	5.2	15.2
Thyroid	14.7	7.5	21.6	17.0	8.9	25.2	9.6	4.0	14.4
Other Endocrine including Thymus	0.7	0.8	0.6	0.6	0.7	0.5	1.0	1.2	0.8
Lymphoma	21.6	25.8	18.1	23.3	28.0	19.3	16.7	19.2	14.8
Hodgkin Lymphoma	2.8	3.1	2.5	3.1	3.4	2.7	2.4	2.8	2.0
Hodgkin - Nodal	2.8	3.1	2.5	3.0	3.3	2.7	2.4	2.8	2.0
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	18.8	22.6	15.6	20.3	24.6	16.6	14.3	16.3	12.8
NHL - Nodal	12.6	15.3	10.3	13.9	16.8	11.3	9.1	10.8	7.8
NHL - Extranodal	6.2	7.3	5.3	6.4	7.7	5.3	5.2	5.5	5.0
Myeloma	8.2	9.9	6.9	6.2	7.9	4.8	13.9	16.0	12.5

Leukemia	14.1	17.9	11.0	15.3	19.0	12.2	11.2	14.6	8.6
Lymphocytic Leukemia	6.9	9.2	5.0	7.9	10.3	5.9	4.5	6.3	3.2
Acute Lymphocytic Leukemia	1.3	1.5	1.2	1.6	1.7	1.5	0.9	1.2	0.7
Chronic Lymphocytic Leukemia	5.1	7.0	3.6	5.7	7.8	4.1	3.4	4.8	2.3
Other Lymphocytic Leukemia	0.5	0.7	0.3	0.6	0.9	0.3	^	^	^
Myeloid and Monocytic Leukemia	6.6	8.0	5.5	6.8	8.2	5.8	6.1	7.5	4.9
Acute Myeloid Leukemia	4.2	5.0	3.5	4.3	5.0	3.7	3.9	4.8	3.2
Acute Monocytic Leukemia	0.1	0.2	^	0.1	^	^	^	^	^
Chronic Myeloid Leukemia	2.2	2.7	1.8	2.3	2.8	1.9	2.0	2.5	1.6
Other Myeloid/Monocytic Leukemia	0.1	0.2	^	0.1	^	^	^	^	^
Other Leukemia	0.6	0.6	0.5	0.5	0.5	0.5	0.6	0.8	0.5
Other Acute Leukemia	0.2	0.2	0.2	0.2	^	^	0.2	^	^
Aleukemic, Subleukemic and NOS	0.4	0.4	0.4	0.4	0.4	0.4	0.4	^	^
Mesothelioma	1.2	2.0	0.7	1.3	2.0	0.8	1.0	1.9	0.5
Kaposi Sarcoma	0.5	0.9	^	0.3	0.5	^	0.8	1.7	^
Miscellaneous	18.0	21.0	15.6	17.8	21.0	15.2	18.6	21.2	16.8
<i>In Situ Cancers (not included above)</i>									
Breast In Situ	13.5	^	25.3	12.6	^	24.2	16.2	^	28.8

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases in the five-year period.

--Not applicable

Table C1. Average Annual Cancer Incidence Rates by Race and Sex,¹ 2015-2019: U.S., Louisiana, and 7-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site <i>Invasive Cancers</i> ³	White Men				Black Men				White Women				Black Women			
	US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.	
All Sites	486.7	547.1	↑	562.3 #	516.8	593.0	↑	613.6	429.7	437.9	↑	428.2	395.6	420.5	↑	417.5
Oral Cavity and Pharynx	18.4	22.0	↑	24.6	13.3	15.9	↑	18.4	6.6	7.4	↑	6.9	4.8	4.9		4.0
Esophagus	7.5	8.0		8.0	5.5	6.9	↑	8.1	1.7	1.5		1.4	1.9	2.2		2.3
Stomach	8.3	7.6	↓	7.8	12.4	14.6	↑	14.2	4.6	3.5	↓	3.3	7.2	7.7		7.5
Colon excluding Rectum	28.2	32.8	↑	27.9 *	36.0	43.9	↑	36.1 *	23.9	26.3	↑	21.3 *	28.7	33.6	↑	30.9
Rectum and Rectosigmoid Junction	14.0	16.3	↑	14.4	14.2	19.9	↑	19.3	8.8	10.3	↑	9.8	9.2	11.3	↑	11.0
Liver and Intrahepatic Bile Duct	12.7	14.4	↑	13.2	16.8	23.4	↑	28.3 #	4.7	4.6		4.0	5.1	5.2		5.5
Pancreas	14.9	15.7	↑	14.1	16.9	18.5		17.3	11.4	12.1		11.4	14.3	14.9		13.5
Larynx	4.6	7.7	↑	7.3	6.9	10.7	↑	10.6	1.0	2.2	↑	1.7	1.3	2.2	↑	^
Lung and Bronchus	56.6	73.9	↑	60.2 *	69.6	92.1	↑	80.4 *	46.9	55.3	↑	47.9 *	43.4	44.6		38.8 *
Melanoma of the Skin	37.0	33.3	↓	45.0 #	1.1	0.9		^	23.3	19.8	↓	23.2 #	0.9	0.9		^
Breast	1.2	1.3		^	1.8	1.6		^	130.3	126.5	↓	132.4	127.3	134.9	↑	136.6
Cervix Uteri	--	--		--	--	--		--	7.6	8.6	↑	6.1 *	8.3	10.8	↑	10.0
Corpus and Uterus, NOS	--	--		--	--	--		--	27.7	20.1	↓	19.9	27.5	24.0	↓	22.2
Ovary	--	--		--	--	--		--	10.9	9.2	↓	11.6 #	8.6	8.4		9.0
Prostate	104.3	120.8	↑	141.6 #	176.9	189.8	↑	208.4 #	--	--		--	--	--		--
Testis	7.0	6.3	↓	6.7	1.5	1.8		^	--	--		--	--	--		--
Urinary Bladder	35.0	36.3	↑	35.9	18.8	17.7		19.2	8.5	8.2		7.1	6.2	5.9		5.1
Kidney and Renal Pelvis	23.3	31.0	↑	29.6	25.0	28.7	↑	33.0	11.9	16.5	↑	15.0	13.0	15.2	↑	15.3
Brain and Other Nervous System	8.1	8.1		7.7	4.6	4.8		5.9	5.9	5.8		6.5	3.3	2.7		3.2
Thyroid	7.9	8.9	↑	11.2 #	3.5	4.0		4.1	21.9	25.2	↑	26.5	12.4	14.4	↑	17.6 #
Hodgkin Lymphoma	2.9	3.4	↑	3.1	2.7	2.8		2.5	2.3	2.7	↑	1.9	2.2	2.0		^
Non-Hodgkin Lymphoma	24.0	24.6		24.2	16.9	16.3		18.7	16.4	16.6		16.1	11.8	12.8		13.8
Myeloma	8.0	7.9		9.9 #	16.5	16.0		20.5 #	5.0	4.8		4.6	12.3	12.5		17.7 #
Leukemia	18.7	19.0		19.1	13.5	14.6		15.1	11.4	12.2	↑	12.3	9.0	8.6		8.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table C2. Average Annual Cancer Incidence Rates by Race and Sex,¹ 2015-2019: U.S., Louisiana, and 11-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site <i>Invasive Cancers</i> ³	White Men				Black Men				White Women				Black Women			
	US	LA		Ind. Corr.	US	LA		Ind. Corr.	US	LA		Ind. Corr.	US	LA		Ind. Corr.
All Sites	486.7	547.1	↑	526.3 *	516.8	593.0	↑	573.7 *	429.7	437.9	↑	425.5 *	395.6	420.5	↑	408.5 *
Oral Cavity and Pharynx	18.4	22.0	↑	22.9	13.3	15.9	↑	14.6	6.6	7.4	↑	6.7	4.8	4.9		4.2
Esophagus	7.5	8.0		7.7	5.5	6.9	↑	6.5	1.7	1.5		1.5	1.9	2.2		1.8
Stomach	8.3	7.6	↓	7.5	12.4	14.6	↑	13.4	4.6	3.5	↓	3.4	7.2	7.7		6.9
Colon excluding Rectum	28.2	32.8	↑	28.4 *	36.0	43.9	↑	37.5 *	23.9	26.3	↑	22.4 *	28.7	33.6	↑	30.3 *
Rectum and Rectosigmoid Junction	14.0	16.3	↑	14.6	14.2	19.9	↑	18.7	8.8	10.3	↑	9.0	9.2	11.3	↑	11.1
Liver and Intrahepatic Bile Duct	12.7	14.4	↑	15.9	16.8	23.4	↑	26.5 #	4.7	4.6		4.5	5.1	5.2		5.7
Pancreas	14.9	15.7	↑	14.6	16.9	18.5		16.0	11.4	12.1		11.3	14.3	14.9		13.3
Larynx	4.6	7.7	↑	7.3	6.9	10.7	↑	10.1	1.0	2.2	↑	1.9	1.3	2.2	↑	1.9
Lung and Bronchus	56.6	73.9	↑	62.2 *	69.6	92.1	↑	83.3 *	46.9	55.3	↑	48.9 *	43.4	44.6		41.4
Melanoma of the Skin	37.0	33.3	↓	35.5	1.1	0.9		^	23.3	19.8	↓	20.7	0.9	0.9		1.1
Breast	1.2	1.3		1.5	1.8	1.6		1.4	130.3	126.5	↓	133.5 #	127.3	134.9	↑	132.8
Cervix Uteri	^	^		^	^	^		^	7.6	8.6	↑	7.1 *	8.3	10.8	↑	10.1
Corpus and Uterus, NOS	^	^		^	^	^		^	27.7	20.1	↓	20.1	27.5	24.0	↓	21.4
Ovary	^	^		^	^	^		^	10.9	9.2	↓	11.1 #	8.6	8.4		8.5
Prostate	104.3	120.8	↑	122.6	176.9	189.8	↑	187.1	^	^		^	^	^		^
Testis	7.0	6.3	↓	6.5	1.5	1.8		1.5	^	^		^	^	^		^
Urinary Bladder	35.0	36.3	↑	36.5	18.8	17.7		18.8	8.5	8.2		7.9	6.2	5.9		5.7
Kidney and Renal Pelvis	23.3	31.0	↑	28.1 *	25.0	28.7	↑	29.9	11.9	16.5	↑	13.8 *	13.0	15.2	↑	16.1
Brain and Other Nervous System	8.1	8.1		7.1	4.6	4.8		5.4	5.9	5.8		5.9	3.3	2.7		2.9
Thyroid	7.9	8.9	↑	8.9	3.5	4.0		4.2	21.9	25.2	↑	24.0	12.4	14.4	↑	15.3
Hodgkin Lymphoma	2.9	3.4	↑	3.6	2.7	2.8		2.4	2.3	2.7	↑	2.4	2.2	2.0		2.0
Non-Hodgkin Lymphoma	24.0	24.6		24.1	16.9	16.3		19.4 #	16.4	16.6		15.9	11.8	12.8		14.1
Myeloma	8.0	7.9		8.5	16.5	16.0		17.3	5.0	4.8		4.7	12.3	12.5		13.2
Leukemia	18.7	19.0		16.9 *	13.5	14.6		13.3	11.4	12.2	↑	12.1	9.0	8.6		7.9

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table D. Cancer Incidence Rates¹ among American Indians/Alaska Natives and Asians and Pacific Islanders, 2015-2019: U.S. and Louisiana

Primary Site	Male		Female		
<i>Invasive Cancers</i> ²	U.S.	LA	U.S.	LA	
All Sites	295.7	277.0	303.4	250.4	↓
Oral Cavity and Pharynx	11.2	9.6	5.2	5.4	
Esophagus	3.7	^	1.0	^	
Stomach	11.3	7.3	6.8	^	
Colon and rectum	35.6	35.3	26.1	22.8	
Liver and Intrahepatic Bile Duct	18.4	25.0	6.7	5.9	
Pancreas	11.1	6.1	9.2	5.6	↓
Larynx	2.0	^	0.2	^	
Lung and Bronchus	41.6	43.7	27.8	31.3	
Melanoma of the Skin	1.9	^	1.6	^	
Breast	0.6	^	103.8	71.4	↓
Cervix Uteri	--	--	6.1	5.1	
Corpus and Uterus, NOS	--	--	22.7	12.9	↓
Ovary	--	--	8.7	5.8	
Prostate	57.3	52.7	--	--	
Testis	2.6	^	--	--	
Urinary Bladder	15.0	12.2	3.5	^	
Kidney and Renal Pelvis	13.1	11.2	6.4	7.6	
Brain and Other Nervous System	4.1	^	2.9	^	
Thyroid	6.3	^	19.6	19.5	
Hodgkin Lymphoma	1.3	^	1.1	^	
Non-Hodgkin Lymphoma	15.6	15.5	11.0	9.7	
Myeloma	4.8	^	3.2	^	
Leukemia	9.7	8.9	6.3	6.6	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases in the five-year period.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table E1. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Males

	All Sites	Prostate	Lung and Bronchus	Colon and Rectum	Urinary Bladder	Melanoma of the Skin	Kidney and Renal Pelvis	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	Leukemia	Pancreas
Louisiana	547.1	120.8	73.9	49.2	36.3	33.3	31.0	24.6	22.0	19.0	15.7
Acadia	621.8	128.4	93.2	60.1	38.2	32.5	42.2	29.8	22.2	21.0	12.8
Allen	589.3	122.5	83.5	54.6	30.3	^	47.8	37.0	^	^	31.5
Ascension	565.5	149.3	67.5	40.5	30.6	44.0	31.9	25.2	22.0	15.7	14.8
Assumption	572.3	137.4	72.3	47.3	44.9	^	26.7	^	^	^	^
Avoyelles	548.0	123.2	87.6	67.5	40.7	22.7	35.9	19.6	^	21.6	19.4
Beauregard	560.9	108.4	83.5	56.3	31.4	34.3	40.2	34.1	22.3	21.8	^
Bienville	568.0	122.5	75.9	65.1	^	^	^	^	^	^	^
Bossier	538.4	110.5	75.1	43.0	42.0	32.6	33.8	23.2	18.9	23.2	15.3
Caddo	530.8	116.5	70.8	46.1	34.8	27.5	28.6	27.2	24.7	21.6	14.9
Calcasieu	565.0	121.9	79.2	51.5	35.6	31.8	31.8	24.2	18.0	20.9	16.2
Caldwell	502.3	120.7	122.4	^	^	^	^	^	^	^	^
Cameron	464.5	104.9	^	^	^	^	^	^	^	^	^
Catahoula	552.8	107.4	79.1	88.7	^	^	^	^	^	^	^
Claiborne	506.5	118.3	63.4	^	^	^	^	^	^	^	^
Concordia	505.9	113.9	78.8	44.4	^	^	^	^	^	^	^
De Soto	525.7	103.7	72.6	52.2	28.9	^	^	^	^	^	^
East Baton Rouge	565.7	149.9	54.0	39.2	35.6	51.9	28.8	24.5	25.1	19.3	13.9
East Carroll	504.8	^	^	^	^	^	^	^	^	^	^
East Feliciana	564.0	137.4	89.2	40.1	^	44.7	^	^	^	^	^
Evangeline	578.6	91.5	88.6	62.2	45.6	28.7	33.4	35.8	27.8	23.6	^
Franklin	628.9	130.3	117.1	60.9	54.1	^	^	^	^	^	^
Grant	586.8	103.9	96.2	67.5	38.1	32.7	^	^	36.6	^	^
Iberia	587.3	129.2	80.0	63.5	40.4	25.6	32.3	20.8	26.0	22.4	15.0
Iberville	658.8	125.3	97.0	39.9	39.6	54.0	46.5	32.9	^	^	^
Jackson	581.2	143.3	91.7	61.7	^	^	^	^	^	^	^
Jefferson	507.5	105.8	65.5	44.7	39.5	23.4	30.6	24.2	22.1	16.0	15.8
Jefferson Davis	575.4	140.0	95.7	36.1	28.2	36.5	32.6	^	25.6	^	^

Lafayette	535.0	144.3	59.9	41.9	34.9	28.3	34.5	25.0	19.5	18.8	15.9
Lafourche	553.9	111.1	71.4	54.4	37.8	20.6	36.8	26.9	22.4	18.9	18.8
La Salle	538.1	91.7	99.5	81.6	53.0	^	^	^	^	^	^
Lincoln	472.8	116.0	55.2	50.2	23.9	28.0	^	26.8	24.2	^	^
Livingston	532.7	101.1	84.4	46.7	28.9	42.6	32.2	25.2	25.0	19.7	12.0
Madison	535.8	113.8	^	^	^	^	^	^	^	^	^
Morehouse	605.7	129.6	84.6	88.1	31.9	^	^	^	37.1	^	^
Natchitoches	573.7	123.6	75.1	61.1	33.3	31.6	28.9	^	25.9	26.8	24.7
Orleans	468.0	113.4	51.9	40.9	29.4	40.3	17.7	23.5	21.5	15.3	14.0
Ouachita	619.2	138.4	87.1	50.1	33.6	49.8	37.8	27.4	23.4	23.3	21.5
Plaquemines	514.6	122.5	67.5	41.0	48.1	^	^	^	^	^	^
Pointe Coupee	564.4	119.7	49.3	48.8	49.9	29.5	39.0	33.8	^	^	^
Rapides	536.5	113.9	68.2	59.6	29.3	33.3	25.5	27.8	20.7	22.8	15.0
Red River	519.5	96.4	108.2	^	^	^	^	^	^	^	^
Richland	502.9	101.3	105.7	44.8	^	45.6	^	^	^	^	^
Sabine	553.2	135.7	70.3	44.6	32.5	28.5	41.2	^	26.2	^	^
St. Bernard	518.8	90.7	89.9	52.5	35.5	^	33.4	25.7	16.5	^	^
St. Charles	499.6	115.9	48.1	50.5	45.5	24.4	25.6	16.5	23.8	21.5	^
St. Helena	512.3	118.2	^	^	^	^	^	^	^	^	^
St. James	617.9	155.5	58.6	104.9	^	^	^	^	^	^	^
St. John the Baptist	504.8	75.8	69.2	38.7	45.4	^	27.5	32.1	^	^	^
St. Landry	596.4	135.3	75.2	72.1	33.6	28.6	40.1	23.0	24.7	21.0	14.6
St. Martin	620.1	143.2	94.5	70.4	40.5	18.1	42.3	27.5	22.0	^	21.6
St. Mary	574.3	112.3	99.1	56.3	34.6	25.6	29.5	37.3	17.9	23.1	20.0
St. Tammany	557.9	118.0	69.0	44.7	43.6	47.2	31.6	24.3	22.8	16.6	17.3
Tangipahoa	516.4	116.7	77.5	45.8	33.2	27.1	27.1	22.4	22.0	14.1	14.3
Tensas	297.3	^	^	^	^	^	^	^	^	^	^
Terrebonne	589.2	118.3	94.7	57.0	41.9	27.2	30.8	28.1	19.9	23.7	15.5
Union	470.9	93.1	86.7	38.1	34.3	^	^	27.7	^	^	^
Vermilion	585.1	154.1	69.2	57.7	42.8	30.3	37.8	23.5	16.8	21.6	13.4
Vernon	571.1	89.9	116.0	64.0	42.9	27.2	22.3	18.0	19.4	^	17.5
Washington	572.4	85.4	94.2	58.4	31.8	33.6	35.9	25.5	20.2	23.6	20.5
Webster	557.2	125.2	98.7	53.6	39.3	27.7	23.4	^	^	19.9	18.5

West Baton Rouge	552.0	139.9	76.4	^	^	46.1	^	^	^	^	^
West Carroll	546.7	123.2	107.4	84.0	^	^	^	^	^	^	^
West Feliciana	505.5	132.1	62.9	^	^	^	^	^	^	^	^
Winn	548.4	81.1	86.5	^	^	^	^	^	51.9	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table E2. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Females

	All Sites	Breast	Lung and Bronchus	Colon and Rectum	Thyroid	Corpus and Uterus, NOS	Melanoma of the Skin	Non-Hodgkin Lymphoma	Kidney and Renal Pelvis	Leukemia	Pancreas
Louisiana	437.9	126.5	55.3	36.6	25.2	20.1	19.8	16.6	16.5	12.2	12.1
Acadia	421.9	113.2	53.1	37.6	24.2	17.6	11.8	18.0	20.2	13.7	13.5
Allen	452.9	97.3	60.9	58.9	^	^	^	^	^	^	^
Ascension	450.0	138.7	63.9	32.0	30.6	17.7	17.9	9.7	18.4	9.1	10.5
Assumption	391.7	86.8	64.3	44.6	^	^	^	^	^	^	^
Avoyelles	376.6	87.0	47.0	45.3	22.4	19.3	^	19.5	24.5	^	^
Beauregard	434.9	109.0	60.2	44.1	28.8	26.6	^	22.9	^	^	^
Bienville	499.3	111.9	70.0	^	^	^	^	^	^	^	^
Bossier	443.5	117.9	65.0	40.3	35.1	16.2	27.0	17.6	10.9	11.6	12.8
Caddo	462.9	127.8	58.2	36.3	32.5	25.2	19.1	14.0	12.7	12.3	12.6
Calcasieu	443.9	123.9	57.7	36.5	21.3	20.1	19.6	15.4	17.6	14.7	11.9
Caldwell	522.5	104.6	94.4	63.3	^	^	^	^	^	^	^
Cameron	459.2	110.8	^	^	^	^	^	^	^	^	^
Catahoula	436.1	113.6	62.6	^	^	^	^	^	^	^	^
Claiborne	459.6	132.8	50.3	59.9	^	^	^	^	^	^	^
Concordia	426.2	83.9	58.6	60.8	^	^	^	^	^	^	^
De Soto	439.6	103.5	47.6	40.0	^	^	^	25.7	^	^	^
East Baton Rouge	417.7	132.1	39.2	29.3	25.0	19.4	29.7	17.4	14.2	13.6	11.0
East Carroll	579.1	232.6	^	^	^	^	^	^	^	^	^
East Feliciana	467.5	147.8	64.1	^	^	^	^	^	^	^	^
Evangeline	463.7	115.8	69.9	47.2	^	25.9	^	20.0	31.0	^	21.1
Franklin	490.7	115.3	65.0	60.7	^	^	^	^	^	^	^
Grant	429.0	112.3	62.1	45.9	39.7	^	^	^	^	^	^
Iberia	425.0	137.2	57.5	41.0	17.3	21.1	12.4	14.5	17.1	11.6	10.1
Iberville	416.3	124.7	61.3	^	^	^	^	^	^	^	^
Jackson	415.0	103.4	57.8	42.1	^	^	^	^	^	^	^
Jefferson	433.3	136.4	50.5	33.2	25.4	20.3	15.5	17.1	13.2	12.6	12.4
Jefferson Davis	478.7	119.6	63.6	58.2	^	29.4	^	19.9	21.6	^	^

Lafayette	432.2	136.9	51.2	34.4	24.8	21.6	15.8	19.0	15.6	11.4	11.6
Lafourche	429.5	124.5	52.2	42.3	26.0	19.2	14.1	16.8	20.7	13.8	11.8
La Salle	402.4	102.6	64.1	48.8	^	^	^	^	^	^	^
Lincoln	372.9	120.3	53.9	33.4	^	23.8	^	^	^	^	^
Livingston	437.6	113.1	65.3	34.8	26.0	19.0	17.5	16.5	18.1	13.6	10.5
Madison	414.4	^	^	^	^	^	^	^	^	^	^
Morehouse	494.3	133.5	80.3	38.4	^	^	^	^	^	^	^
Natchitoches	483.1	151.2	49.9	43.7	^	23.0	^	^	^	^	^
Orleans	409.6	140.7	39.0	29.6	15.7	20.4	27.5	13.5	9.6	10.7	9.7
Ouachita	465.6	124.9	62.2	36.1	28.8	15.1	31.0	15.7	16.4	14.6	13.2
Plaquemines	377.0	98.2	70.0	^	^	^	^	^	^	^	^
Pointe Coupee	441.2	128.4	35.6	32.8	^	^	^	^	^	^	^
Rapides	414.3	108.7	52.5	33.9	28.0	19.0	21.3	19.4	12.4	14.5	13.8
Red River	322.0	98.8	^	^	^	^	^	^	^	^	^
Richland	449.9	115.4	55.8	37.6	^	^	^	^	^	^	^
Sabine	460.9	140.4	53.7	40.4	^	^	^	^	^	^	^
St. Bernard	410.4	112.4	65.6	28.6	20.3	24.3	^	^	20.5	^	^
St. Charles	442.4	131.5	56.1	30.0	23.2	22.6	^	17.6	^	15.9	16.2
St. Helena	486.0	145.2	85.6	^	^	^	^	^	^	^	^
St. James	447.8	120.3	41.4	42.9	^	^	^	^	^	^	^
St. John the Baptist	465.2	124.3	45.5	44.4	35.5	29.0	^	25.4	^	^	^
St. Landry	472.0	119.9	66.9	49.4	27.9	23.6	19.8	19.5	20.4	12.3	17.7
St. Martin	455.8	133.7	61.5	41.2	28.1	23.8	^	19.5	13.9	^	^
St. Mary	437.9	113.0	64.0	39.3	^	22.4	^	22.7	24.4	^	^
St. Tammany	444.7	139.5	49.8	33.0	24.5	17.1	24.1	17.1	14.9	13.7	11.8
Tangipahoa	412.5	109.5	50.7	35.0	15.9	22.5	20.0	15.7	18.3	9.4	12.2
Tensas	462.3	^	^	^	^	^	^	^	^	^	^
Terrebonne	466.1	138.3	62.3	43.0	21.7	20.1	16.7	22.0	17.7	11.8	15.3
Union	533.3	118.5	69.7	42.7	51.9	^	^	^	^	^	^
Vermilion	457.6	127.2	66.4	38.2	26.0	18.2	19.8	21.0	20.8	9.6	14.6
Vernon	501.5	117.7	74.6	49.7	25.4	34.8	23.5	^	21.0	^	^
Washington	456.4	128.5	76.4	33.6	22.7	12.4	18.2	16.7	24.1	16.2	^
Webster	479.0	124.1	49.6	42.2	48.4	26.0	^	19.4	20.7	^	18.5

West Baton Rouge	420.2	123.4	81.2	^	^	^	^	^	^	^	^
West Carroll	484.1	144.0	73.3	39.4	^	^	^	^	^	^	^
West Feliciana	372.8	155.6	^	^	^	^	^	^	^	^	^
Winn	484.3	107.5	57.8	63.7	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period

Table E3. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Males

	All Sites	Prostate	Lung and Bronchus	Colon and Rectum	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	Pancreas	Urinary Bladder	Non-Hodgkin Lymphoma	Myeloma	Oral Cavity and Pharynx
Louisiana	593.0	189.8	92.1	63.8	28.7	23.4	18.5	17.7	16.3	16.0	15.9
Acadia	606.0	145.7	113.0	91.5	^	^	^	^	^	^	^
Allen	591.2	200.5	^	^	^	^	^	^	^	^	^
Ascension	570.7	201.3	62.2	67.0	^	^	^	^	^	^	^
Assumption	579.1	125.3	110.9	104.1	^	^	^	^	^	^	^
Avoyelles	740.0	176.8	140.7	94.1	^	^	^	^	^	^	^
Beauregard	560.8	189.1	^	^	^	^	^	^	^	^	^
Bienville	656.7	243.7	^	^	^	^	^	^	^	^	^
Bossier	504.6	179.1	64.0	57.3	^	^	^	^	^	^	^
Caddo	598.6	166.8	109.2	68.6	28.0	24.4	23.6	16.4	14.2	15.6	23.0
Calcasieu	635.5	195.4	106.4	72.4	30.8	26.6	20.7	16.2	^	^	14.9
Caldwell	457.1	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	768.2	^	^	^	^	^	^	^	^	^	^
Claiborne	616.5	179.3	132.8	72.3	^	^	^	^	^	^	^
Concordia	476.0	180.9	112.2	^	^	^	^	^	^	^	^
De Soto	757.5	213.2	127.7	95.7	^	^	^	^	^	^	^
East Baton Rouge	614.8	203.4	82.6	55.6	32.4	31.4	18.9	17.0	19.1	19.5	19.0
East Carroll	761.2	283.0	^	^	^	^	^	^	^	^	^
East Feliciana	688.5	246.2	131.0	64.4	^	^	^	^	^	^	^
Evangeline	620.8	147.0	107.2	^	^	^	^	^	^	^	^
Franklin	672.6	225.1	^	^	^	^	^	^	^	^	^
Grant	475.8	^	^	^	^	^	^	^	^	^	^
Iberia	630.5	160.4	85.5	82.5	^	^	40.5	^	^	^	^
Iberville	772.4	245.1	108.1	71.6	^	35.3	^	^	^	^	^
Jackson	646.4	184.2	135.9	^	^	^	^	^	^	^	^
Jefferson	574.9	183.4	92.5	54.0	27.6	24.6	15.7	19.3	22.7	20.4	12.0
Jefferson Davis	514.6	183.2	^	^	^	^	^	^	^	^	^

Lafayette	567.2	161.3	92.5	73.6	27.9	29.0	13.9	^	^	20.0	12.3
Lafourche	607.7	147.8	98.7	77.7	^	^	^	^	^	^	^
La Salle	512.1	^	^	^	^	^	^	^	^	^	^
Lincoln	538.8	197.4	89.2	^	^	^	^	^	^	^	^
Livingston	695.6	251.6	^	^	^	^	^	^	^	^	^
Madison	614.5	192.9	^	^	^	^	^	^	^	^	^
Morehouse	652.1	243.0	121.2	80.9	^	^	^	^	^	^	^
Natchitoches	529.6	137.9	93.6	73.5	^	^	^	^	^	^	^
Orleans	532.6	167.5	83.6	57.1	28.0	25.6	15.1	18.3	18.2	13.6	11.7
Ouachita	593.3	233.2	100.0	58.8	26.9	^	15.5	15.4	^	^	11.9
Plaquemines	634.6	158.8	^	^	^	^	^	^	^	^	^
Pointe Coupee	569.7	203.4	77.0	80.7	^	^	^	^	^	^	^
Rapides	618.2	208.6	98.7	70.2	23.1	17.0	^	21.4	^	^	19.0
Red River	554.2	^	^	^	^	^	^	^	^	^	^
Richland	728.3	211.5	148.0	^	^	^	^	^	^	^	^
Sabine	313.7	^	^	^	^	^	^	^	^	^	^
St. Bernard	501.3	141.8	^	^	^	^	^	^	^	^	^
St. Charles	567.7	223.1	^	^	^	^	^	^	^	^	^
St. Helena	671.3	248.8	^	^	^	^	^	^	^	^	^
St. James	509.2	162.6	93.8	^	^	^	^	^	^	^	^
St. John the Baptist	589.2	221.4	78.3	46.1	39.2	^	^	^	^	^	^
St. Landry	671.2	184.6	103.9	96.3	23.1	30.9	26.7	^	^	^	^
St. Martin	693.1	197.5	85.9	94.6	^	^	48.1	^	^	^	^
St. Mary	496.0	155.9	63.9	56.3	^	^	^	^	^	^	^
St. Tammany	610.3	232.4	58.6	80.9	29.9	^	29.7	26.6	^	^	^
Tangipahoa	635.9	240.5	108.8	52.4	33.4	25.3	^	^	^	^	^
Tensas	515.1	239.5	^	^	^	^	^	^	^	^	^
Terrebonne	696.7	212.0	140.5	70.3	^	26.6	^	^	^	^	^
Union	608.5	216.1	150.0	^	^	^	^	^	^	^	^
Vermilion	726.1	174.0	110.0	^	^	^	^	^	^	^	^
Vernon	587.6	219.8	^	^	^	^	^	^	^	^	^
Washington	663.6	205.2	92.1	80.9	^	^	^	^	^	^	^
Webster	545.4	188.1	99.1	55.1	^	^	^	^	^	^	^

West Baton Rouge	695.5	268.0	86.3	^	^	^	^	^	^	^	^
West Carroll	552.8	^	^	^	^	^	^	^	^	^	^
West Feliciana	678.1	223.2	114.5	76.2	^	^	^	^	^	^	^
Winn	497.9	168.8	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table E4. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Females

	All Sites	Breast	Colon and Rectum	Lung and Bronchus	Corpus and Uterus, NOS	Kidney and Renal Pelvis	Pancreas	Thyroid	Non-Hodgkin Lymphoma	Myeloma	Cervix Uteri
Louisiana	420.5	134.9	45.0	44.6	24.0	15.2	14.9	14.4	12.8	12.5	10.8
Acadia	469.8	125.9	59.2	75.5	^	^	^	^	^	^	^
Allen	496.4	^	^	^	^	^	^	^	^	^	^
Ascension	373.8	133.1	28.6	29.0	^	^	^	^	^	^	^
Assumption	454.2	157.6	^	^	^	^	^	^	^	^	^
Avoyelles	428.5	169.5	^	^	^	^	^	^	^	^	^
Beauregard	413.2	^	^	^	^	^	^	^	^	^	^
Bienville	385.4	115.2	^	^	^	^	^	^	^	^	^
Bossier	440.9	147.2	47.1	53.9	31.7	^	26.1	23.7	^	^	^
Caddo	427.3	128.6	50.3	48.4	29.1	12.4	15.4	11.8	14.1	12.8	11.1
Calcasieu	449.6	127.4	45.7	52.8	19.7	15.5	22.6	^	15.4	^	13.7
Caldwell	405.1	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	289.3	^	^	^	^	^	^	^	^	^	^
Claiborne	403.4	166.2	^	^	^	^	^	^	^	^	^
Concordia	360.9	130.8	^	^	^	^	^	^	^	^	^
De Soto	510.8	165.8	^	^	^	^	^	^	^	^	^
East Baton Rouge	420.2	132.5	43.4	38.7	23.4	15.4	14.5	18.7	15.6	18.4	10.0
East Carroll	537.6	^	^	141.0	^	^	^	^	^	^	^
East Feliciana	442.1	167.8	^	^	^	^	^	^	^	^	^
Evangeline	475.6	112.1	^	80.9	^	^	^	^	^	^	^
Franklin	354.6	93.7	^	^	^	^	^	^	^	^	^
Grant	411.6	^	^	^	^	^	^	^	^	^	^
Iberia	435.8	158.5	44.7	47.0	^	^	^	^	^	^	^
Iberville	437.9	147.6	38.5	45.8	^	^	^	^	^	^	^
Jackson	396.5	179.3	^	^	^	^	^	^	^	^	^
Jefferson	447.1	148.3	45.2	41.5	25.5	22.8	13.4	13.8	13.5	12.4	11.7
Jefferson Davis	408.3	175.6	^	^	^	^	^	^	^	^	^

Lafayette	443.1	156.9	47.7	48.5	25.3	15.1	13.6	13.2	^	12.9	^
Lafourche	445.5	121.0	^	^	^	^	^	^	^	^	^
La Salle	395.8	^	^	^	^	^	^	^	^	^	^
Lincoln	395.9	138.0	^	45.4	^	^	^	^	^	^	^
Livingston	421.3	133.3	^	^	^	^	^	^	^	^	^
Madison	341.6	157.3	^	^	^	^	^	^	^	^	^
Morehouse	422.4	102.1	81.4	^	^	^	^	^	^	^	^
Natchitoches	477.7	139.7	71.9	49.8	^	^	^	^	^	^	^
Orleans	377.9	120.4	39.1	43.1	19.3	13.6	12.7	13.3	14.2	9.1	9.5
Ouachita	443.9	123.9	53.0	47.6	34.9	17.6	24.0	12.9	11.4	^	14.0
Plaquemines	601.5	193.0	^	^	^	^	^	^	^	^	^
Pointe Coupee	351.1	113.6	56.1	^	^	^	^	^	^	^	^
Rapides	414.4	130.0	47.6	49.1	17.0	^	13.6	^	^	15.9	^
Red River	383.7	^	^	^	^	^	^	^	^	^	^
Richland	472.1	98.7	71.8	^	^	^	^	^	^	^	^
Sabine	428.2	153.2	^	^	^	^	^	^	^	^	^
St. Bernard	496.4	134.3	^	^	^	^	^	^	^	^	^
St. Charles	462.3	163.4	46.3	^	^	^	^	^	^	^	^
St. Helena	404.7	150.0	^	^	^	^	^	^	^	^	^
St. James	488.3	181.4	55.0	47.0	^	^	^	^	^	^	^
St. John the Baptist	362.5	120.1	37.0	36.5	^	^	^	^	^	^	^
St. Landry	506.3	182.7	56.2	58.1	36.3	16.2	17.3	^	^	^	^
St. Martin	370.0	119.8	38.5	40.0	^	^	^	^	^	^	^
St. Mary	444.7	146.7	49.0	49.6	33.9	^	^	^	^	^	^
St. Tammany	418.2	150.2	43.4	42.1	21.1	^	^	21.3	^	^	^
Tangipahoa	407.6	139.1	33.3	36.6	23.4	18.7	^	^	^	^	^
Tensas	375.8	^	^	^	^	^	^	^	^	^	^
Terrebonne	425.2	142.5	47.7	67.6	30.2	^	^	^	^	^	^
Union	502.1	152.3	^	^	^	^	^	^	^	^	^
Vermilion	428.1	128.9	^	^	^	^	^	^	^	^	^
Vernon	458.5	^	^	^	^	^	^	^	^	^	^
Washington	484.7	135.0	44.5	42.3	^	^	^	^	^	^	^
Webster	414.9	109.4	52.0	45.9	^	^	^	^	^	^	^

West Baton Rouge	468.4	158.7	^	^	^	^	^	^	^	^	^
West Carroll	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	440.6	155.3	^	^	^	^	^	^	^	^	^
Winn	375.2	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases.

Table F1. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Males

Primary Site				New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region				
Invasive cancers ³				U.S. ⁴		LA																
All Sites				486.7	547.1	↑	497.7	*	554.1		555.8		573.6	#	564.5		546.7		538.3		564.1	
Prostate				104.3	120.8	↑	106.8	*	132.6	#	114.1	*	135.1	#	122.1		107.4	*	116.6		125.4	
Lung and Bronchus				56.6	73.9	↑	63.6	*	68.2	*	73.2		75.8		81.4	#	84.1	#	75.1		89.6	#
Colon and Rectum				42.2	49.2	↑	43.9	*	42.8	*	50.1		55.7	#	49.7		62.0	#	47.1		53.3	
Melanoma of the Skin				37.0	33.3	↓	28.0	*	43.0	#	34.5		27.7	*	31.5		29.4		28.6	*	39.1	#
Urinary Bladder				35.0	36.3	↑	36.7		33.7		41.6	#	37.5		34.4		35.0		35.7		32.7	
Non-Hodgkin Lymphoma				24.0	24.6		24.3		24.5		24.9		26.4		25.3		24.2		22.8		24.3	
Kidney and Renal Pelvis				23.3	31.0	↑	26.9	*	29.9		31.9		36.1	#	34.6		26.8		31.0		31.4	
Leukemia				18.7	19.0		15.1	*	18.2		19.3		20.2		21.0		21.4		21.9		19.6	
Oral Cavity and Pharynx				18.4	22.0	↑	21.5		23.5		22.4		21.2		19.3		21.7		22.2		22.0	
Pancreas				14.9	15.7	↑	15.2		13.9		16.6		16.1		16.6		15.7		17.0		16.1	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F2. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	429.7	437.9	↑	425.3 *	425.8 *	443.5	441.0	447.4	426.5	456.9 #	461.4 #
Breast	130.3	126.5	↓	135.5 #	125.1	133.1 #	128.2	118.6	106.1 *	125.2	122.0
Lung and Bronchus	46.9	55.3	↑	48.9 *	51.9	54.3	58.3	59.2	57.3	58.0	64.4 #
Colon and Rectum	32.7	36.6	↑	32.0 *	32.1 *	36.4	39.1	41.4	42.3 #	39.8	39.8
Corpus and Uterus, NOS	27.7	20.1	↓	20.5	18.9	18.4	21.3	22.8	21.8	22.2	17.9
Melanoma of the Skin	23.3	19.8	↓	18.9	22.4 #	19.2	14.5 *	19.1	20.9	20.2	25.6
Thyroid	21.9	25.2	↑	22.1 *	24.7	24.2	24.2	20.9	28.0	33.3 #	29.1
Non-Hodgkin Lymphoma	16.4	16.6		15.8	15.4	18.3	19.1 #	17.1	17.3	15.5	14.1
Kidney and Renal Pelvis	11.9	16.5	↑	12.6 *	16.3	16.9	18.6	18.9	16.7	15.0	19.5
Pancreas	11.4	12.1		11.5	10.9	12.5	12.8	12.5	11.8	12.8	13.7
Leukemia	11.4	12.2	↑	12.1	12.3	13.2	11.1	14.4	10.1	11.9	12.6

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F3. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Males

Primary Site				New Orleans Region	Baton Rouge Region	Southwest Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	516.8	593.0	↑	543.9 *	628.1 #	613.9	612.6	612.0	606.9	585.0	608.5
Prostate	176.9	189.8	↑	171.8 *	213.1 #	207.1 #	168.2 *	194.2	198.8	173.4 *	220.9 #
Lung and Bronchus	69.6	92.1	↑	85.6	88.6	83.7	92.5	99.2	100.6	101.8	105.2
Colon and Rectum	50.3	63.8	↑	56.3 *	60.2	64.4	80.7 #	71.8	69.7	65.5	61.8
Kidney and Renal Pelvis	25.0	28.7	↑	27.6	31.9	32.0	26.5	31.5	23.0	25.6	32.0
Urinary Bladder	18.8	17.7		18.6	18.8	17.3	16.4	13.4	21.7	18.1	13.9
Pancreas	16.9	18.5		15.5	16.8	19.2	25.2 #	20.5	13.5	20.9	19.3
Non-Hodgkin Lymphoma	16.9	16.3		19.5	17.4	17.3	13.6	14.5	13.2	14.2	14.1
Liver and Intrahepatic Bile Duct	16.8	23.4	↑	25.6	29.3 #	21.6	26.1	26.2	15.9 *	21.7	5.8 *
Myeloma	16.5	16.0		15.4	20.6 #	13.8	14.6	13.7	12.9	16.7	13.3
Leukemia	13.5	14.6		11.8	14.7	20.9 #	16.6	16.4	22.4 #	12.1 #	10.9

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F4. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	395.6	420.5	↑	399.4 *	414.5	436.5	448.6 #	447.6	405.3	431.0	423.9
Breast	127.3	134.9	↑	128.9	135.4	145.2	151.5 #	131.3	129.7	133.8	124.5
Lung and Bronchus	43.4	44.6		42.6	39.0 *	47.5	52.2 #	49.0	44.4	46.7	46.0
Colon and Rectum	37.8	45.0	↑	40.9	41.9	43.0	50.1	44.7	44.0	50.2	52.0
Corpus and Uterus, NOS	27.5	24.0	↓	21.0	21.6	24.9	25.7	24.0	19.1	28.9 #	32.0 #
Pancreas	14.3	14.9		13.0	14.6	11.9	13.9	21.5 #	13.8	16.2	21.0 #
Kidney and Renal Pelvis	13.0	15.2	↑	16.6	15.0	15.0	15.0	16.3	13.0	12.3	18.2
Thyroid	12.4	14.4	↑	13.6	17.2	18.6	14.2	^	11.2	13.0	12.9
Myeloma	12.3	12.5		10.1	16.9 #	14.9	10.0	^	11.1	13.4	10.4
Non-Hodgkin Lymphoma	11.8	12.8		14.2	14.1	10.4	11.1	15.2	9.1	13.1	9.3
Leukemia	9.0	8.6		7.6	7.2	7.1	11.1	9.4	7.2	10.2	10.5

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G1. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Males

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	486.7	547.1	↑	498.4 *	568.3 #	558.0	573.5 #	564.5	546.7	538.3	564.1	544.5
Prostate	104.3	120.8	↑	107.4 *	145.9 #	114.8	137.1 #	122.1	107.4 *	116.6	125.4	111.5 *
Lung and Bronchus	56.6	73.9	↑	63.8 *	61.7 *	77.7	73.9	81.4 #	84.1 #	75.1	89.6 #	75.5
Colon and Rectum	42.2	49.2	↑	43.7 *	40.0 *	55.1 #	55.6 #	49.7	62.0 #	47.1	53.3	46.9
Melanoma of the Skin	37.0	33.3	↓	27.9 *	48.1 #	23.6 *	27.9 *	31.5	29.4	28.6 *	39.1 #	40.7 #
Urinary Bladder	35.0	36.3	↑	37.1	34.8	40.1	37.8	34.4	35.0	35.7	32.7	37.1
Non-Hodgkin Lymphoma	24.0	24.6		24.2	24.8	26.7	25.5	25.3	24.2	22.8	24.3	24.3
Kidney and Renal Pelvis	23.3	31.0	↑	26.8 *	30.0	31.3	36.6 #	34.6	26.8	31.0	31.4	31.1
Leukemia	18.7	19.0		15.4 *	18.6	20.7	19.9	21.0	21.4	21.9	19.6	17.4
Oral Cavity and Pharynx	18.4	22.0	↑	21.5	23.7	21.3	21.5	19.3	21.7	22.2	22.0	23.0
Pancreas	14.9	15.7	↑	15.0	14.2	16.4	15.7	16.6	29.4	17.0	16.1	15.6

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G2. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
White Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	429.7	437.9	↑	423.7 *	425.8	442.4	441.0	447.4	426.5	456.9 #	461.4 #	437.9
Breast	130.3	126.5	↓	134.3 #	134.0 #	125.6	129.4	118.6	106.1 *	125.2	122.0	126.6
Lung and Bronchus	46.9	55.3	↑	49.7 *	47.3 *	56.6	57.8	59.2	57.3	58.0	64.4 #	55.6
Colon and Rectum	32.7	36.6	↑	31.8 *	30.0 *	41.0	39.0	41.4	42.3 #	39.8	39.8	34.0
Corpus and Uterus, NOS	27.7	20.1	↓	20.2	18.6	20.4	21.2	22.8	21.8	22.2	17.9	18.2
Melanoma of the Skin	23.3	19.8	↓	18.6	24.7 #	14.2 *	15.1 *	19.1	20.9	20.2	25.6 #	21.3
Thyroid	21.9	25.2	↑	22.1 *	26.2	23.7	24.8	20.9	28.0	33.3 #	29.1	23.1
Non-Hodgkin Lymphoma	16.4	16.6		15.9	14.9	20.0 #	18.7	17.1	17.3	15.5	14.1	16.6
Kidney and Renal Pelvis	11.9	16.5	↑	12.7 *	15.0	18.7	18.1	18.9	16.7	15.0	19.5	17.1
Pancreas	11.4	12.1		11.3	10.6	13.2	13.2	12.5	11.8	12.8	13.7	11.4
Leukemia	11.4	12.2	↑	12.0	12.9	12.4	10.8	14.4	10.1	11.9	12.6	13.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G3. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Males

Primary Site				New Orleans Region	Baton Rouge Region	Southwest Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	516.8	593.0	↑	545.4 *	626.6 #	579.3	628.2 #	612.0	606.9	585.0	608.5	638.7 #
Prostate	176.9	189.8	↑	171.9 *	211.1 #	185.8	169.8 *	194.2	198.8	173.4 *	220.9 #	232.4 #
Lung and Bronchus	69.6	92.1	↑	85.4	85.8	87.8	96.2	99.2	100.6	101.8	105.2	84.5
Colon and Rectum	50.3	63.8	↑	56.5 *	59.5	57.8	84.0 #	71.8	69.7	65.5	61.8	68.8
Kidney and Renal Pelvis	25.0	28.7	↑	28.0	32.1	31.8	25.8	31.5	23.0	25.6	32.0	30.6
Urinary Bladder	18.8	17.7		18.5	18.4	16.2	16.9	13.4	21.7	18.1	13.9	20.2
Pancreas	16.9	18.5		15.4	17.8	15.0	26.6 #	20.5	13.5	20.9	19.3	20.4
Non-Hodgkin Lymphoma	16.9	16.3		19.8	18.0	15.1	14.5	14.5	13.2	14.2	14.1	14.5
Liver and Intrahepatic Bile Duct	16.8	23.4	↑	25.4	30.2 #	20.5	27.7	26.2	15.9 *	21.7	5.8 *	23.4
Myeloma	16.5	16.0		15.1	20.7 #	14.2	15.2	13.7	12.9	16.7	13.3	17.5
Leukemia	13.5	14.6		11.9	14.2	20.2	18.1	16.4	22.4 #	12.1	10.9	16.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G4. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2015-2019:
Black Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	395.6	420.5	↑	401.7 *	414.4	429.1	449.5 #	447.6	405.3	431.0	423.9	424.5
Breast	127.3	134.9	↑	129.7	134.4	143.2	152.4 #	131.3	129.7	133.8	124.5	142.0
Lung and Bronchus	43.4	44.6		43.3	39.5	47.4	52.6 #	49.0	44.4	46.7	46.0	39.0
Colon and Rectum	37.8	45.0	↑	40.8	43.1	43.8	50.2	44.7	44.0	50.2	52.0	39.0
Corpus and Uterus, NOS	27.5	24.0	↓	21.1	21.6	25.8	24.8	24.0	19.1	28.9 #	32.0 #	23.4
Pancreas	14.3	14.9		13.2	13.6	13.6	14.1	21.5 #	13.8	16.2	21.0 #	13.5
Kidney and Renal Pelvis	13.0	15.2	↑	16.7	14.7	13.2	15.4	16.3	13.0	12.3	18.2	17.1
Thyroid	12.4	14.4	↑	13.7	17.2	16.3	13.2	^	11.2	13.0	12.9	20.8 #
Myeloma	12.3	12.5		10.1	18.0 #	14.2	10.4	^	11.1	13.4	10.4	12.5
Non-Hodgkin Lymphoma	11.8	12.8		14.2	14.0	9.3	11.6	15.2	9.1	13.1	9.3	13.0
Leukemia	9.0	8.6		7.7	7.5	7.7	10.8	9.4	7.2	10.2	10.5	6.5

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table H1. Number of Children and Adolescent Cancer Diagnoses,¹ 2015-2019 Combined, Louisiana

ICCC ² Primary Site	All Races			Whites			Blacks		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites including Borderline and Benign Brain/CNS Tumors	1241	665	576	841	459	382	378	198	180
I Leukemias, myeloproliferative & myelodysplastic diseases	262	154	108	180	102	78	79	50	29
II Lymphomas & reticuloendothelial neoplasms	162	108	54	106	76	30	52	30	22
III CNS & miscellaneous intracranial & intraspinal neoplasms	322	169	153	220	118	102	99	51	48
IV Neuroblastoma & other peripheral nervous cell tumors	39	22	17	25	14	11	13	7	6
V Retinoblastoma	18	9	9	10	7	^	8	^	6
VI Renal tumors	43	19	24	28	15	13	14	^	10
VII Hepatic tumors	17	9	8	13	8	^	^	^	^
VIII Malignant bone tumors	43	28	15	31	19	12	12	9	^
IX Soft tissue & other extraosseous sarcomas	80	44	36	43	25	18	35	19	16
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads	67	40	27	46	33	13	20	6	14
XI Other malignant epithelial neoplasms & malignant melanomas	138	39	99	108	28	80	25	9	16
XII Other & unsecified malignant neoplasms	^	^	^	^	^	^	^	^	^
Not classified by SEER or in situ	49	24	25	30	14	16	18	10	8

¹Children and adolescent cancers include patients aged 0-19 years.

²ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

³Group I includes myelodysplastic syndromes.

⁴Group III includes benign and borderline brain/CNS tumors.

⁵Group XI includes in situ urinary bladder tumors.

^ Count is not displayed due to fewer than 6 cases during the five-year period.

Table H2. Percent Distribution of Children and Adolescent Cancers,¹ 2015-2019, Louisiana

ICCC ² Primary Site	All Races			Whites			Blacks		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites including Borderline and Benign Brain/CNS Tumors	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
I Leukemias, myeloproliferative & myelodysplastic diseases	21.1	23.2	18.8	21.4	22.2	20.4	20.9	25.3	16.1
II Lymphomas & reticuloendothelial neoplasms	13.1	16.2	9.4	12.6	16.6	7.9	13.8	15.2	12.2
III CNS & miscellaneous intracranial & intraspinal neoplasms	25.9	25.4	26.6	26.2	25.7	26.7	26.2	25.8	26.7
IV Neuroblastoma & other peripheral nervous cell tumors	3.1	3.3	3.0	3.0	3.1	2.9	3.4	3.5	3.3
V Retinoblastoma	1.5	1.4	1.6	1.2	1.5	0.8	2.1	1.0	3.3
VI Renal tumors	3.5	2.9	4.2	3.3	3.3	3.4	3.7	2.0	5.6
VII Hepatic tumors	1.4	1.4	1.4	1.5	1.7	1.3	0.8	0.5	1.1
VIII Malignant bone tumors	3.5	4.2	2.6	3.7	4.1	3.1	3.2	4.5	1.7
IX Soft tissue & other extraosseous sarcomas	6.4	6.6	6.3	5.1	5.4	4.7	9.3	9.6	8.9
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads	5.4	6.0	4.7	5.5	7.2	3.4	5.3	3.0	7.8
XI Other malignant epithelial neoplasms & malignant melanomas	11.1	5.9	17.2	12.8	6.1	20.9	6.6	4.5	8.9
XII Other & unspecified malignant neoplasms	0.1	0.0	0.2	0.1	0.0	0.3	0.0	0.0	0.0
Not classified by SEER or in situ	3.9	3.6	4.3	3.6	3.1	4.2	4.8	5.1	4.4

¹Children and adolescent cancers include patients aged 0-19 years.

²ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

³Group I includes myelodysplastic syndromes.

⁴Group III includes benign and borderline brain/CNS tumors.

⁵Group XI includes in situ urinary bladder tumors.

Table H3. Average Annual Cancer Incidence Rates¹ of Children and Adolescent Cancers,² 2015-2019, Louisiana

ICCC ³ Primary Site	All Races			Whites			Blacks		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites excluding Borderline & Benign Brain/CNS Tumors	173.5	184.6	161.8	206.6	222.1	190.5	129.9	137.1	122.5
All ICCC Sites including Borderline & Benign Brain/CNS Tumors	203.6	214.1	192.6	239.3	255.1	222.9	157.6	163.6	151.5
I Leukemias, myeloproliferative & myelodysplastic diseases	42.4	49.0	35.4	50.5	56.0	44.7	32.5	40.9	23.9
II Lymphomas & reticuloendothelial neoplasms	27.0	35.2	18.4	30.5	42.7	17.8	22.1	25.1	19.0
III CNS & miscellaneous intracranial & intraspinal neoplasms	52.8	54.5	51.1	62.5	65.6	59.3	41.4	42.3	40.6
IV Neuroblastoma & other peripheral nervous cell tumors	6.2	6.8	5.5	6.9	^	^	^	^	^
V Retinoblastoma	2.8	^	^	^	^	^	^	^	^
VI Renal tumors	6.9	6.0	7.8	7.8	^	^	^	^	^
VII Hepatic tumors	2.7	^	^	^	^	^	^	^	^
VIII Malignant bone tumors	7.2	9.2	^	8.9	10.7	^	^	^	^
IX Soft tissue & other extraosseous sarcomas	13.2	14.2	12.0	12.2	13.9	10.5	14.7	15.8	13.5
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads	11.1	13.1	9.0	13.3	18.7	^	8.3	^	^
XI Other malignant epithelial neoplasms & malignant melanomas	23.1	12.8	33.9	31.3	15.8	47.7	10.6	^	13.8
XII Other & unspecified malignant neoplasms	^	^	^	^	^	^	^	^	^
Not classified by SEER or in situ	8.1	7.8	8.5	8.7	^	9.5	7.5	^	^

¹Rates are per 1,000,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

²Children and adolescent cancers include patients aged 0-19 years.

³ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

⁴Group I includes myelodysplastic syndromes.

⁵Group III includes benign and borderline brain/CNS tumors.

⁶Group XI includes in situ urinary bladder tumors.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table I1. Age-specific Number of Cancer Cases¹, 2015-2019, Louisiana

Primary Site														
<i>Invasive Cancers</i> ³	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
All Sites	545	971	1,599	2,454	3,362	5,486	9,972	15,408	20,071	21,992	18,162	13,768	9,452	7,808
Oral Cavity and Pharynx	11	12	29	45	83	201	405	597	633	578	400	260	187	156
Lip	^	^	^	^	^	^	15	22	23	22	23	18	17	19
Tongue	^	^	11	10	26	66	110	179	199	210	121	90	48	41
Salivary Gland	^	^	9	7	8	14	13	24	45	43	34	33	29	31
Floor of Mouth	^	^	^	^	7	12	25	31	41	31	19	9	9	7
Gum and Other Mouth	^	^	^	9	14	18	43	79	74	75	56	37	46	39
Nasopharynx	^	^	^	6	6	10	25	27	24	21	13	9	^	^
Tonsil	^	^	^	10	15	46	110	144	129	90	64	33	16	6
Oropharynx	^	^	^	^	^	20	23	37	49	36	30	11	10	^
Hypopharynx	^	^	^	^	^	10	24	33	38	27	25	17	7	6
Other Oral Cavity and Pharynx	^	^	^	^	^	^	17	21	11	23	15	^	^	^
Digestive System	46	92	162	345	500	1,019	2,116	3,116	3,857	4,036	3,266	2,558	1,908	1,800
Esophagus	^	^	^	6	9	40	97	190	221	210	197	137	72	71
Stomach	^	7	22	43	29	78	130	223	278	275	238	195	147	181
Small Intestine	^	^	6	21	27	50	83	103	132	128	138	82	57	39
Colon and Rectum	32	62	105	216	337	614	1,257	1,397	1,658	1,937	1,503	1,185	934	869
Colon excluding Rectum	25	52	74	128	198	370	726	857	1,108	1,410	1,144	911	741	709
Cecum	^	^	14	17	28	59	117	140	188	286	238	214	170	177
Appendix	17	32	28	23	33	41	43	38	61	45	34	25	8	^
Ascending Colon	^	^	^	21	18	50	102	148	194	262	278	204	178	171
Hepatic Flexure	^	^	^	6	6	8	33	29	43	71	65	57	40	36
Transverse Colon	^	^	6	9	20	29	55	81	100	134	108	93	96	73
Splenic Flexure	^	^	^	^	^	6	30	24	38	46	24	32	18	19
Descending Colon	^	6	^	12	19	28	53	83	82	92	66	42	43	37
Sigmoid Colon	^	6	13	33	59	134	265	283	321	397	270	184	139	111
Large Intestine, NOS	^	^	^	^	11	15	28	31	81	77	61	60	49	81
Rectum and Rectosigmoid Junction	7	10	31	88	139	244	531	540	550	527	359	274	193	160
Rectosigmoid Junction	^	^	^	15	24	40	93	95	102	102	75	70	40	32

Rectum	7	10	26	73	115	204	438	445	448	425	284	204	153	128
Anus, Anal Canal and Anorectum	^	^	^	10	23	38	71	93	91	82	47	36	28	35
Liver and Intrahepatic Bile Duct	6	^	10	8	19	60	204	579	761	567	378	263	130	114
Liver	6	^	9	^	16	43	182	525	711	508	316	224	111	95
Intrahepatic Bile Duct	^	^	^	^	^	17	22	54	50	59	62	39	19	19
Gallbladder	^	^	^	^	^	11	23	39	57	57	62	34	35	30
Other Biliary	^	^	^	^	^	8	24	47	61	64	65	58	47	42
Pancreas	^	8	8	34	45	107	200	411	539	646	591	528	426	390
Retroperitoneum	^	^	^	^	^	^	6	9	11	14	^	7	^	^
Peritoneum, Omentum and Mesentery	^	^	^	^	^	6	7	10	11	23	13	12	8	9
Other Digestive Organs	^	^	^	^	^	^	14	15	37	33	30	21	19	15
Respiratory System	12	13	42	74	125	365	1,106	2,230	3,080	3,448	3,301	2,723	1,746	1,182
Nose, Nasal Cavity and Middle Ear	^	^	^	^	6	8	11	18	28	29	28	22	16	17
Larynx	^	^	6	12	19	49	148	239	284	248	178	129	65	48
Lung and Bronchus	6	13	27	57	99	308	943	1,969	2,762	3,170	3,090	2,565	1,661	1,114
Pleura	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Bones and Joints	12	12	9	11	8	13	9	12	14	7	20	10	8	7
Soft Tissue including Heart	25	25	30	26	45	50	54	77	105	128	103	86	78	76
Skin excluding Basal and Squamous Melanoma of the Skin	42	101	156	197	241	315	378	535	627	670	660	525	411	395
Other Non-Epithelial Skin	34	96	145	182	221	287	358	508	563	608	593	460	349	323
Breast	8	^	11	15	20	28	20	27	64	62	67	65	62	72
Female Genital System	15	96	250	514	900	1,325	1,797	2,175	2,614	2,836	2,223	1,604	1,082	919
Cervix Uteri	20	72	192	271	321	373	596	841	976	941	694	389	324	256
Corpus and Uterus, NOS	^	35	111	142	144	116	125	128	109	80	37	35	23	23
Corpus Uteri	^	8	38	82	95	147	289	486	605	574	405	203	123	81
Uterus, NOS	^	8	37	81	92	141	277	473	592	553	387	193	118	74
Ovary	^	^	^	^	^	6	12	13	13	21	18	10	^	7
Vagina	12	24	27	33	53	68	99	145	184	180	165	93	105	76
Vulva	^	^	^	^	^	^	14	21	13	14	17	9	20	11
Other Female Genital Organs	^	^	11	12	20	34	52	43	40	56	46	35	33	52
Male Genital System	^	^	^	^	6	^	17	18	25	37	24	14	20	13
	60	99	105	103	116	360	1,260	2,517	3,903	4,592	3,131	1,832	875	522

Prostate	^	^	^	13	68	317	1,223	2,464	3,875	4,559	3,104	1,807	858	510
Testis	60	99	103	87	44	36	26	30	9	^	^	^	^	^
Penis	^	^	^	^	^	^	7	19	15	25	22	19	13	10
Other Male Genital Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Urinary System	11	33	61	168	280	443	753	1,197	1,633	1,830	1,639	1,356	983	854
Urinary Bladder	^	8	14	27	47	86	194	412	621	782	813	771	545	582
Kidney and Renal Pelvis	9	25	47	141	233	355	547	753	982	999	789	535	388	238
Ureter	^	^	^	^	^	^	^	13	17	22	20	32	26	15
Other Urinary Organs	^	^	^	^	^	^	10	19	13	27	17	18	24	19
Eye and Orbit	^	^	^	^	9	9	9	29	18	26	23	23	11	8
Brain and Other Nervous System	29	42	47	56	42	74	107	136	162	174	163	107	97	61
Brain	28	36	42	50	38	68	104	130	153	166	158	103	93	59
Cranial Nerves Other Nervous System	^	6	^	6	^	6	^	6	9	8	^	^	^	^
Endocrine System	93	158	248	314	340	350	381	439	447	370	255	171	92	43
Thyroid	87	157	245	308	336	341	369	423	423	345	235	154	86	40
Other Endocrine including Thymus	6	^	^	6	^	9	12	16	24	25	20	17	6	^
Lymphoma	107	136	155	159	153	262	358	551	664	748	738	635	438	393
Hodgkin Lymphoma	72	70	67	51	43	47	39	48	41	40	31	15	18	9
Hodgkin - Nodal	71	70	66	51	43	46	39	47	40	38	31	15	16	9
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	35	66	88	108	110	215	319	503	623	708	707	620	420	384
NHL - Nodal	23	33	57	60	74	149	217	339	417	481	492	437	273	241
NHL - Extranodal	12	33	31	48	36	66	102	164	206	227	215	183	147	143
Myeloma	^	^	9	19	25	84	155	221	305	402	349	302	205	177
Leukemia	39	36	53	77	71	107	244	316	393	489	469	427	394	319
Lymphocytic Leukemia	8	7	13	22	20	46	103	167	203	244	251	226	180	155
Acute Lymphocytic Leukemia	7	6	9	10	^	8	12	19	14	14	14	11	8	^
Chronic Lymphocytic Leukemia	^	^	^	8	9	30	84	136	182	207	221	203	161	144
Other Lymphocytic Leukemia	^	^	^	^	7	8	7	12	7	23	16	12	11	8
Myeloid and Monocytic Leukemia	29	28	40	54	48	58	130	140	180	230	200	181	194	139
Acute Myeloid Leukemia	16	18	19	29	19	35	80	85	97	164	132	121	131	96
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	8	^
Chronic Myeloid Leukemia	13	9	19	25	28	20	48	51	78	58	62	53	53	36

Other Myeloid/Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Other Leukemia	^	^	^	^	^	^	11	9	10	15	18	20	20	25
Other Acute Leukemia	^	^	^	^	^	^	^	^	^	^	6	8	7	8
Aleukemic, Subleukemic and NOS	^	^	^	^	^	^	9	8	8	14	12	12	13	17
Mesothelioma	^	^	^	^	^	8	11	15	28	63	67	66	30	29
Kaposi Sarcoma	8	13	16	7	11	11	6	^	^	^	^	6	^	6
Miscellaneous	13	26	32	59	87	117	227	400	609	652	657	688	578	605

In Situ Cancers (not included above)

Breast In Situ	^	8	17	63	197	281	403	481	598	585	457	298	143	74
----------------	---	---	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

^Statistic not displayed due to fewer than 6 cases.

¹Number of cases is the total for the 5-year time period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

Table I2. Age-Specific Average Annual Cancer Incidence Rates,¹ 2015-2019, Louisiana

Primary Site														
<i>Invasive Cancers³</i>	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
All Sites	34.1	56.3	97.7	159.6	248.1	393.6	670.0	980.1	1,389.6	1,835.3	2,065.6	2,264.1	2,319.9	1,959.8
Oral Cavity and Pharynx	^	^	1.8	2.9	6.1	14.4	27.2	38.0	43.8	48.2	45.5	42.8	45.9	39.2
Lip	^	^	^	^	^	^	^	1.4	1.6	1.8	2.6	3.0	4.2	4.8
Tongue	^	^	^	^	1.9	4.7	7.4	11.4	13.8	17.5	13.8	14.8	11.8	10.3
Salivary Gland	^	^	^	^	^	^	^	1.5	3.1	3.6	3.9	5.4	7.1	7.8
Floor of Mouth	^	^	^	^	^	^	1.7	2.0	2.8	2.6	2.2	^	^	^
Gum and Other Mouth	^	^	^	^	^	1.3	2.9	5.0	5.1	6.3	6.4	6.1	11.3	9.8
Nasopharynx	^	^	^	^	^	^	1.7	1.7	1.7	1.8	^	^	^	^
Tonsil	^	^	^	^	^	3.3	7.4	9.2	8.9	7.5	7.3	5.4	3.9	^
Oropharynx	^	^	^	^	^	1.4	1.5	2.4	3.4	3.0	3.4	^	^	^
Hypopharynx	^	^	^	^	^	^	1.6	2.1	2.6	2.3	2.8	2.8	^	^
Other Oral Cavity and Pharynx	^	^	^	^	^	^	1.1	1.3	^	1.9	^	^	^	^
Digestive System	2.9	^	9.9	22.4	36.9	73.1	142.2	198.2	267.0	336.8	371.4	420.7	468.3	451.8
Esophagus	^	^	^	^	^	2.9	6.5	12.1	15.3	17.5	22.4	22.5	17.7	17.8
Stomach	^	^	1.3	2.8	2.1	5.6	8.7	14.2	19.2	23.0	27.1	32.1	36.1	45.4
Small Intestine	^	^	^	1.4	2.0	3.6	5.6	6.6	9.1	10.7	15.7	13.5	14.0	9.8
Colon and Rectum	2.0	^	6.4	14.1	24.9	44.0	84.4	88.9	114.8	161.7	170.9	194.9	229.2	218.1
Colon excluding Rectum	1.6	^	4.5	8.3	14.6	26.5	48.8	54.5	76.7	117.7	130.1	149.8	181.9	178.0
Cecum	^	^	^	1.1	2.1	4.2	7.9	8.9	13.0	23.9	27.1	35.2	41.7	44.4
Appendix	1.1	^	1.7	1.5	2.4	2.9	2.9	2.4	4.2	3.8	3.9	4.1	^	^
Ascending Colon	^	^	^	1.4	1.3	3.6	6.9	9.4	13.4	21.9	31.6	33.5	43.7	42.9
Hepatic Flexure	^	^	^	^	^	^	2.2	1.8	3.0	5.9	7.4	9.4	9.8	9.0
Transverse Colon	^	^	^	^	1.5	2.1	3.7	5.2	6.9	11.2	12.3	15.3	23.6	18.3
Splenic Flexure	^	^	^	^	^	^	2.0	1.5	2.6	3.8	2.7	5.3	4.4	4.8
Descending Colon	^	^	^	^	1.4	2.0	3.6	5.3	5.7	7.7	7.5	6.9	10.6	9.3
Sigmoid Colon	^	^	^	2.1	4.4	9.6	17.8	18.0	22.2	33.1	30.7	30.3	34.1	27.9
Large Intestine, NOS	^	^	^	^	^	^	1.9	2.0	5.6	6.4	6.9	9.9	12.0	20.3
Rectum and Rectosigmoid Junction	^	^	1.9	5.7	10.3	17.5	35.7	34.3	38.1	44.0	40.8	45.1	47.4	40.2
Rectosigmoid Junction	^	^	^	^	1.8	2.9	6.2	6.0	7.1	8.5	8.5	11.5	9.8	8.0
Rectum	^	^	1.6	4.7	8.5	14.6	29.4	28.3	31.0	35.5	32.3	33.5	37.6	32.1

Anus, Anal Canal and Anorectum	^	^	^	^	1.7	2.7	4.8	5.9	6.3	6.8	5.3	5.9	6.9	8.8
Liver and Intrahepatic Bile Duct	^	^	^	^	1.4	4.3	13.7	36.8	52.7	47.3	43.0	43.3	31.9	28.6
Liver	^	^	^	^	1.2	3.1	12.2	33.4	49.2	42.4	35.9	36.8	27.2	23.8
Intrahepatic Bile Duct	^	^	^	^	^	1.2	1.5	3.4	3.5	4.9	7.1	6.4	4.7	4.8
Gallbladder	^	^	^	^	^	^	1.5	2.5	3.9	4.8	7.1	5.6	8.6	7.5
Other Biliary	^	^	^	^	^	^	1.6	3.0	4.2	5.3	7.4	9.5	11.5	10.5
Pancreas	^	^	^	2.2	3.3	7.7	13.4	26.1	37.3	53.9	67.2	86.8	104.6	97.9
Retroperitoneum	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Peritoneum, Omentum and Mesentery	^	^	^	^	^	^	^	^	^	1.9	^	^	^	^
Other Digestive Organs	^	^	^	^	^	^	^	^	2.6	2.8	3.4	3.5	4.7	^
Respiratory System	^	^	2.6	4.8	9.2	26.2	74.3	141.9	213.2	287.8	375.4	447.8	428.5	296.7
Nose, Nasal Cavity and Middle Ear	^	^	^	^	^	^	^	1.1	1.9	2.4	3.2	3.6	3.9	4.3
Larynx	^	^	^	^	1.4	3.5	9.9	15.2	19.7	20.7	20.2	21.2	16.0	12.0
Lung and Bronchus	^	^	1.6	3.7	7.3	22.1	63.4	125.2	191.2	264.6	351.4	421.8	407.7	279.6
Pleura	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Bones and Joints	^	^	^	^	^	^	^	^	^	^	2.3	^	^	^
Soft Tissue including Heart	1.6	^	1.8	1.7	3.3	3.6	3.6	4.9	7.3	10.7	11.7	14.1	19.1	19.1
Skin excluding Basal and Squamous	2.6	^	9.5	12.8	17.8	22.6	25.4	34.0	43.4	55.9	75.1	86.3	100.9	99.1
Melanoma of the Skin	2.1	^	8.9	11.8	16.3	20.6	24.1	32.3	39.0	50.7	67.4	75.6	85.7	81.1
Other Non-Epithelial Skin	^	^	^	^	1.5	2.0	1.3	1.7	4.4	5.2	7.6	10.7	15.2	18.1
Breast	^	^	15.3	33.4	66.4	95.1	120.7	138.4	181.0	236.7	252.8	263.8	265.6	230.7
Female Genital System	1.3	^	11.7	17.6	23.7	26.8	40.0	53.5	67.6	78.5	78.9	64.0	79.5	64.3
Cervix Uteri	^	^	6.8	9.2	10.6	8.3	8.4	8.1	7.5	6.7	4.2	5.8	5.6	5.8
Corpus and Uterus, NOS	^	^	2.3	5.3	7.0	10.5	19.4	30.9	41.9	47.9	46.1	33.4	30.2	20.3
Corpus Uteri	^	^	2.3	5.3	6.8	10.1	18.6	30.1	41.0	46.2	44.0	31.7	29.0	18.6
Uterus, NOS	^	^	^	^	^	^	^	^	^	1.8	2.0	^	^	^
Ovary	^	^	1.6	2.1	3.9	4.9	6.7	9.2	12.7	15.0	18.8	15.3	25.8	19.1
Vagina	^	^	^	^	^	^	^	1.3	^	^	1.9	^	4.9	^
Vulva	^	^	^	^	1.5	2.4	3.5	2.7	2.8	4.7	5.2	5.8	8.1	13.1
Other Female Genital Organs	^	^	^	^	^	^	1.1	1.1	1.7	3.1	2.7	^	4.9	^
Male Genital System	3.8	^	6.4	6.7	8.6	25.8	84.7	160.1	270.2	383.2	356.1	301.3	214.8	131.0
Prostate	^	^	^	^	5.0	22.7	82.2	156.7	268.3	380.5	353.0	297.2	210.6	128.0
Testis	3.8	^	6.3	5.7	3.2	2.6	1.7	1.9	^	^	^	^	^	^

Penis	^	^	^	^	^	^	^	1.2	^	2.1	2.5	3.1	^	^
Other Male Genital Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Urinary System	^	^	3.7	10.9	20.7	31.8	50.6	76.1	113.1	152.7	186.4	223.0	241.3	214.4
Urinary Bladder	^	^	^	1.8	3.5	6.2	13.0	26.2	43.0	65.3	92.5	126.8	133.8	146.1
Kidney and Renal Pelvis	^	^	2.9	9.2	17.2	25.5	36.7	47.9	68.0	83.4	89.7	88.0	95.2	59.7
Ureter	^	^	^	^	^	^	^	^	1.2	1.8	2.3	5.3	6.4	^
Other Urinary Organs	^	^	^	^	^	^	^	1.2	^	2.3	1.9	3.0	5.9	4.8
Eye and Orbit	^	^	^	^	^	^	^	1.8	1.2	2.2	2.6	3.8	^	^
Brain and Other Nervous System	1.8	^	2.9	3.6	3.1	5.3	7.2	8.7	11.2	14.5	18.5	17.6	23.8	15.3
Brain	1.8	^	2.6	3.3	2.8	4.9	7.0	8.3	10.6	13.9	18.0	16.9	22.8	14.8
Cranial Nerves Other Nervous System	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Endocrine System	5.8	^	15.1	20.4	25.1	25.1	25.6	27.9	30.9	30.9	29.0	28.1	22.6	10.8
Thyroid	5.4	^	15.0	20.0	24.8	24.5	24.8	26.9	29.3	28.8	26.7	25.3	21.1	10.0
Other Endocrine including Thymus	^	^	^	^	^	^	^	1.0	1.7	2.1	2.3	2.8	^	^
Lymphoma	6.7	^	9.5	10.3	11.3	18.8	24.1	35.0	46.0	62.4	83.9	104.4	107.5	98.6
Hodgkin Lymphoma	4.5	^	4.1	3.3	3.2	3.4	2.6	3.1	2.8	3.3	3.5	^	4.4	^
Hodgkin - Nodal	4.4	^	4.0	3.3	3.2	3.3	2.6	3.0	2.8	3.2	3.5	^	3.9	^
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	2.2	^	5.4	7.0	8.1	15.4	21.4	32.0	43.1	59.1	80.4	102.0	103.1	96.4
NHL - Nodal	1.4	^	3.5	3.9	5.5	10.7	14.6	21.6	28.9	40.1	56.0	71.9	67.0	60.5
NHL - Extranodal	^	^	1.9	3.1	2.7	4.7	6.9	10.4	14.3	18.9	24.5	30.1	36.1	35.9
Myeloma	^	^	^	1.2	1.8	6.0	10.4	14.1	21.1	33.5	39.7	49.7	50.3	44.4
Leukemia	2.4	^	3.2	5.0	5.2	7.7	16.4	20.1	27.2	40.8	53.3	70.2	96.7	80.1
Lymphocytic Leukemia	^	^	^	1.4	1.5	3.3	6.9	10.6	14.1	20.4	28.5	37.2	44.2	38.9
Acute Lymphocytic Leukemia	^	^	^	^	^	^	^	1.2	^	^	^	^	^	^
Chronic Lymphocytic Leukemia	^	^	^	^	^	2.2	5.6	8.7	12.6	17.3	25.1	33.4	39.5	36.1
Other Lymphocytic Leukemia	^	^	^	^	^	^	^	^	^	1.9	1.8	^	^	^
Myeloid and Monocytic Leukemia	1.8	^	2.4	3.5	3.5	4.2	8.7	8.9	12.5	19.2	22.7	29.8	47.6	34.9
Acute Myeloid Leukemia	1.0	^	1.2	1.9	1.4	2.5	5.4	5.4	6.7	13.7	15.0	19.9	32.2	24.1
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	^	^	1.2	1.6	2.1	1.4	3.2	3.2	5.4	4.8	7.1	8.7	13.0	9.0
Other Myeloid/Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Other Leukemia	^	^	^	^	^	^	^	^	^	^	2.0	3.3	4.9	6.3
Other Acute Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^

Aleukemic, Subleukemic and NOS	^	^	^	^	^	^	^	^	^	^	^	^	^	4.3
Mesothelioma	^	^	^	^	^	^	^	^	1.9	5.3	7.6	10.9	7.4	7.3
Kaposi Sarcoma	^	^	1.0	^	^	^	^	^	^	^	^	^	^	^
Miscellaneous	^	^	2.0	3.8	6.4	8.4	15.3	25.4	42.2	54.4	74.7	113.1	141.9	151.9
<i>In Situ Cancers (not included above)</i>														
Breast In Situ	^	^	1.2	4.1	13.5	20.4	26.7	28.9	42.4	49.2	53.8	53.1	36.3	19.8

¹Rates are per 100,000 and age-adjusted to the 2000 US Population

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases.

Mortality Tables

Table J1. Average Annual Number of Cancer Deaths by Site, Race, and Sex, 2015-2019, Louisiana

Primary Site	All races			White			Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	9,385	5,070	4,315	6,424	3,479	2,945	2,863	1,535	1,328
Oral Cavity and Pharynx	175	129	46	119	88	31	55	40	14
Lip	^	^	^	^	^	^	^	^	^
Tongue	36	24	11	27	18	9	8	6	2
Salivary Gland	13	9	3	10	8	2	3	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	25	13	11	17	9	8	7	4	3
Nasopharynx	12	9	3	7	6	^	5	3	^
Tonsil	15	12	3	11	9	2	4	3	^
Oropharynx	19	15	4	10	8	2	8	7	^
Hypopharynx	7	5	^	4	3	^	2	^	^
Other Oral Cavity and Pharynx	48	39	9	32	26	5	16	13	3
Digestive System	2,596	1,538	1,058	1,683	999	684	877	515	362
Esophagus	215	173	42	156	130	26	57	42	15
Stomach	177	108	70	90	55	35	83	50	33
Small Intestine	22	13	9	15	9	6	7	4	3
Colon and Rectum	866	474	392	553	303	250	302	164	137
Colon excluding Rectum	698	377	321	440	239	201	249	133	116
Rectum and Rectosigmoid Junction	167	96	71	113	64	49	53	32	21
Anus, Anal Canal and Anorectum	14	8	7	11	6	6	3	2	^
Liver and Intrahepatic Bile Duct	512	367	145	316	221	95	183	136	48
Liver	447	333	114	271	197	74	165	127	38
Intrahepatic Bile Duct	65	34	31	45	24	21	18	9	10
Gallbladder	37	13	24	23	8	15	13	5	9
Other Biliary	26	15	11	21	12	9	5	3	2
Pancreas	687	350	337	471	245	227	210	103	107
Retroperitoneum	5	3	2	3	2	^	^	^	^
Peritoneum, Omentum and Mesentery	17	5	12	13	3	9	4	^	3
Other Digestive Organs	19	10	9	11	6	5	7	4	3
Respiratory System	2,619	1,520	1,099	1,857	1,038	818	738	466	271
Nose, Nasal Cavity and Middle Ear	8	4	4	5	3	^	2	^	^
Larynx	75	61	14	44	35	8	31	25	6
Lung and Bronchus	2,525	1,446	1,078	1,799	993	806	702	439	263
Pleura	7	5	^	6	5	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	4	3	^	3	2	^	^	^	^
Bones and Joints	39	22	18	27	15	12	12	6	6
Soft Tissue including Heart	65	33	31	44	23	21	20	10	10
Skin	136	95	42	124	86	38	11	8	4

Melanoma of the Skin	83	55	29	79	52	27	4	2	^
Non-Melanoma Skin	53	40	13	46	34	11	7	5	^
Breast	663	6	657	411	3	408	246	3	243
Female Genital System	438	^	438	271	^	271	163	^	163
Cervix Uteri	81	^	81	43	^	43	37	^	37
Corpus and Uterus, NOS	144	^	144	76	^	76	67	^	67
Corpus Uteri	81	^	81	44	^	44	38	^	38
Uterus, NOS	63	^	63	33	^	33	30	^	30
Ovary	179	^	179	127	^	127	51	^	51
Vagina	8	^	8	6	^	6	^	^	^
Vulva	16	^	16	13	^	13	3	^	3
Other Female Genital Organs	9	^	9	6	^	6	3	^	3
Male Genital System	442	442	^	266	266	^	174	174	^
Prostate	432	432	^	258	258	^	171	171	^
Testis	4	4	^	3	3	^	^	^	^
Penis	5	5	^	3	3	^	^	^	^
Other Male Genital Organs	2	2	^	^	^	^	^	^	^
Urinary System	465	308	157	355	242	113	105	63	42
Urinary Bladder	209	145	64	166	121	45	41	22	19
Kidney and Renal Pelvis	246	158	88	181	116	65	62	40	22
Ureter	3	2	^	2	2	^	^	^	^
Other Urinary Organs	8	3	4	6	3	3	^	^	^
Eye and Orbit	4	2	2	3	^	^	^	^	^
Brain and Other Nervous System	232	129	103	189	106	83	39	22	17
Endocrine System	42	19	24	29	14	15	13	4	8
Thyroid	26	10	16	18	8	10	7	^	6
Other Endocrine including Thymus	16	8	8	11	5	5	5	3	3
Lymphoma	308	176	132	239	138	101	64	36	28
Hodgkin Lymphoma	15	7	8	11	5	6	4	2	^
Non-Hodgkin Lymphoma	293	169	124	228	133	95	60	34	27
Myeloma	195	106	89	114	64	50	80	41	39
Leukemia	329	187	143	249	143	106	76	41	35
Lymphocytic Leukemia	82	48	34	62	36	26	20	12	8
Acute Lymphocytic Leukemia	18	10	8	13	7	7	5	3	^
Chronic Lymphocytic Leukemia	53	32	21	40	25	15	13	8	6
Other Lymphocytic Leukemia	10	5	5	8	4	4	^	^	^
Myeloid and Monocytic Leukemia	156	86	70	116	65	50	38	19	19
Acute Myeloid Leukemia	125	67	59	94	51	42	30	14	16
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	15	9	5	11	7	3	4	^	2
Other Myeloid/Monocytic Leukemia	14	9	5	10	6	4	4	3	^
Other Leukemia	92	53	39	72	42	30	18	11	8
Other Acute Leukemia	15	8	7	12	7	5	3	^	2
Aleukemic, Subleukemic and NOS	77	45	32	60	35	25	15	9	6
Miscellaneous Malignant Cancer	637	360	277	443	252	191	189	105	84

^The NCI does not present counts for cells smaller than 10 for the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
-- Not Applicable

Table J2. Percent Distribution of Cancer Deaths by Site, Race, and Sex,
2015-2019, Louisiana

Primary Site	All races			White			Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Oral Cavity and Pharynx	1.9	2.6	1.1	1.9	2.5	1.1	1.9	2.6	1.1
Lip	^	^	^	^	^	^	^	^	^
Tongue	0.4	0.5	0.3	0.4	0.5	0.3	0.3	0.4	0.2
Salivary Gland	0.1	0.2	0.1	0.2	0.2	0.1	0.1	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2
Nasopharynx	0.1	0.2	0.1	0.1	0.2	^	0.2	0.2	^
Tonsil	0.2	0.2	0.1	0.2	0.3	0.1	0.1	0.2	^
Oropharynx	0.2	0.3	0.1	0.2	0.2	0.1	0.3	0.5	^
Hypopharynx	0.1	0.1	^	0.1	0.1	^	0.1	^	^
Other Oral Cavity and Pharynx	0.5	0.8	0.2	0.5	0.8	0.2	0.6	0.8	0.3
Digestive System	27.7	30.3	24.5	26.2	28.7	23.2	30.6	33.5	27.3
Esophagus	2.3	3.4	1.0	2.4	3.7	0.9	2.0	2.7	1.2
Stomach	1.9	2.1	1.6	1.4	1.6	1.2	2.9	3.3	2.5
Small Intestine	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.3
Colon and Rectum	9.2	9.3	9.1	8.6	8.7	8.5	10.5	10.7	10.3
Colon excluding Rectum	7.4	7.4	7.4	6.8	6.9	6.8	8.7	8.6	8.7
Rectum and Rectosigmoid Junction	1.8	1.9	1.6	1.8	1.8	1.7	1.8	2.1	1.6
Anus, Anal Canal and Anorectum	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	^
Liver and Intrahepatic Bile Duct	5.5	7.2	3.4	4.9	6.4	3.2	6.4	8.8	3.6
Liver	4.8	6.6	2.6	4.2	5.7	2.5	5.8	8.3	2.9
Intrahepatic Bile Duct	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.7
Gallbladder	0.4	0.3	0.6	0.4	0.2	0.5	0.5	0.3	0.6
Other Biliary	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Pancreas	7.3	6.9	7.8	7.3	7.0	7.7	7.3	6.7	8.1
Retroperitoneum	0.1	0.1	0.1	0.1	0.1	^	^	^	^
Peritoneum, Omentum and Mesentery	0.2	0.1	0.3	0.2	0.1	0.3	0.2	^	0.2
Other Digestive Organs	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2
Respiratory System	27.9	30.0	25.5	28.9	29.9	27.8	25.8	30.4	20.4
Nose, Nasal Cavity and Middle Ear	0.1	0.1	0.1	0.1	0.1	^	0.1	^	^
Larynx	0.8	1.2	0.3	0.7	1.0	0.3	1.1	1.7	0.4
Lung and Bronchus	26.9	28.5	25.0	28.0	28.5	27.4	24.5	28.6	19.8
Pleura	0.1	0.1	^	0.1	0.1	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	0.0	0.1	^	0.0	0.1	^	^	^	^
Bones and Joints	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Soft Tissue including Heart	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.8
Skin	1.5	1.9	1.0	1.9	2.5	1.3	0.4	0.5	0.3
Melanoma of the Skin	0.9	1.1	0.7	1.2	1.5	0.9	0.1	0.2	^
Non-Melanoma Skin	0.6	0.8	0.3	0.7	1.0	0.4	0.3	0.4	^

Breast	7.1	0.1	15.2	6.4	0.1	13.9	8.6	0.2	18.3
Female Genital System	4.7	^	10.1	4.2	^	9.2	5.7	^	12.3
Cervix Uteri	0.9	^	1.9	0.7	^	1.5	1.3	^	2.8
Corpus and Uterus, NOS	1.5	^	3.3	1.2	^	2.6	2.4	^	5.1
Corpus Uteri	0.9	^	1.9	0.7	^	1.5	1.3	^	2.8
Uterus, NOS	0.7	^	1.5	0.5	^	1.1	1.0	^	2.2
Ovary	1.9	^	4.1	2.0	^	4.3	1.8	^	3.9
Vagina	0.1	^	0.2	0.1	^	0.2	^	^	^
Vulva	0.2	^	0.4	0.2	^	0.4	0.1	^	0.2
Other Female Genital Organs	0.1	^	0.2	0.1	^	0.2	0.1	^	0.2
Male Genital System	4.7	8.7	^	4.1	7.6	^	6.1	11.3	^
Prostate	4.6	8.5	^	4.0	7.4	^	6.0	11.1	^
Testis	0.0	0.1	^	0.0	0.1	^	^	^	^
Penis	0.0	0.1	^	0.0	0.1	^	^	^	^
Other Male Genital Organs	0.0	0.0	^	^	^	^	^	^	^
Urinary System	5.0	6.1	3.6	5.5	7.0	3.9	3.7	4.1	3.2
Urinary Bladder	2.2	2.9	1.5	2.6	3.5	1.5	1.4	1.5	1.4
Kidney and Renal Pelvis	2.6	3.1	2.0	2.8	3.3	2.2	2.2	2.6	1.6
Ureter	0.0	0.0	^	0.0	0.1	^	^	^	^
Other Urinary Organs	0.1	0.1	0.1	0.1	0.1	0.1	^	^	^
Eye and Orbit	0.0	0.0	0.0	0.0	^	^	^	^	^
Brain and Other Nervous System	2.5	2.5	2.4	2.9	3.0	2.8	1.4	1.4	1.3
Endocrine System	0.5	0.4	0.6	0.5	0.4	0.5	0.4	0.3	0.6
Thyroid	0.3	0.2	0.4	0.3	0.2	0.3	0.3	^	0.4
Other Endocrine including Thymus	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Lymphoma	3.3	3.5	3.0	3.7	4.0	3.4	2.2	2.3	2.1
Hodgkin Lymphoma	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	^
Non-Hodgkin Lymphoma	3.1	3.3	2.9	3.6	3.8	3.2	2.1	2.2	2.0
Myeloma	2.1	2.1	2.1	1.8	1.9	1.7	2.8	2.7	2.9
Leukemia	3.5	3.7	3.3	3.9	4.1	3.6	2.7	2.7	2.6
Lymphocytic Leukemia	0.9	0.9	0.8	1.0	1.0	0.9	0.7	0.8	0.6
Acute Lymphocytic Leukemia	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	^
Chronic Lymphocytic Leukemia	0.6	0.6	0.5	0.6	0.7	0.5	0.5	0.5	0.4
Other Lymphocytic Leukemia	0.1	0.1	0.1	0.1	0.1	0.1	^	^	^
Myeloid and Monocytic Leukemia	1.7	1.7	1.6	1.8	1.9	1.7	1.3	1.3	1.4
Acute Myeloid Leukemia	1.3	1.3	1.4	1.5	1.5	1.4	1.1	0.9	1.2
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	0.2	0.2	0.1	0.2	0.2	0.1	0.1	^	0.2
Other Myeloid/Monocytic Leukemia	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.2	^
Other Leukemia	1.0	1.1	0.9	1.1	1.2	1.0	0.6	0.7	0.6
Other Acute Leukemia	0.2	0.2	0.2	0.2	0.2	0.2	0.1	^	0.2
Aleukemic, Subleukemic and NOS	0.8	0.9	0.7	0.9	1.0	0.9	0.5	0.6	0.4
Miscellaneous Malignant Cancer	6.8	7.1	6.4	6.9	7.2	6.5	6.6	6.8	6.3

^The NCI does not present counts for cells smaller than 10 for the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

-- Not Applicable

Table K. Average Annual Death Rate¹ by Site, Race, and Sex,
2015-2019, Louisiana

Primary Site	All races			White			Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	172.5	211.2	143.9	164.4	198.9	138.5	198.9	254.3	161.5
Oral Cavity and Pharynx	3.2	5.1	1.6	3.0	4.9	1.5	3.5	5.8	1.7
Lip	^	^	^	^	^	^	^	^	^
Tongue	0.7	1.0	0.4	0.7	1.0	0.4	0.5	0.9	^
Salivary Gland	0.2	0.4	0.1	0.3	0.5	^	^	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	0.5	0.5	0.4	0.4	0.5	0.4	0.5	0.6	0.4
Nasopharynx	0.2	0.3	^	0.2	0.3	^	0.3	0.4	^
Tonsil	0.3	0.5	^	0.3	0.5	^	0.3	0.5	^
Oropharynx	0.3	0.6	0.1	0.3	0.4	^	0.5	1.0	^
Hypopharynx	0.1	0.2	^	0.1	0.2	^	^	^	^
Other Oral Cavity and Pharynx	0.8	1.5	0.3	0.8	1.4	0.3	1.0	1.9	0.4
Digestive System	47.0	61.5	35.0	42.6	55.5	31.8	59.3	79.6	44.1
Esophagus	3.8	6.8	1.4	4.0	7.1	1.3	3.7	6.2	1.8
Stomach	3.3	4.4	2.3	2.3	3.2	1.6	5.8	8.0	4.1
Small Intestine	0.4	0.6	0.3	0.4	0.6	0.3	0.5	0.7	0.4
Colon and Rectum	15.9	19.5	13.1	14.2	17.3	11.7	20.8	26.5	16.8
Colon excluding Rectum	12.9	15.6	10.7	11.3	13.7	9.3	17.3	21.8	14.2
Rectum and Rectosigmoid Junction	3.1	3.9	2.4	2.9	3.6	2.3	3.5	4.7	2.5
Anus, Anal Canal and Anorectum	0.3	0.3	0.2	0.3	0.3	0.3	^	^	^
Liver and Intrahepatic Bile Duct	8.8	13.6	4.7	7.7	11.6	4.4	11.4	18.8	5.6
Liver	7.6	12.3	3.7	6.6	10.3	3.4	10.1	17.4	4.4
Intrahepatic Bile Duct	1.2	1.3	1.0	1.1	1.3	1.0	1.3	1.4	1.2
Gallbladder	0.7	0.5	0.8	0.6	0.4	0.7	0.9	0.8	1.0
Other Biliary	0.5	0.6	0.4	0.5	0.7	0.4	0.4	^	^
Pancreas	12.6	14.3	11.1	12.0	13.8	10.5	14.7	16.5	13.2
Retroperitoneum	0.1	^	^	0.1	^	^	^	^	^
Peritoneum, Omentum and Mesentery	0.3	0.2	0.4	0.3	0.2	0.4	0.3	^	^
Other Digestive Organs	0.3	0.4	0.3	0.3	0.3	0.3	0.5	0.7	0.4
Respiratory System	47.3	61.9	35.9	46.7	57.9	37.8	50.7	76.2	32.5
Nose, Nasal Cavity and Middle Ear	0.1	0.2	0.1	0.1	0.2	^	^	^	^
Larynx	1.3	2.4	0.4	1.1	1.9	0.4	2.1	4.0	0.7
Lung and Bronchus	45.7	59.0	35.3	45.2	55.4	37.2	48.3	71.9	31.6
Pleura	0.1	0.2	^	0.2	0.3	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	0.1	^	^	^	^	^	^	^	^
Bones and Joints	0.8	1.0	0.6	0.8	0.9	0.6	0.8	1.1	0.7
Soft Tissue including Heart	1.2	1.4	1.1	1.2	1.4	1.1	1.3	1.4	1.2
Skin	2.6	4.2	1.4	3.2	5.2	1.8	0.8	1.2	0.5
Melanoma of the Skin	1.6	2.4	1.0	2.1	3.1	1.3	0.3	^	^
Non-Melanoma Skin	1.0	1.7	0.4	1.2	2.0	0.5	0.4	0.8	^
Breast	12.5	0.2	22.4	10.8	0.2	19.7	17.3	^	29.6

Female Genital System	8.2	--	14.9	7.2	--	13.3	11.2	--	19.4
Cervix Uteri	1.7	--	3.2	1.3	--	2.6	2.6	--	4.7
Corpus and Uterus, NOS	2.6	--	4.7	1.9	--	3.5	4.5	--	7.7
Corpus Uteri	1.4	--	2.6	1.1	--	2.1	2.5	--	4.2
Uterus, NOS	1.1	--	2.0	0.8	--	1.5	2.0	--	3.5
Ovary	3.3	--	6.0	3.3	--	6.0	3.5	--	6.1
Vagina	0.2	--	0.3	0.2	--	0.3	^	--	^
Vulva	0.3	--	0.5	0.3	--	0.6	0.2	--	0.4
Other Female Genital Organs	0.2	--	0.3	0.1	--	0.3	^	--	^
Male Genital System	8.4	20.4	--	6.8	16.5	--	13.3	35.0	--
Prostate	8.2	20.0	--	6.6	16.1	--	13.1	34.5	--
Testis	0.1	0.2	--	0.1	0.2	--	^	^	--
Penis	0.1	0.2	--	^	^	--	^	^	--
Other Male Genital Organs	^	^	--	^	^	--	^	^	--
Urinary System	8.6	13.3	5.1	9.1	14.2	5.1	7.6	10.8	5.3
Urinary Bladder	4.0	6.6	2.1	4.3	7.3	2.0	3.1	4.1	2.4
Kidney and Renal Pelvis	4.5	6.5	2.9	4.6	6.5	3.0	4.3	6.7	2.7
Ureter	^	^	^	^	^	^	^	^	^
Other Urinary Organs	0.1	0.1	0.1	0.1	^	^	^	^	^
Eye and Orbit	0.1	^	^	0.1	^	^	^	^	^
Brain and Other Nervous System	4.3	5.3	3.5	5.0	6.1	4.1	2.7	3.5	2.1
Endocrine System	0.8	0.8	0.8	0.8	0.8	0.7	0.9	0.7	1.0
Thyroid	0.5	0.4	0.5	0.5	0.5	0.4	0.6	^	0.8
Other Endocrine including Thymus	0.3	0.3	0.3	0.3	0.3	0.3	0.4	^	^
Lymphoma	5.9	7.9	4.4	6.3	8.4	4.6	4.5	5.9	3.5
Hodgkin Lymphoma	0.3	0.3	0.3	0.3	0.4	0.3	0.2	^	^
Non-Hodgkin Lymphoma	5.6	7.5	4.1	5.9	8.0	4.3	4.3	5.6	3.3
Myeloma	3.7	4.7	2.9	2.9	3.8	2.3	6.0	7.6	4.9
Leukemia	6.4	8.4	4.9	6.6	8.7	5.1	5.6	7.4	4.5
Lymphocytic Leukemia	1.6	2.2	1.1	1.6	2.2	1.2	1.5	2.1	1.1
Acute Lymphocytic Leukemia	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.5	^
Chronic Lymphocytic Leukemia	1.0	1.5	0.7	1.0	1.5	0.7	1.1	1.5	0.8
Other Lymphocytic Leukemia	0.2	0.3	0.2	0.2	0.3	0.2	^	^	^
Myeloid and Monocytic Leukemia	3.0	3.7	2.4	3.1	3.8	2.4	2.7	3.2	2.3
Acute Myeloid Leukemia	2.4	2.8	2.0	2.5	3.0	2.1	2.1	2.3	1.9
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	0.3	0.4	0.2	0.3	0.5	0.2	0.3	^	^
Other Myeloid/Monocytic Leukemia	0.3	0.4	0.2	0.3	0.3	0.2	0.3	0.5	^
Other Leukemia	1.8	2.5	1.3	1.9	2.6	1.4	1.4	2.1	1.0
Other Acute Leukemia	0.3	0.4	0.2	0.3	0.4	0.2	0.3	^	^
Aleukemic, Subleukemic and NOS	1.5	2.1	1.1	1.6	2.2	1.2	1.2	1.9	0.7
Miscellaneous Malignant Cancer	11.7	15.1	9.2	11.3	14.5	9.0	13.2	17.5	10.3
In situ, benign or unknown behavior neoplasm	4.2	5.4	3.3	4.2	5.4	3.2	4.3	5.6	3.4

¹Rates are per 100,000 and age-adjusted to the 2000 Population (19 age groups – Census P25-1130) standard.

[^]Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

--Not Applicable

Table L1. Average Annual Death Rates¹ for Selected Cancers by Race and Sex, 2015-2019:
U.S., Louisiana, and 7-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site	White Males				White Females				Black Males				Black Females			
	US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.	
All Malignant Cancers	182.0	198.9	↑	173.8 *	132.0	138.5	↑	121.5 *	215.3	254.3	↑	245.3	147.6	161.5	↑	152.6
Oral Cavity and Pharynx	3.9	4.9	↑	4.2	1.4	1.5		1.3	4.3	5.8	↑	6.7	1.2	1.7	↑	^
Esophagus	7.3	7.1		6.5	1.4	1.3		^	4.8	6.2	↑	6.3	1.5	1.8		2.1
Stomach	3.4	3.2		2.1	1.9	1.6		1.5	7.3	8.0		7.3	3.4	4.1	↑	4.2
Small Intestine	0.5	0.6		^	0.3	0.3		^	0.8	0.7		^	0.6	0.4		^
Colon and Rectum	15.6	17.3	↑	13.5 *	11.1	11.7		8.5 *	22.1	26.5	↑	27.0	14.4	16.8	↑	13.9
Liver and Intrahepatic Bile Duct	9.1	11.6	↑	10.1	3.9	4.4	↑	3.6	13.0	18.8	↑	21.6	4.7	5.6	↑	6.3
Pancreas	12.8	13.8	↑	12.5	9.5	10.5	↑	9.0	14.9	16.5	↑	16.4	12.0	13.2	↑	13.1
Larynx	1.6	1.9	↑	1.5	0.3	0.4		^	2.8	4.0	↑	3.5	0.5	0.7		^
Lung and Bronchus	44.7	55.4	↑	42.8 *	32.0	37.2	↑	32.4 *	52.4	71.9	↑	64.0	28.3	31.6	↑	26.8 *
Breast	0.3	0.2		^	19.4	19.7		17.6	0.5	^		^	27.1	29.6	↑	30.8
Cervix Uteri	--	--		--	2.1	2.6	↑	1.5	--	--		--	3.2	4.7	↑	3.9
Corpus and Uterus, NOS	--	--		--	4.6	3.5	↓	1.6 *	--	--		--	8.8	7.7	↓	7.3
Ovary	--	--		--	6.7	6.0	↓	6.8	--	--		--	5.7	6.1		5.3
Prostate	17.7	16.1	↓	15.3	--	--		--	36.9	34.5		32.4	--	--		--
Urinary Bladder	7.7	7.3		6.9	2.1	2.0		1.5	5.2	4.1	↓	3.7	2.3	2.4		2.5
Kidney and Renal Pelvis	5.4	6.5	↑	5.1	2.3	3.0	↑	2.2	5.1	6.7	↑	7.6	2.1	2.7	↑	2.8
Brain and Other Nervous System	5.9	6.1		6.8	3.9	4.1		4.8	3.2	3.5		3.3	2.2	2.1		2.3
Hodgkin Lymphoma	0.4	0.4		^	0.2	0.3		^	0.3	^		^	0.2	^		^
Non-Hodgkin Lymphoma	7.1	8.0	↑	7.6	4.2	4.3		4.1	5.0	5.6		5.2	3.0	3.3		3.2
Myeloma	3.8	3.8		3.7	2.3	2.3		2.1	7.2	7.6		8.9	4.9	4.9		7.5 #
Leukemia	8.5	8.7		8.1	4.7	5.1		5.7	6.6	7.4		4.7 *	4.2	4.5		4.3

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate. -- Not applicable

Table L2. Average Annual Death Rates¹ for Selected Cancers by Race and Sex, 2015-2019:
U.S., Louisiana, and 11-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site	White Males				White Females				Black Males				Black Females			
	US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.	
All Malignant Cancers	182.0	198.9	↑	175.9 *	132.0	138.5	↑	125.7 *	215.3	254.3	↑	234.5 *	147.6	161.5	↑	153.8 *
Oral Cavity and Pharynx	3.9	4.9	↑	4.6	1.4	1.5		1.2	4.3	5.8	↑	4.9	1.2	1.7	↑	1.2
Esophagus	7.3	7.1		6.5	1.4	1.3		1.1	4.8	6.2	↑	5.5	1.5	1.8		1.5
Stomach	3.4	3.2		2.7	1.9	1.6		1.4	7.3	8.0		7.0	3.4	4.1	↑	3.9
Small Intestine	0.5	0.6		0.7	0.3	0.3		^	0.8	0.7		^	0.6	0.4		^
Colon and Rectum	15.6	17.3	↑	13.8 *	11.1	11.7		9.3 *	22.1	26.5	↑	23.7	14.4	16.8	↑	15.5
Liver and Intrahepatic Bile Duct	9.1	11.6	↑	10.9	3.9	4.4	↑	3.7	13.0	18.8	↑	19.4	4.7	5.6	↑	5.5
Pancreas	12.8	13.8	↑	12.1	9.5	10.5	↑	8.9 *	14.9	16.5	↑	14.7	12.0	13.2	↑	11.7
Larynx	1.6	1.9	↑	1.6	0.3	0.4		^	2.8	4.0	↑	3.9	0.5	0.7		^
Lung and Bronchus	44.7	55.4	↑	45.1 *	32.0	37.2	↑	32.3 *	52.4	71.9	↑	64.6 *	28.3	31.6	↑	29.2
Breast	0.3	0.2		^	19.4	19.7		18.6	0.5	^		^	27.1	29.6	↑	29.6
Cervix Uteri	--	--		--	2.1	2.6	↑	2.0	--	--		--	3.2	4.7	↑	4.0
Corpus and Uterus, NOS	--	--		--	4.6	3.5	↓	3.2	--	--		--	8.8	7.7	↓	7.1
Ovary	--	--		--	6.7	6.0	↓	6.4	--	--		--	5.7	6.1		6.2
Prostate	17.7	16.1	↓	14.9	--	--		--	36.9	34.5		31.3	--	--		--
Urinary Bladder	7.7	7.3		6.3	2.1	2.0		1.7	5.2	4.1	↓	3.9	2.3	2.4		2.4
Kidney and Renal Pelvis	5.4	6.5	↑	5.6	2.3	3.0	↑	2.2 *	5.1	6.7	↑	6.4	2.1	2.7	↑	2.7
Brain and Other Nervous System	5.9	6.1		5.3	3.9	4.1		4.3	3.2	3.5		3.1	2.2	2.1		2.0
Hodgkin Lymphoma	0.4	0.4		^	0.2	0.3		^	0.3	^		^	0.2	^		^
Non-Hodgkin Lymphoma	7.1	8.0	↑	7.9	4.2	4.3		4.0	5.0	5.6		6.2	3.0	3.3		3.3
Myeloma	3.8	3.8		3.6	2.3	2.3		2.1	7.2	7.6		8.0	4.9	4.9		5.1
Leukemia	8.5	8.7		7.8	4.7	5.1		4.6	6.6	7.4		6.6	4.2	4.5		3.9

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate. -- Not applicable

Table M1. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2015-2019:
White Males

	All Malignant Cancers	Lung and Bronchus	Colon and Rectum	Prostate	Pancreas	Liver and Intrahepatic Bile Duct	Leukemia	Non- Hodgkin Lymphoma	Urinary Bladder	Esophagus	Kidney and Renal Pelvis
Louisiana	198.9	55.4	17.3	16.1	13.8	11.6	8.7	8.0	7.3	7.1	6.5
Acadia Parish	236.3	72.9	31.8	18.6	12.0	^	^	^	^	^	^
Allen Parish	251.3	79.3	^	^	^	^	^	^	^	^	^
Ascension Parish	160.5	46.0	13.3	10.8	15.4	10.8	^	^	^	^	^
Assumption Parish	198.3	62.4	^	^	^	^	^	^	^	^	^
Avoyelles Parish	223.5	74.4	30.5	^	^	^	^	^	^	^	^
Beauregard Parish	245.2	86.4	18.5	^	^	20.7	^	^	^	^	^
Bienville Parish	289.9	74.7	^	^	^	^	^	^	^	^	^
Bossier Parish	198.4	48.6	13.7	13.4	14.5	11.4	11.7	8.8	9.3	^	9.2
Caddo Parish	195.9	54.6	18.2	15.1	13.3	10.9	9.8	6.5	9.7	9.2	6.4
Calcasieu Parish	211.1	58.2	14.8	15.7	17.0	14.7	9.5	10.0	7.0	9.7	8.4
Caldwell Parish	201.2	73.0	^	^	^	^	^	^	^	^	^
Cameron Parish	119.0	^	^	^	^	^	^	^	^	^	^
Catahoula Parish	252.9	67.2	^	^	^	^	^	^	^	^	^
Claiborne Parish	184.2	53.1	^	^	^	^	^	^	^	^	^
Concordia Parish	229.3	69.4	^	^	^	^	^	^	^	^	^
De Soto Parish	218.2	71.6	^	^	^	^	^	^	^	^	^
East Baton Rouge Parish	170.5	40.0	12.8	15.9	11.5	9.4	8.7	7.4	7.6	6.0	5.0
East Carroll Parish	178.7	^	^	^	^	^	^	^	^	^	^
East Feliciana Parish	218.2	63.1	^	^	^	^	^	^	^	^	^
Evangeline Parish	222.2	65.7	21.5	^	^	^	^	^	^	^	^
Franklin Parish	193.5	72.5	^	^	^	^	^	^	^	^	^
Grant Parish	215.5	60.5	33.2	^	^	^	^	^	^	^	^
Iberia Parish	213.7	57.7	19.8	23.0	17.2	14.4	^	^	^	^	^
Iberville Parish	215.0	63.9	^	^	^	^	^	^	^	^	^
Jackson Parish	239.3	64.6	^	^	^	^	^	^	^	^	^
Jefferson Parish	185.8	48.6	14.3	14.0	12.4	11.9	8.3	9.0	6.1	6.5	6.7

Jefferson Davis Parish	235.3	70.1	28.2	23.4	^	^	^	^	^	^	^
Lafayette Parish	180.1	44.1	15.8	16.5	15.0	10.0	10.2	6.2	9.1	5.9	3.9
Lafourche Parish	211.0	60.0	23.5	11.4	14.5	17.2	^	11.3	^	8.6	6.4
La Salle Parish	203.3	72.3	^	^	^	^	^	^	^	^	^
Lincoln Parish	175.5	44.9	^	26.6	^	^	^	^	^	^	^
Livingston Parish	200.5	66.6	17.7	13.8	12.5	14.1	7.8	7.2	^	^	6.3
Madison Parish	222.5	^	^	^	^	^	^	^	^	^	^
Morehouse Parish	248.0	68.7	^	^	^	^	^	^	^	^	^
Natchitoches Parish	225.3	54.3	25.9	^	^	^	^	^	^	^	^
Orleans Parish	147.9	34.6	12.5	14.8	11.1	9.8	6.0	6.4	5.9	5.9	^
Ouachita Parish	234.2	64.5	24.5	18.9	18.3	7.6	8.6	10.6	10.7	7.1	7.3
Plaquemines Parish	194.2	52.8	^	^	^	^	^	^	^	^	^
Pointe Coupee Parish	188.4	48.3	^	^	^	^	^	^	^	^	^
Rapides Parish	186.0	47.7	19.0	12.4	13.1	9.4	13.0	8.3	^	8.8	^
Red River Parish	286.7	88.4	^	^	^	^	^	^	^	^	^
Richland Parish	204.1	86.4	^	^	^	^	^	^	^	^	^
Sabine Parish	215.8	54.9	^	^	^	^	^	^	^	^	^
St. Bernard Parish	206.7	75.7	^	^	^	13.8	^	^	^	^	^
St. Charles Parish	177.1	38.6	21.4	19.6	^	^	^	^	^	^	^
St. Helena Parish	222.5	^	^	^	^	^	^	^	^	^	^
St. James Parish	191.1	52.9	^	^	^	^	^	^	^	^	^
St. John the Baptist Parish	198.3	45.4	^	^	^	^	^	^	^	^	^
St. Landry Parish	214.6	54.5	18.5	15.7	14.9	15.3	^	^	^	^	^
St. Martin Parish	206.0	65.1	26.8	^	^	^	^	15.6	^	^	^
St. Mary Parish	244.9	76.7	20.9	16.3	^	^	^	^	^	^	^
St. Tammany Parish	189.1	48.3	14.8	16.0	13.1	9.8	7.5	5.8	9.6	5.9	5.9
Tangipahoa Parish	211.9	67.7	14.7	20.6	14.9	9.7	12.6	8.7	^	6.2	6.8
Tensas Parish	^	^	^	^	^	^	^	^	^	^	^
Terrebonne Parish	229.5	73.3	19.4	16.5	14.4	13.7	^	11.8	^	8.7	^
Union Parish	200.9	48.8	^	^	^	^	^	^	^	^	^
Vermilion Parish	185.1	44.8	17.8	21.0	11.3	12.4	11.3	^	^	^	^
Vernon Parish	260.8	91.6	26.1	^	18.7	^	^	^	^	^	^
Washington Parish	231.2	70.5	16.4	17.1	17.5	18.3	^	^	^	^	^

Webster Parish	247.4	73.5	26.3	^	17.6	17.7	^	^	^	^	^
West Baton Rouge Parish	176.4	33.8	^	^	^	^	^	^	^	^	^
West Carroll Parish	260.2	90.7	^	^	^	^	^	^	^	^	^
West Feliciana Parish	177.2	58.2	^	^	^	^	^	^	^	^	^
Winn Parish	226.7	79.3	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M2. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2015-2019:
White Females

	All Malignant Cancers	Lung and Bronchus	Breast	Colon and Rectum	Pancreas	Ovary	Leukemia	Liver and Intrahepatic Bile Duct	Non- Hodgkin Lymphoma	Brain and Other Nervous System	Corpus and Uterus, NOS
Louisiana	138.5	37.2	19.7	11.7	10.5	6.0	5.1	4.4	4.3	4.1	3.5
Acadia	148.6	41.0	22.3	18.1	12.5	^	^	^	^	^	^
Allen	150.2	38.9	^	^	^	^	^	^	^	^	^
Ascension	116.0	36.9	16.2	^	9.6	^	^	^	^	^	^
Assumption	118.8	42.2	^	^	^	^	^	^	^	^	^
Avoyelles	142.6	40.1	^	19.3	^	^	^	^	^	^	^
Beauregard	147.7	53.4	^	18.8	^	^	^	^	^	^	^
Bienville	152.9	43.9	^	^	^	^	^	^	^	^	^
Bossier	139.2	43.7	18.3	10.4	9.4	6.8	^	^	^	5.3	^
Caddo	148.0	36.7	21.9	12.6	11.1	7.5	5.1	5.6	4.6	6.0	3.6
Calcasieu	156.1	39.9	23.5	16.1	13.5	4.9	6.8	6.1	3.5	4.2	3.6
Caldwell	142.8	^	^	^	^	^	^	^	^	^	^
Cameron	102.0	^	^	^	^	^	^	^	^	^	^
Catahoula	151.0	^	^	^	^	^	^	^	^	^	^
Claiborne	172.7	^	^	^	^	^	^	^	^	^	^
Concordia	177.6	48.8	^	^	^	^	^	^	^	^	^
De Soto	146.2	^	^	^	^	^	^	^	^	^	^
East Baton Rouge	120.2	28.4	18.1	8.9	8.6	7.9	6.0	3.4	4.2	5.6	2.5
East Carroll	201.6	^	^	^	^	^	^	^	^	^	^
East Feliciana	160.2	52.3	^	^	^	^	^	^	^	^	^
Evangeline	146.4	45.0	^	^	^	^	^	^	^	^	^
Franklin	153.5	36.9	^	^	^	^	^	^	^	^	^
Grant	125.7	35.7	^	^	^	^	^	^	^	^	^
Iberia	142.5	44.1	17.4	10.5	^	^	^	^	^	^	^
Iberville	122.8	43.3	^	^	^	^	^	^	^	^	^
Jackson	129.9	34.0	^	^	^	^	^	^	^	^	^
Jefferson	132.0	31.6	20.1	10.2	9.5	5.7	4.6	3.7	4.1	4.4	5.3
Jefferson Davis	187.1	51.3	31.9	18.7	18.6	^	^	^	^	^	^

Lafayette	142.1	37.9	21.8	12.1	11.8	6.3	4.3	4.1	6.1	^	^
Lafourche	149.8	39.6	20.3	17.1	9.5	6.6	7.0	^	8.2	^	^
La Salle	131.0	42.0	^	^	^	^	^	^	^	^	^
Lincoln	129.2	36.1	21.3	^	^	^	^	^	^	^	^
Livingston	130.9	39.1	17.6	8.9	10.5	^	5.8	4.6	^	^	^
Madison	197.1	^	^	^	^	^	^	^	^	^	^
Morehouse	153.8	40.4	^	^	^	^	^	^	^	^	^
Natchitoches	161.2	29.1	24.7	20.2	^	^	^	^	^	^	^
Orleans	115.4	29.5	17.3	9.0	7.1	6.6	^	^	^	^	^
Ouachita	148.1	39.1	22.7	11.2	11.5	7.8	7.2	^	^	^	^
Plaquemines	134.3	38.2	^	^	^	^	^	^	^	^	^
Pointe Coupee	102.8	^	^	^	^	^	^	^	^	^	^
Rapides	137.8	36.8	23.3	12.9	12.6	5.0	^	7.2	4.8	^	^
Red River	132.7	^	^	^	^	^	^	^	^	^	^
Richland	103.8	^	^	^	^	^	^	^	^	^	^
Sabine	150.6	47.3	^	^	^	^	^	^	^	^	^
St. Bernard	145.7	46.7	17.3	^	^	^	^	^	^	^	^
St. Charles	146.8	39.4	19.0	^	16.4	^	^	^	^	^	^
St. Helena	160.3	^	^	^	^	^	^	^	^	^	^
St. James	87.8	^	^	^	^	^	^	^	^	^	^
St. John the Baptist	144.6	34.4	31.7	^	^	^	^	^	^	^	^
St. Landry	165.1	47.5	24.7	19.8	15.5	^	^	^	^	^	^
St. Martin	128.8	38.3	16.9	^	^	^	^	^	^	^	^
St. Mary	152.4	43.3	16.7	^	^	^	^	^	^	^	^
St. Tammany	127.0	33.9	17.9	8.4	10.6	6.3	5.7	3.3	4.0	4.3	3.7
Tangipahoa	141.2	36.5	19.5	10.7	8.7	8.3	^	5.4	^	^	^
Tensas	^	^	^	^	^	^	^	^	^	^	^
Terrebonne	160.2	39.7	23.1	12.9	11.6	^	^	^	9.7	^	^
Union	159.7	26.1	^	^	^	^	^	^	^	^	^
Vermilion	144.0	41.9	19.0	16.7	^	^	^	^	^	^	^
Vernon	181.5	51.5	25.3	17.3	18.1	^	^	^	^	^	^
Washington	151.5	41.6	22.7	15.2	^	^	^	^	^	^	^
Webster	152.6	45.6	21.7	^	15.6	^	^	^	^	^	^

West Baton Rouge	118.9	46.4	^	^	^	^	^	^	^	^	^
West Carroll	145.9	44.2	^	^	^	^	^	^	^	^	^
West Feliciana	117.4	^	^	^	^	^	^	^	^	^	^
Winn	128.8	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M3. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Males

	All Malignant Cancers	Lung and Bronchus	Prostate	Colon and Rectum	Liver and Intrahepatic Bile Duct	Pancreas	Stomach	Myeloma	Leukemia	Kidney and Renal Pelvis	Esophagus
Louisiana	254.3	71.9	34.5	26.5	18.8	16.5	8.0	7.6	7.4	6.7	6.2
Acadia	327.1	108.8	^	^	^	^	^	^	^	^	^
Allen	242.3	^	^	^	^	^	^	^	^	^	^
Ascension	198.6	50.4	^	^	^	^	^	^	^	^	^
Assumption	315.6	124.6	^	^	^	^	^	^	^	^	^
Avoyelles	332.2	84.1	^	^	^	^	^	^	^	^	^
Beauregard	214.3	^	^	^	^	^	^	^	^	^	^
Bienville	219.1	^	^	^	^	^	^	^	^	^	^
Bossier	191.5	48.9	38.7	^	^	^	^	^	^	^	^
Caddo	264.8	71.2	33.6	29.2	22.7	20.4	7.1	8.2	7.1	7.7	7.9
Calcasieu	265.4	80.0	23.5	31.5	28.1	27.0	^	^	^	^	^
Caldwell	^	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	608.0	^	^	^	^	^	^	^	^	^	^
Claiborne	250.7	86.8	^	^	^	^	^	^	^	^	^
Concordia	356.8	113.6	^	^	^	^	^	^	^	^	^
De Soto	315.4	75.6	^	^	^	^	^	^	^	^	^
East Baton Rouge	254.3	67.7	31.9	26.7	24.1	17.5	6.9	8.3	^	8.1	7.2
East Carroll	469.7	^	^	^	^	^	^	^	^	^	^
East Feliciana	241.2	^	^	^	^	^	^	^	^	^	^
Evangeline	284.4	103.0	^	^	^	^	^	^	^	^	^
Franklin	270.6	^	^	^	^	^	^	^	^	^	^
Grant	^	^	^	^	^	^	^	^	^	^	^
Iberia	296.6	82.5	^	^	^	^	^	^	^	^	^
Iberville	295.1	90.6	^	^	^	^	^	^	^	^	^
Jackson	335.8	^	^	^	^	^	^	^	^	^	^
Jefferson	246.1	74.0	33.5	21.0	15.3	14.2	^	11.6	^	^	6.6
Jefferson Davis	282.1	^	^	^	^	^	^	^	^	^	^

Lafayette	255.1	69.3	26.1	29.4	28.2	15.6	^	^	^	^	^
Lafourche	330.3	82.1	^	^	^	^	^	^	^	^	^
La Salle	^	^	^	^	^	^	^	^	^	^	^
Lincoln	259.8	95.7	^	^	^	^	^	^	^	^	^
Livingston	226.9	^	^	^	^	^	^	^	^	^	^
Madison	284.4	^	^	^	^	^	^	^	^	^	^
Morehouse	346.3	132.6	^	^	^	^	^	^	^	^	^
Natchitoches	281.1	77.3	^	^	^	^	^	^	^	^	^
Orleans	217.6	61.2	29.6	21.9	18.8	13.5	7.4	5.9	7.4	5.3	3.9
Ouachita	264.9	79.1	54.1	23.9	^	^	^	^	^	^	^
Plaquemines	310.9	^	^	^	^	^	^	^	^	^	^
Pointe Coupee	256.0	^	^	^	^	^	^	^	^	^	^
Rapides	279.4	96.0	54.0	33.5	14.0	^	^	^	^	^	^
Red River	332.2	^	^	^	^	^	^	^	^	^	^
Richland	309.2	^	^	^	^	^	^	^	^	^	^
Sabine	210.1	^	^	^	^	^	^	^	^	^	^
St. Bernard	251.3	^	^	^	^	^	^	^	^	^	^
St. Charles	251.4	^	^	^	^	^	^	^	^	^	^
St. Helena	197.4	^	^	^	^	^	^	^	^	^	^
St. James	195.2	55.0	^	^	^	^	^	^	^	^	^
St. John the Baptist	226.2	48.7	^	^	^	^	^	^	^	^	^
St. Landry	314.6	82.7	34.7	37.8	29.0	21.6	^	^	^	^	^
St. Martin	287.6	71.1	^	64.7	^	^	^	^	^	^	^
St. Mary	268.2	54.4	42.5	^	^	^	^	^	^	^	^
St. Tammany	226.4	56.6	40.6	^	^	22.8	^	^	^	^	^
Tangipahoa	309.7	93.3	58.1	^	27.4	^	^	^	^	^	^
Tensas	180.0	^	^	^	^	^	^	^	^	^	^
Terrebonne	312.7	96.9	^	^	^	^	^	^	^	^	^
Union	260.6	^	^	^	^	^	^	^	^	^	^
Vermilion	250.2	^	^	^	^	^	^	^	^	^	^
Vernon	248.3	^	^	^	^	^	^	^	^	^	^
Washington	281.2	73.5	^	^	^	^	^	^	^	^	^
Webster	239.4	86.8	^	^	^	^	^	^	^	^	^

West Baton Rouge	229.1	^	^	^	^	^	^	^	^	^	^
West Carroll	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	219.7	69.4	^	^	^	^	^	^	^	^	^
Winn	210.3	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M4. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Females

	All Malignant Cancers	Lung and Bronchus	Breast	Colon and Rectum	Pancreas	Corpus and Uterus, NOS	Ovary	Liver and Intrahepatic Bile Duct	Myeloma	Cervix Uteri	Leukemia
Louisiana	161.5	31.6	29.6	16.8	13.2	7.7	6.1	5.6	4.9	4.7	4.5
Acadia	189.3	^	^	^	^	^	^	^	^	^	^
Allen	145.0	^	^	^	^	^	^	^	^	^	^
Ascension	130.6	^	41.2	^	^	^	^	^	^	^	^
Assumption	195.4	^	^	^	^	^	^	^	^	^	^
Avoyelles	180.1	^	^	^	^	^	^	^	^	^	^
Beauregard	139.4	^	^	^	^	^	^	^	^	^	^
Bienville	126.5	^	^	^	^	^	^	^	^	^	^
Bossier	163.7	27.8	25.6	^	^	^	^	^	^	^	^
Caddo	168.1	33.9	32.5	16.6	15.1	10.2	^	^	^	^	5.8
Calcasieu	190.0	35.4	32.1	20.2	18.8	^	^	^	^	^	^
Caldwell	^	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	^	^	^	^	^	^	^	^	^	^	^
Claiborne	136.5	^	^	^	^	^	^	^	^	^	^
Concordia	164.6	^	^	^	^	^	^	^	^	^	^
De Soto	188.9	^	^	^	^	^	^	^	^	^	^
East Baton Rouge	150.6	25.5	27.2	16.3	13.7	8.1	5.5	6.4	8.5	4.1	4.6
East Carroll	317.2	122.1	^	^	^	^	^	^	^	^	^
East Feliciana	152.1	^	^	^	^	^	^	^	^	^	^
Evangeline	194.1	75.4	^	^	^	^	^	^	^	^	^
Franklin	132.2	^	^	^	^	^	^	^	^	^	^
Grant	^	^	^	^	^	^	^	^	^	^	^
Iberia	160.0	30.8	35.8	^	^	^	^	^	^	^	^
Iberville	168.5	^	38.4	^	^	^	^	^	^	^	^
Jackson	166.8	^	^	^	^	^	^	^	^	^	^
Jefferson	176.6	31.3	30.5	17.9	11.3	7.9	^	5.7	^	5.9	^
Jefferson Davis	124.9	^	^	^	^	^	^	^	^	^	^

Lafayette	151.1	25.7	25.7	15.1	13.5	^	^	^	^	^	^
Lafourche	196.0	^	^	^	^	^	^	^	^	^	^
La Salle	^	^	^	^	^	^	^	^	^	^	^
Lincoln	181.3	32.8	41.0	^	^	^	^	^	^	^	^
Livingston	185.3	^	^	^	^	^	^	^	^	^	^
Madison	210.6	^	^	^	^	^	^	^	^	^	^
Morehouse	161.4	^	^	^	^	^	^	^	^	^	^
Natchitoches	174.0	40.6	^	^	^	^	^	^	^	^	^
Orleans	144.9	30.2	27.7	15.2	10.5	6.9	7.2	4.7	3.0	3.7	3.5
Ouachita	171.4	40.2	25.8	12.6	20.0	^	^	^	^	^	^
Plaquemines	188.0	^	^	^	^	^	^	^	^	^	^
Pointe Coupee	137.6	^	^	^	^	^	^	^	^	^	^
Rapides	158.3	27.8	33.2	23.6	^	^	^	^	^	^	^
Red River	160.1	^	^	^	^	^	^	^	^	^	^
Richland	215.4	^	^	^	^	^	^	^	^	^	^
Sabine	132.8	^	^	^	^	^	^	^	^	^	^
St. Bernard	247.9	^	^	^	^	^	^	^	^	^	^
St. Charles	154.9	^	^	^	^	^	^	^	^	^	^
St. Helena	130.3	^	^	^	^	^	^	^	^	^	^
St. James	202.8	47.7	52.6	^	^	^	^	^	^	^	^
St. John the Baptist	143.8	^	24.9	^	^	^	^	^	^	^	^
St. Landry	183.2	40.6	28.2	21.6	^	^	^	^	^	^	^
St. Martin	153.8	40.1	^	^	^	^	^	^	^	^	^
St. Mary	202.6	43.0	^	^	^	^	^	^	^	^	^
St. Tammany	136.7	25.7	23.7	^	^	^	^	^	^	^	^
Tangipahoa	160.4	33.9	19.9	16.6	^	^	^	^	^	^	^
Tensas	181.9	^	^	^	^	^	^	^	^	^	^
Terrebonne	180.8	42.6	48.8	^	^	^	^	^	^	^	^
Union	171.5	^	^	^	^	^	^	^	^	^	^
Vermilion	151.1	^	^	^	^	^	^	^	^	^	^
Vernon	206.8	^	^	^	^	^	^	^	^	^	^
Washington	198.2	33.5	45.3	^	^	^	^	^	^	^	^
Webster	161.8	^	^	^	^	^	^	^	^	^	^

West Baton Rouge	194.1	^	^	^	^	^	^	^	^	^	^
West Carroll	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	151.3	^	^	^	^	^	^	^	^	^	^
Winn	154.1	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N1. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2015-2019:
White Males

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region	
All Malignant Cancers	182.0	198.9	↑	177.0	*	186.2	*	201.3		203.4		218.9	#	212.1	#	208.9	#	218.3	#
Lung and Bronchus	44.7	55.4	↑	46.7	*	52.2		55.2		55.5		64.9	#	64.0	#	56.6		64.3	#
Prostate	17.7	16.1	↓	14.4		15.7		15.6		17.0		16.3		16.3		15.9		19.5	
Colon and Rectum	15.6	17.3	↑	13.9	*	14.6	*	17.5		20.2	#	16.3		22.9	#	18.4		19.8	
Pancreas	12.8	13.8	↑	12.0		13.3		13.3		14.4		16.2		13.9		14.7		14.7	
Liver and Intrahepatic Bile Duct	9.1	11.6	↑	11.6		11.5		11.9		11.3		15.2	#	9.1		12.7		8.6	*
Leukemia	8.5	8.7		7.2		8.7		7.9		8.9		8.1		10.5		10.7		8.1	
Urinary Bladder	7.7	7.3		5.9		6.6		7.7		7.1		8.1		8.2		8.5		8.7	
Esophagus	7.3	7.1		6.4		5.8		7.7		6.8		8.8		8.3		8.3		6.3	
Non-Hodgkin Lymphoma	7.1	8.0	↑	8.0		7.6		8.5		8.4		10.2		7.6		6.7		8.3	
Brain and Other Nervous System	5.9	6.1		4.2	*	6.4		6.7		5.8		7.5		5.9		5.9		6.9	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N2. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2015-2019:
White Females

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region
All Malignant Cancers	132.0	138.5	↑	128.8 *		125.5 *		138.3		145.1 #		156.4 #		145.7		147.4 #		144.0
Lung and Bronchus	32.0	37.2	↑	32.0 *		34.7		36.5		41.1 #		42.8 #		40.4		39.2		38.1
Breast	19.4	19.7		19.2		17.3 *		19.9		20.1		23.0		20.9		21.0		18.4
Colon and Rectum	11.1	11.7		10.0		9.0 *		11.0		13.8 #		15.5 #		14.8 #		12.4		11.6
Pancreas	9.5	10.5	↑	8.9		9.1		10.5		11.1		13.5 #		11.8		10.8		12.0
Ovary	6.7	6.0	↓	6.0		6.6		5.8		5.7		4.8		4.4		6.8		6.6
Leukemia	4.7	5.1		3.9 *		5.5		5.9		4.6		5.8		4.7		5.1		5.8
Corpus and Uterus, NOS	4.6	3.5	↓	4.5		2.9		3.3		3.1		4.1		2.7		3.2		5.2 #
Non-Hodgkin Lymphoma	4.2	4.3		3.9		3.7		5.8 #		4.8		4.1		4.8		4.0		3.4
Liver and Intrahepatic Bile Duct	3.9	4.4	↑	3.8		4.3		3.9		4.2		5.1		6.2 #		5.2		3.6
Brain and Other Nervous System	3.9	4.1		4.1		4.0		4.4		3.5		3.9		2.9		5.8 #		4.2

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N3. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Males

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region	Southeast Region	Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region	
All Malignant Cancers	215.3	254.3	↑	225.5	*	253.3	257.6	283.0	#	257.4		287.9	#	255.5		281.0	#
Lung and Bronchus	52.4	71.9	↑	64.7	*	70.9	64.6	76.4		79.2		89.3	#	70.2		88.5	#
Prostate	36.9	34.5		30.4		34.2	35.4	29.3		23.1	*	49.0	#	36.5		49.3	#
Colon and Rectum	22.1	26.5	↑	21.4	*	25.2	26.4	33.9	#	30.1		34.0		28.3		27.3	
Pancreas	14.9	16.5	↑	13.8		15.7	18.1	20.6		23.0		10.7		17.9		17.4	
Liver and Intrahepatic Bile Duct	13	18.8	↑	18.0		21.8	20.4	23.3		25.3		12.6		18.5		6.9	*
Stomach	7.3	8.0		6.7		7.2	9.9	9.9		^		8.1		7.3		9.7	
Myeloma	7.2	7.6		7.3		9.1	7.2	7.7		^		^		6.9		7.5	
Leukemia	6.6	7.4		7.5		5.8	9.4	10.9		^		^		6.1		7.4	
Urinary Bladder	5.2	4.1	↓	4.1		3.9	^	5.5		^		^		^		^	
Kidney and Renal Pelvis	5.1	6.7	↑	5.2		7.8	^	8.1		^		^		7.7		7.4	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N4. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Females

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	
All Malignant Cancers	147.6	161.5	↑	154.3	152.8	166.9	167.6	177.2	166.9	164.4	178.4	#
Lung and Bronchus	28.3	31.6	↑	30.5	27.5	34.9	36.4	33.5	28.9	31.2	37.0	
Breast	27.1	29.6	↑	28.7	29.1	34.2	27.2	30.3	34.6	29.7	28.3	
Colon and Rectum	14.4	16.8	↑	16.6	15.3	15.6	18.2	18.9	20.4	16.2	17.9	
Pancreas	12.0	13.2	↑	10.8	13.6	10.4	12.5	18.8	13.5	14.2	19.1	#
Corpus and Uterus, NOS	8.8	7.7	↓	7.0	8.5	6.4	6.7	^	^	10.6	#	8.7
Ovary	5.7	6.1		6.8	5.5	6.9	6.1	^	^	4.4	7.4	
Myeloma	4.9	4.9		3.5	7.0	#	5.5	5.4	^	5.5	^	
Liver and Intrahepatic Bile Duct	4.7	5.6	↑	4.9	6.6	6.5	6.6	^	^	5.1	4.7	
Uterus, NOS	4.5	3.5	↓	3.0	4.9	^	^	^	^	3.6	^	
Corpus Uteri	4.3	4.2		4.0	3.6	^	4.4	^	^	7.0	#	5.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O1. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2015-2019:
White Males

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region		Northlake Region
All Malignant Cancers	182.0	198.9	↑	177.6 *		174.2 *		213.1 #		199.8		218.9 #		212.1 #		208.9 #		218.3 #		199.7
Lung and Bronchus	44.7	55.4	↑	47.0 *		44.2 *		61.8 #		53.6		64.9 #		64.0 #		56.6		64.3 #		57.8
Prostate	17.7	16.1	↓	14.5		15.5		14.3		17.1		16.3		16.3		15.9		19.5		16.5
Colon and Rectum	15.6	17.3	↑	14.0 *		13.3 *		20.2		20.1 #		16.3		22.9 #		18.4		19.8		15.8
Pancreas	12.8	13.8	↑	11.9		12.8		13.6		14.5		16.2		13.9		14.7		14.7		13.6
Liver and Intrahepatic Bile Duct	9.1	11.6	↑	11.4		10.9		13.3		11.1		15.2 #		9.1		12.7		8.6 *		11.6
Leukemia	8.5	8.7		7.5		8.3		6.9		9.1		8.1		10.5		10.7		8.1		8.8
Urinary Bladder	7.7	7.3		5.8		7.2		6.6		6.7		8.1		8.2		8.5		8.7		7.7
Esophagus	7.3	7.1		6.5		5.7		9.4 #		6.8		8.8		8.3		8.3		6.3		5.6
Non-Hodgkin Lymphoma	7.1	8.0	↑	8.0		7.4		10.5 #		8.0		10.2		7.6		6.7		8.3		7.2
Brain and Other Nervous System	5.9	6.1		4.2 *		6.6		6.2		6.3		7.5		5.9		5.9		6.9		6.3

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O2. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2015-2019:
White Females

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
All Malignant Cancers	132.0	138.5	↑	129.0 *	119.8 *	146.8 #	144.6	156.4 #	145.7	147.4 #	144.0	132.7
Lung and Bronchus	32.0	37.2	↑	32.2 *	32.0 *	39.0	40.9 #	42.8 #	40.4	39.2	38.1	36.6
Breast	19.4	19.7		19.4	17.2	20.0	20.4	23.0	20.9	21.0	18.4	18.3
Colon and Rectum	11.1	11.7		9.9	8.4 *	13.0	13.9 #	15.5 #	14.8 #	12.4	11.6	9.6 *
Pancreas	9.5	10.5	↑	8.8	8.7	10.4	11.5	13.5 #	11.8	10.8	12.0	10.1
Ovary	6.7	6.0	↓	6.1	6.9	5.6	5.7	4.8	4.4	6.8	6.6	6.0
Leukemia	4.7	5.1		3.8 *	5.8	5.7	4.5	5.8	4.7	5.1	5.8	5.7
Corpus and Uterus, NOS	4.6	3.5	↓	4.4	2.1 *	2.9	3.3	4.1	2.7	3.2	5.2 #	3.9
Non-Hodgkin Lymphoma	4.2	4.3		3.9	3.8	7.4 #	4.7	4.1	4.8	4.0	3.4	3.7
Liver and Intrahepatic Bile Duct	3.9	4.4	↑	3.9	3.9	4.2	4.3	5.1	6.2 #	5.2	3.6	4.0
Brain and Other Nervous System	3.9	4.1		3.9	4.5	4.4	3.5	3.9	2.9	5.8 #	4.2	3.9

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O3. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Males

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
All Malignant Cancers	215.3	254.3	↑	226.7 *	247.7	266.1	284.6 #	257.4	287.9 #	255.5	281.0 #	260.0
Lung and Bronchus	52.4	71.9	↑	64.8 *	66.0	67.9	79.1	79.2	89.3 #	70.2	88.5 #	74.2
Prostate	36.9	34.5		30.6	33.0	32.2	27.7	23.1 *	49.0 #	36.5	49.3 #	42.9
Colon and Rectum	22.1	26.5	↑	21.5 *	26.4	28.4	35.3 #	30.1	34.0	28.3	27.3	18.9
Pancreas	14.9	16.5	↑	13.7	16.2	15.0	21.1	23.0	10.7	17.9	17.4 *	20.3
Liver and Intrahepatic Bile Duct	13.0	18.8	↑	17.9	21.9	17.9	25.4 #	25.3	12.6	18.5	6.9 *	21.3
Stomach	7.3	8.0		6.9	7.1	11.6	9.2	^	8.1	7.3	9.7	^
Myeloma	7.2	7.6		7.4	9.1	8.1	7.9	^	^	6.9	7.5	^
Leukemia	6.6	7.4		7.9	4.2 *	8.0	11.6 #	^	^	6.1	7.4	11.3
Urinary Bladder	5.2	4.1	↓	4.0	4.2	^	^	^	^	^	^	^
Kidney and Renal Pelvis	5.1	6.7	↑	5.5	8.4	^	8.5	^	^	7.7	7.4	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O4. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2015-2019:
Black Females

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region		Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region		Northlake Region
All Malignant Cancers	147.6	161.5	↑	154.7	150.6	*	177.0	163.6	177.2	166.9	164.4	178.4	#	158.8
Lung and Bronchus	28.3	31.6	↑	30.9	27.0	*	36.1	35.4	33.5	28.9	31.2	37.0		30.1
Breast	27.1	29.6	↑	28.7	30.7		34.5	26.8	30.3	34.6	29.7	28.3		25.5
Colon and Rectum	14.4	16.8	↑	16.6	15.0		16.5	17.6	18.9	20.4	16.2	17.9		16.7
Pancreas	12.0	13.2	↑	10.8	12.7		14.9	12.2	18.8	13.5	14.2	19.1	#	10.2
Corpus and Uterus, NOS	8.8	7.7	↓	6.9	8.2		6.0	6.4	^	^	10.6	#	8.7	9.6
Ovary	5.7	6.1		6.8	5.0		7.4	6.2	^	^	4.4	7.4		7.1
Myeloma	4.9	4.9		3.5	7.6	#	^	5.9	^	^	5.5	^		^
Liver and Intrahepatic Bile Duct	4.7	5.6	↑	5.1	6.1		5.4	6.8	^	^	5.1	4.7		8.2
Uterus, NOS	4.5	3.5	↓	3.0	4.9		^	^	^	^	3.6	^		^
Corpus Uteri	4.3	4.2		4.0	3.3		^	4.2	^	^	7.0	#	5.1	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2008-2018, Louisiana

Primary Site ¹	All Race			White					Black		
	Total	Male	Female	Total	Male		Female		Total	Male	Female
All Sites	63.4%	63.1%	63.8%	65.1%	64.7%	↑	65.6%	↑	59.3%	59.5%	59.2%
Oral Cavity and Pharynx	59.6%	59.1%	61.0%	64.7%	65.3%	↑	62.8%	↑	41.9%	37.6%	52.7%
Lip	83.6%	84.4%	76.3%	83.7%	84.3%		76.9%		84.5%	88.3%	55.5%
Tongue	61.2%	61.2%	61.0%	66.9%	67.4%	↑	65.1%	↑	33.8%	29.8%	42.0%
Salivary Gland	69.1%	62.1%	79.2%	65.3%	60.7%		73.1%	↓	78.0%	65.8%	89.4%
Floor of Mouth	51.3%	49.7%	54.9%	56.5%	55.2%	↑	58.5%		37.9%	38.7%	33.7%
Gum and Other Mouth	54.3%	51.0%	58.6%	55.8%	53.8%	↑	58.0%		50.1%	44.0%	58.2%
Nasopharynx	55.7%	55.6%	55.5%	57.1%	59.0%		48.5%		45.0%	45.0%	44.0%
Tonsil	68.2%	69.8%	59.6%	72.7%	74.4%	↑	63.1%		48.5%	49.7%	42.9%
Oropharynx	41.1%	41.1%	41.1%	50.9%	52.2%	↑	46.5%		18.8%	17.4%	24.4%
Hypopharynx	30.3%	28.1%	40.5%	38.7%	36.1%	↑	51.1%		17.9%	16.8%	21.5%
Other Oral Cavity and Pharynx	47.2%	45.0%	53.7%	55.6%	56.6%	↑	50.8%		26.7%	14.1%	57.4%
Digestive System	43.0%	40.0%	46.8%	44.5%	42.2%	↑	47.7%	↑	40.1%	35.6%	45.5%
Esophagus	18.3%	16.6%	24.6%	20.1%	18.4%	↑	28.2%		13.0%	10.5%	19.3%
Stomach	29.8%	26.5%	35.5%	31.1%	28.5%		36.1%		28.4%	24.4%	34.4%
Small Intestine	69.2%	69.6%	68.5%	70.7%	68.8%		72.7%		66.3%	69.5%	63.0%
Colon and Rectum	62.7%	61.9%	63.6%	64.5%	64.5%	↑	64.5%	↑	59.1%	56.3%	61.8%
Colon excluding Rectum	62.2%	61.9%	62.5%	64.4%	64.6%	↑	64.1%	↑	58.1%	56.3%	59.7%
Cecum	61.7%	61.2%	62.0%	63.7%	63.1%		64.1%		57.5%	56.8%	58.0%
Appendix	75.8%	77.7%	73.8%	78.8%	81.3%		76.7%		67.3%	70.1%	64.5%
Ascending Colon	65.1%	62.7%	67.2%	66.5%	64.5%		68.3%		63.5%	60.2%	65.9%
Hepatic Flexure	63.0%	62.1%	63.5%	63.7%	64.2%		63.0%		60.5%	57.1%	63.4%
Transverse Colon	61.9%	60.6%	63.2%	63.7%	64.9%	↑	62.5%		57.7%	51.0%	64.0%
Splenic Flexure	63.6%	64.1%	62.4%	63.8%	62.7%		64.0%		63.3%	64.4%	61.8%
Descending Colon	63.4%	64.5%	62.1%	65.1%	67.9%		61.7%		61.2%	59.4%	62.8%
Sigmoid Colon	64.1%	64.4%	63.7%	66.6%	67.2%	↑	65.8%		58.7%	58.1%	59.6%
Large Intestine, NOS	29.1%	32.4%	25.3%	30.3%	35.6%		23.2%		27.2%	27.0%	27.5%
Rectum and Rectosigmoid Junction	63.8%	61.9%	66.4%	64.8%	64.3%	↑	65.6%		61.4%	56.2%	68.1%
Rectosigmoid Junction	59.2%	58.8%	59.8%	62.6%	63.7%	↑	60.8%		50.8%	46.1%	56.4%
Rectum	65.0%	62.7%	68.3%	65.5%	64.5%	↑	66.9%		63.9%	58.4%	70.8%
Anus, Anal Canal and Anorectum	66.3%	56.1%	73.9%	69.4%	60.9%		74.6%		56.5%	45.4%	69.3%
Liver and Intrahepatic Bile Duct	16.1%	15.5%	18.0%	17.6%	17.0%	↑	19.4%		12.9%	12.5%	14.8%
Liver	16.9%	16.1%	20.2%	18.8%	17.9%	↑	22.0%		13.4%	12.7%	16.6%
Intrahepatic Bile Duct	5.2%	4.0%	6.8%	5.7%	0.0%		8.7%		4.3%	6.3%	0.0%
Gallbladder	18.4%	16.6%	19.0%	19.5%	19.7%		19.4%		16.1%	11.6%	17.6%
Other Biliary	13.6%	11.3%	16.1%	13.6%	11.2%		16.6%		12.1%	9.4%	14.1%
Pancreas	8.0%	7.4%	8.5%	8.1%	7.6%	↑	8.6%		7.6%	6.4%	8.7%
Retroperitoneum	47.8%	41.4%	52.4%	45.9%	38.9%		51.8%		51.1%	43.1%	54.8%
Peritoneum, Omentum and Mesentery	29.4%	8.7%	31.3%	30.3%	0.0%		32.3%		25.6%	16.8%	27.2%
Other Digestive Organs	11.2%	11.1%	11.1%	10.9%	11.9%		9.5%		12.6%	10.8%	13.5%

Respiratory System	20.9%	19.9%	22.4%	21.3%	20.1%		22.9%		19.9%	19.3%	21.0%
Nose, Nasal Cavity and Middle Ear	61.8%	64.1%	58.2%	64.9%	66.2%		62.6%		48.0%	49.6%	40.7%
Larynx	56.5%	57.0%	54.6%	59.1%	59.3%	↑	58.3%		51.6%	52.7%	47.2%
Lung and Bronchus	17.5%	14.9%	20.7%	17.9%	15.2%		21.1%		16.4%	14.4%	19.4%
Pleura	7.1%	10.4%	0.0%	8.8%	13.1%		0.0%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other											
Respiratory Organs	42.1%	41.0%	44.4%	42.0%	41.0%		44.2%		39.2%	38.2%	41.7%
Bones and Joints	62.5%	58.1%	67.1%	63.1%	52.2%		72.5%		60.4%	66.5%	51.9%
Soft Tissue including Heart	61.2%	62.8%	58.9%	63.8%	64.4%		62.7%	↑	55.0%	59.2%	50.9%
Skin excluding Basal and Squamous	89.5%	88.1%	91.6%	89.9%	88.5%	↑	92.0%		77.7%	70.8%	83.8%
Melanoma of the Skin	90.0%	88.5%	92.1%	90.5%	89.0%	↑	92.8%	↑	63.6%	55.7%	69.6%
Other Non-Epithelial Skin	85.1%	84.0%	86.3%	83.7%	83.9%		83.0%	↓	89.8%	82.8%	93.4%
Breast	86.4%	76.9%	86.5%	89.1%	79.1%		89.2%	↑	80.4%	73.3%	80.5%
Female Genital System	63.7%	0.0%	63.7%	67.3%	0.0%		67.3%	↑	55.5%	0.0%	55.5%
Cervix Uteri	63.0%	0.0%	63.0%	65.9%	0.0%		65.9%	↑	58.1%	0.0%	58.1%
Corpus and Uterus, NOS	73.9%	0.0%	73.9%	79.7%	0.0%		79.7%	↑	60.9%	0.0%	60.9%
Corpus Uteri	75.6%	0.0%	75.6%	81.1%	0.0%		81.1%	↑	63.2%	0.0%	63.2%
Uterus, NOS	22.6%	0.0%	22.6%	25.6%	0.0%		25.6%	##	17.7%	0.0%	17.7%
Ovary	43.7%	0.0%	43.7%	45.8%	0.0%		45.8%	↑	37.6%	0.0%	37.6%
Vagina	44.4%	0.0%	44.4%	43.4%	0.0%		43.4%		47.2%	0.0%	47.2%
Vulva	71.1%	0.0%	71.1%	72.1%	0.0%		72.1%		66.9%	0.0%	66.9%
Other Female Genital Organs	52.0%	0.0%	52.0%	55.5%	0.0%		55.5%		39.5%	0.0%	39.5%
Male Genital System	96.8%	96.8%	0.0%	97.9%	97.9%	↑	0.0%		94.8%	94.8%	0.0%
Prostate	97.0%	97.0%	0.0%	98.1%	98.1%	↑	0.0%		95.1%	95.1%	0.0%
Testis	96.1%	96.1%	0.0%	96.7%	96.7%		0.0%		92.1%	92.1%	0.0%
Penis	65.5%	65.5%	0.0%	69.0%	69.0%		0.0%		56.6%	56.6%	0.0%
Other Male Genital Organs	90.7%	90.7%	0.0%	97.9%	97.9%		0.0%		74.6%	74.6%	0.0%
Urinary System	74.2%	74.7%	73.1%	75.4%	75.9%	↑	74.4%	↑	69.8%	70.0%	69.5%
Urinary Bladder	75.2%	77.0%	69.3%	77.1%	78.0%	↑	73.6%	↑	64.8%	70.5%	53.6%
Kidney and Renal Pelvis	74.4%	73.3%	76.0%	75.0%	74.5%	↑	75.7%		73.2%	70.2%	76.9%
Ureter	44.0%	43.3%	45.4%	44.7%	44.7%		44.9%		39.9%	32.5%	46.2%
Other Urinary Organs	44.4%	50.5%	33.0%	48.3%	48.0%		42.8%		37.8%	55.1%	23.7%
Eye and Orbit	74.7%	73.4%	76.2%	74.3%	74.2%		74.3%		76.0%	67.3%	85.7%
Brain and Other Nervous System	33.1%	31.5%	34.9%	31.9%	30.0%	↓	34.1%		37.2%	37.3%	37.0%
Brain	30.2%	29.5%	31.1%	29.0%	27.9%	↓	30.4%		34.3%	35.7%	32.5%
Cranial Nerves Other Nervous System	73.1%	67.0%	78.0%	75.5%	69.6%		79.8%		67.7%	59.7%	74.3%
Endocrine System	96.1%	92.2%	97.4%	96.6%	93.1%		97.9%		94.6%	88.2%	96.2%
Thyroid	97.9%	95.8%	98.6%	98.2%	96.0%		98.8%		97.4%	93.8%	97.8%
Other Endocrine including Thymus	63.0%	63.3%	62.4%	59.0%	60.3%		56.6%		68.0%	66.5%	69.4%
Lymphoma	70.4%	68.3%	72.8%	71.7%	70.3%	↑	73.3%		66.0%	61.7%	70.6%
Hodgkin Lymphoma	84.6%	84.4%	84.7%	83.8%	85.1%		82.0%	↓	85.7%	82.3%	89.6%
Hodgkin - Nodal	85.2%	85.1%	85.2%	84.5%	85.8%		82.8%		85.8%	82.4%	89.6%
Hodgkin - Extranodal	53.6%	55.5%	50.3%	51.5%	52.2%		50.3%		76.3%	76.3%	0.0%
Non-Hodgkin Lymphoma	68.1%	65.7%	70.9%	69.9%	68.2%	↑	72.0%	↑	61.6%	56.9%	66.5%
NHL - Nodal	66.1%	62.9%	70.0%	68.1%	65.1%	↑	71.8%	↑	58.0%	54.3%	62.3%
NHL - Extranodal	72.0%	71.4%	72.5%	73.6%	74.6%	↑	72.5%		67.2%	61.7%	72.3%

Myeloma	51.9%	50.8%	53.2%	52.4%	52.8%		51.8%		50.8%	47.5%	54.0%
Leukemia	60.9%	60.6%	61.2%	62.7%	61.7%	↑	64.0%	↑	54.8%	56.6%	52.8%
Lymphocytic Leukemia	79.0%	78.3%	79.9%	80.5%	79.5%		81.8%	↑	71.6%	72.5%	70.1%
Acute Lymphocytic Leukemia	66.6%	64.3%	69.1%	68.4%	66.9%		69.8%		59.3%	56.6%	63.0%
Chronic Lymphocytic Leukemia	82.5%	81.8%	83.5%	83.4%	82.0%		85.3%	↑	77.3%	79.7%	73.6%
Other Lymphocytic Leukemia	77.1%	76.1%	77.9%	81.9%	81.0%	↑	82.4%		54.1%	54.2%	51.7%
Myeloid and Monocytic Leukemia	40.8%	39.1%	42.6%	40.1%	37.9%		42.8%		42.5%	42.2%	42.8%
Acute Myeloid Leukemia	25.4%	23.5%	27.4%	24.3%	21.8%		27.2%		28.0%	27.8%	28.4%
Acute Monocytic Leukemia	30.5%	38.5%	17.9%	28.1%	35.2%		16.9%		33.7%	43.1%	19.3%
Chronic Myeloid Leukemia	67.3%	63.8%	71.4%	66.1%	62.6%		70.4%		70.2%	66.5%	73.9%
Other Myeloid/Monocytic Leukemia	30.7%	33.9%	26.4%	30.3%	32.0%		27.9%		30.3%	33.8%	20.4%
Other Leukemia	49.5%	47.5%	51.4%	51.1%	49.5%		51.8%		45.7%	41.0%	48.4%
Other Acute Leukemia	26.9%	15.5%	37.0%	28.4%	19.7%		34.9%		22.3%	0.0%	42.1%
Aleukemic, Subleukemic and NOS	61.5%	65.5%	57.8%	63.5%	65.6%		60.9%		57.1%	64.6%	50.2%
Mesothelioma	8.0%	4.7%	16.9%	7.9%	5.5%		14.5%		8.4%	0.0%	24.4%
Kaposi Sarcoma	64.7%	65.2%	56.7%	77.0%	78.6%	↑	61.7%		50.7%	51.1%	43.8%
Miscellaneous	36.3%	35.5%	37.2%	37.8%	38.1%	↑	37.5%	↑	32.0%	27.7%	36.1%

¹Except for urinary bladder (in situ and invasive), only invasive cases are included.

[^]The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly ($p < 0.05$) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2019^{1,2}

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	183,409	34,426	37,818	27,041	25,427	11,780	11,599	22,318	13,425
Oral Cavity and Pharynx	4,764	808	975	746	646	315	322	600	360
Esophagus	630	116	135	98	75	48	43	69	46
Stomach	1,451	337	264	202	195	83	101	182	86
Colon and Rectum	18,584	3,287	3,613	2,480	2,872	1,227	1,326	2,291	1,495
Liver and Intrahepatic Bile Duct	1,303	380	245	227	161	72	46	131	42
Pancreas	1,105	247	203	187	145	64	58	124	77
Larynx	1,951	377	383	292	288	126	130	238	119
Lung and Bronchus	8,515	1,651	1,604	1,254	1,240	539	555	1,008	670
Melanoma of the Skin	8,909	1,337	2,166	1,472	998	619	560	978	788
Breast	37,824	7,804	7,695	5,611	5,251	2,267	2,018	4,510	2,718
Cervix Uteri	2,302	456	433	290	314	166	148	325	172
Corpus and Uterus, NOS	5,663	1,084	1,079	767	785	373	367	761	447
Ovary	1,646	329	367	272	207	96	101	186	89
Prostate	43,418	7,850	9,828	5,718	5,984	2,754	2,705	5,496	3,082
Testis	1,643	312	344	233	223	130	122	174	106
Urinary Bladder	7,720	1,444	1,521	1,310	1,042	521	518	887	484
Kidney and Renal Pelvis	9,554	1,717	1,957	1,543	1,399	619	613	1,048	667
Brain and Other Nervous System	1,418	268	291	226	189	101	104	146	94
Thyroid	8,318	1,415	1,478	1,301	1,279	570	580	1,023	673
Hodgkin Lymphoma	1,765	330	337	289	248	113	123	209	117
Non-Hodgkin Lymphoma	8,002	1,564	1,541	1,280	1,111	566	517	918	508
Myeloma	2,223	468	491	318	248	115	119	298	168
Leukemia	4,780	750	924	761	674	352	323	619	378
Acute Lymphocytic Leukemia	698	118	149	110	104	52	37	83	44
Mesothelioma	115	27	28	22	12	12	^	^	^
Kaposi Sarcoma	188	87	37	14	17	8	^	15	6

¹ January 1, 2019, 19-Year Limited Duration Prevalence counts are based on 2019 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2018 and 2019 populations.

²Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 19 years (2000-2018). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 19 years (2000-2018).

³ Breast tumor includes both sexes. ⁴ Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers
Only, January 1, 2019^{1,2}

Site/Ages	All ages	0-20	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	183,412	3,075	13,721	22,348	48,185	59,405	33,657	9,737
Oral Cavity and Pharynx	4,764	43	267	712	1,564	1,437	615	205
Esophagus	630	^	7	49	180	221	148	27
Stomach	1,451	^	68	166	342	462	305	107
Colon and Rectum	18,584	42	750	2,000	5,290	5,797	3,555	1,272
Liver and Intrahepatic Bile Duct	1,303	39	27	64	424	503	207	42
Pancreas	1,105	^	52	86	244	366	257	97
Larynx	1,951	^	40	229	608	669	332	81
Lung and Bronchus	8,515	9	114	442	1,847	3,087	2,395	758
Melanoma of the Skin	8,909	103	1,313	1,406	2,080	2,107	1,417	591
Breast	37,824	6	2,238	6,823	10,542	10,759	6,190	1,974
Cervix Uteri	2,302	^	846	654	452	249	70	31
Corpus and Uterus, NOS	5,663	^	352	742	1,733	1,892	771	171
Ovary	1,646	44	226	261	422	407	221	65
Prostate	43,419	^	36	1,539	11,275	19,678	9,479	1,412
Testis	1,643	84	1,047	325	148	29	7	^
Urinary Bladder	7,720	8	153	487	1,569	2,582	2,126	853
Kidney and Renal Pelvis	9,554	157	513	1,291	2,582	3,023	1,651	420
Brain and Other Nervous System	1,418	507	349	193	163	139	55	14
Thyroid	8,318	143	2,137	1,808	2,021	1,478	609	128
Hodgkin Lymphoma	1,765	255	842	261	210	124	61	13
Non-Hodgkin Lymphoma	8,003	222	793	914	1,793	2,248	1,587	517
Myeloma	2,223	^	51	203	525	761	500	187
Leukemia	4,780	709	420	469	891	1,173	795	327
Acute Lymphocytic Leukemia	698	549	63	24	34	16	8	^
Mesothelioma	115	^	11	9	17	32	35	9
Kaposi Sarcoma	188	^	81	44	25	14	16	8

¹ January 1, 2019, 19-Year Limited Duration Prevalence. Populations were estimated by averaging 2018 and 2019 populations.

² Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 19 years (2000-2018). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 19 years (2000-2018).

³ Breast tumor includes both sexes.

⁴ Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2015-2019, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	124,136	132,131	93.9%
Oral Cavity and Pharynx	3,543	3,609	98.2%
Esophagus	1,215	1,252	97.0%
Stomach	1,812	1,849	98.0%
Small Intestine	861	872	98.7%
Colon and Rectum	11,830	12,144	97.4%
Colon excluding Rectum	8,218	8,487	96.8%
Rectum and Rectosigmoid Junction	3,612	3,657	98.8%
Liver	1,501	2,774	54.1%
Pancreas	3,376	3,940	85.7%
Larynx	1,403	1,426	98.4%
Lung and Bronchus	15,983	17,785	89.9%
Melanoma of the Skin	4,740	4,751	99.8%
Breast	18,174	18,351	99.0%
Corpus and Uterus, NOS	3,097	3,138	98.7%
Ovary	1,190	1,278	93.1%
Prostate	18,466	18,798	98.2%
Urinary Bladder	4,830	4,906	98.5%
Kidney and Renal Pelvis	5,539	6,086	91.0%
Brain and Other Nervous System	1,296	1,492	86.9%
Thyroid	3,588	3,600	99.7%
Hodgkin Lymphoma	659	664	99.2%
Non-Hodgkin Lymphoma	4,864	4,992	97.4%
Myeloma	1,895	2,254	84.1%
Leukemia	3,381	3,681	91.9%
Mesothelioma	314	330	95.2%
Kaposi Sarcoma	99	103	96.1%

¹Case counts represent the total combined number of cases for the 5-year period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

References

- [1] A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D. M. Parkin and S. Whelan, Eds., International Classification of Diseases for Oncology, 3rd ed., Geneva: World Health Organization, 2000.
- [2] U.S. Cancer Statistics Working Group, "U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999-2019)," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, June 2022. [Online]. Available: <https://www.cdc.gov/cancer/dataviz>. [Accessed 17 August 2022].
- [3] American Cancer Society, "Cancer Facts & Figures 2022," Atlanta, 2022.
- [4] Campaign for Tobacco-Free Kids, "State Cigarette Excise Tax Rates & Rankings," 21 December 2021. [Online]. Available: <https://www.tobaccofreekids.org/assets/factsheets/0097.pdf>. [Accessed 25 August 2022].
- [5] Centers for Disease Control and Prevention, "Cancer and Obesity," 3 October 2017. [Online]. Available: <https://www.cdc.gov/vitalsigns/obesity-cancer/index.html>. [Accessed 25 August 2022].
- [6] Centers for Disease Control and Prevention, "Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2020," 15 July 2022. [Online]. Available: <https://www.cdc.gov/obesity/data/prevalence-maps.html>. [Accessed 17 August 2022].
- [7] Centers for Disease Control and Prevention, "Cancers Caused by HPV," 28 February 2022. [Online]. Available: <https://www.cdc.gov/hpv/parents/cancer.html>. [Accessed 25 August 2022].
- [8] Centers for Disease Control and Prevention, "HPV Vaccine," 23 July 2021. [Online]. Available: <https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html>. [Accessed 25 August 2022].

Appendices

Appendix A. Abbreviations and Symbols

ICD-O-2	<i>International Classification of Diseases for Oncology, 2nd edition</i>
ICD-O-3	<i>International Classification of Diseases for Oncology, 3rd edition</i>
LTR	Louisiana Tumor Registry
NCI	National Cancer Institute
NAACCR	North American Association of Central Cancer Registries
NPCR	National Program of Cancer Registries
OPH	Louisiana Office of Public Health
SEER	Surveillance, Epidemiology and End Results Program of the National Cancer Institute
--	Not applicable
^	Rate is not calculated for a case count lower than sixteen during the five-year period.

Appendix B. Regions of Louisiana

Because the Louisiana Tumor Registry was created as an agency of the Louisiana Office of Public Health (OPH), it follows the Department of Health and Hospitals' regional divisions that were in effect when the LTR was created in LTR analyses and publications. Using OPH boundaries enables state officials to take advantage of the existing public health structure in case alarming cancer incidence patterns emerged.

Later, the OPH revised its health regions to respond to changing population patterns (especially the growth of the area north of Lake Pontchartrain, now Region 9) and to eliminate the geographic isolation of Plaquemines Parish for public health operations. Regions 5-8 did not change.

The Tumor Registry, however, has retained the traditional OPH regional boundaries, in order to monitor historical incidence trends.

Maps of the regions are available at:

OPH: <http://www.dhh.louisiana.gov/assets/images/maps/regionmap.jpg>

LTR: <http://sph.lsuhscc.edu/louisiana-tumor-registry/about-the-registry/host-institutions/>

Regions of the Louisiana Tumor Registry

Regional Registry	Beginning Date of the Registry	Average Annual Population, 2015-2019 ¹	Parishes Covered
Region 1 – New Orleans	1974	873,129	Jefferson, Orleans, St. Bernard
Region 2 – Baton Rouge	1983	987,542	Ascension, Assumption, East Baton Rouge, East Feliciana, Iberville, Livingston, Pointe Coupée, St. Helena, Tangipahoa, West Baton Rouge, West Feliciana
Region 3 – Southeast Louisiana	1983	652,946	Lafourche, Plaquemines, St. Charles, St. James, St. John, St. Tammany, Terrebonne, Washington
Region 4 – Acadiana	1983	657,964	Acadia, Evangeline, Iberia, Lafayette, St. Landry, St. Martin, St. Mary, Vermilion
Region 5 – Southwest Louisiana	1983	303,036	Allen, Beauregard, Calcasieu, Cameron, Jefferson Davis
Region 6 – Central Louisiana	1988	302,905	Avoyelles, Catahoula, Concordia, Grant, La Salle, Rapides, Vernon, Winn
Region 7 – Northwest Louisiana	1988	540,083	Bienville, Bossier, Caddo, Claiborne, De Soto, Natchitoches, Red River, Sabine, Webster
Region 8 – Northeast Louisiana	1988	351,344	Caldwell, East Carroll, Franklin, Jackson, Lincoln, Madison, Morehouse, Ouachita, Richland, Tensas, Union, West Carroll
Entire State	1988	4,668,950	

¹Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019) - Linked To County Attributes - Total U.S., 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

Regions of the Office of Public Health

Region	Parishes Covered
Region 1 – New Orleans	Jefferson, Orleans, Plaquemines, St. Bernard
Region 2 – Baton Rouge	Ascension, East Baton Rouge, East Feliciana, Iberville, , Pointe Coupée, Baton Rouge, West Feliciana
Region 3 – Southeast	Assumption, Lafourche, St. Charles, St. James, St. John the Baptist, St. Mary, Terrebonne
Region 4 – Acadiana	Acadia, Evangeline, Iberia, Lafayette, St. Landry, St. Martin, Vermilion
Region 5 – Southwest	Allen, Beauregard, Calcasieu, Cameron, Jefferson Davis
Region 6 – Central	Avoyelles, Catahoula, Concordia, Grant, La Salle, Rapides, Vernon, Winn
Region 7 – Northwest	Bienville, Bossier, Caddo, Claiborne, De Soto, Natchitoches, Red River, Sabine, Webster
Region 8 – Northeast	Caldwell, East Carroll, Franklin, Jackson, Lincoln, Madison, Morehouse, Ouachita, Richland, Tensas, Union, West Carroll
Region 9 - Northlake	Livingston, St. Helena, St. Tammany, Tangipahoa, Washington

Appendix C. Host Institutions of the LTR Regional Registries

The Louisiana Tumor Registry sincerely thanks the following healthcare institutions for their generosity in providing a home, along with internet and other support services, to the LTR regional offices for many years:

Regions 1 & 3: LSU Board of Supervisors and LSU Health Sciences Center-New Orleans (since 1995)

Region 2: Mary Bird Perkins Cancer Center (since 1983)

Region 4: Acadiana Medical Research Foundation (since 1983)

Region 5: Mary Bird Perkins Cancer Center (since 2013)

Regions 6, 7, & 8: University of Louisiana at Monroe (since 1988)

Previous host institutions included

Christus St. Patrick Hospital (Region 5, 1983-2013)

Louisiana Office of Public Health (Regions 1 & 3, 1983-1995)

Appendix D. Cancer-Related Organizations

American Cancer Society: <http://www.cancer.org/>

Behavioral Risk Factor Surveillance System: <http://www.cdc.gov/brfss/>

Centers for Disease Control and Prevention: <http://www.cdc.gov/>

Louisiana Breast and Cervical Health Program: <http://lbchp.org/>

Louisiana Cancer Prevention and Control Programs: <http://louisianacancer.org/>

Louisiana Cancer Registrars' Association: <http://www.lcra-usa.org/>

Louisiana Department of Health: <http://dhh.louisiana.gov/>

National Cancer Institute: <https://www.cancer.gov/>

National Cancer Registrars Association: <https://www.ncra-usa.org/>

National Program of Cancer Registries, CDC: <https://www.cdc.gov/cancer/npcr/index.htm>

North American Association of Central Cancer Registries: <http://www.naaccr.org/>

SEER Program (NCI): <http://seer.cancer.gov/>

State Cancer Profiles: <http://statecancerprofiles.cancer.gov/>

Tobacco-Free Louisiana: <http://tobaccofreeliving.org/>

Appendix E. Data Use

LTR data are included in the following publications that accept only high-quality data:

- American Cancer Society Cancer Statistics Center:
<https://cancerstatisticscenter.cancer.org/#/>
- NAACCR's annual publication, *Cancer in North America* (CINA):
<https://www.naaccr.org/cancer-in-north-america-cina-volumes/>
- *Cancer Incidence in Five Continents*, published by the World Health Organization's International Association for Research on Cancer:
<https://ci5.iarc.fr/Default.aspx>
- *United States Cancer Statistics*, published by the CDC and the NCI:
<https://www.cdc.gov/cancer/uscs/about/publications.htm>
- United States Cancer Statistics: Data Visualizations:
<https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/>
- SEER Cancer Explorer Network, published by the SEER Program:
<https://seer.cancer.gov/statistics-network/>
- State Cancer Profiles, published by the CDC:
<http://statecancerprofiles.cancer.gov/>
- SEER Public Use Data File:
<http://seer.cancer.gov/data/>